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Microfluidic Approaches to Thrombosis and Hemostasis: Towards a PatientSpecific Test of Antiplatelet Therapeutics and the Assessment of Coagulopathy
in Hemophilic and Trauma Patients
Abstract
Current in vitro or ex vivo models of hemostasis and thrombosis fail to recapitulate the hemodynamic
conditions and biorheologic phenomena found throughout the vasculature. Microfluidic technology
enables physiologic hemodynamics for the study of platelet deposition and coagulation using minimum
volumes of human whole blood. This dissertation describes the application of microfluidic assays, the
manipulation of surface-patterned procoagulant and sub-endothelial proteins, anti-coagulation, and flow
conditions to investigate platelet function and coagulation under flow. First, we demonstrate a novel
method to assess the in vivo or in vitro therapeutic efficacy of anti-platelet therapies on platelet
aggregates adhering to collagen type I surfaces. We phenotyped individual healthy donor platelet function
responses to in vivo or in vitro aspirin, a common antiplatelet therapy over collagen type I surfaces at
venous shear rates. Utilizing the same flow assay, we also characterized mechanism-based resistance to
aspirin conferred by non-steroidal anti-inflammatory drugs. Furthermore, we have also developed a new
model to assess the intrinsic pathway of coagulation under flow on collagen type I surfaces and
investigated the role of the intrinsic pathway in recombinant coagulation factor VIIa (rFVIIa) therapeutic
efficacy. We then extended this mechanistic investigation of rFVIIa to flow assays where clotting is
initiated by collagen and immobilized lipidated tissue factor to evaluate the role of the intrinsic tenase in
conjunction with exogenous rFVIIa when surface-triggered extrinsic pathway is present. Finally, we
continued to assess coagulopathic patients by first mimicking resuscitation-driven hemodilution,
hyperfibrinolysis, and plasmin-inhibitor therapy under flow. We then evaluated downregulation of platelet
function in whole blood from trauma patients during the acute phase of trauma-induced coagulopathy.
The development of microfluidics, microfabrication, and its applications in hemostasis and thrombosis is
essential in advancing our knowledge of clinical and pathological disorders such as myocardial infracts,
hemophilia, and deep vein thrombosis. Beyond this work, microfluidic platforms in hemostasis and
thrombosis can potentially be used as drug screening platforms for antiplatelet or clotting factor
therapies, or a point of care diagnostic test for bleeding and pin-pointing the therapeutic index of novel
biopharmaceutics.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Chemical and Biomolecular Engineering

First Advisor
Scott L. Diamond

Keywords
Fibrin, Hemophilia, Hemostasis, Microfluidics, Platelets, Thrombosis

Subject Categories
Biomedical | Chemical Engineering
This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/1857

MICROFLUIDIC APPROACHES TO THROMBOSIS
AND HEMOSTASIS: TOWARDS A PATIENT-SPECIFIC
TEST OF ANTIPLATELET THERAPEUTICS AND THE
ASSESSMENT OF COAGULOPATHY IN
HEMOPHILIC AND TRAUMA PATIENTS
Ruizhi Li
A DISSERTATION
in
Chemical and Biomolecular Engineering
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2016
Supervisor of Dissertation
_______________________________
Scott L. Diamond
Professor, Chemical and Biomolecular Engineering
Graduate Group Chairperson
________________________________
John C. Crocker, Professor, Chemical and Biomolecular Engineering
Dissertation Committee
Lawrence F. Brass, Professor, Department of Medicine
Talid R. Sinno, Professor, Department of Chemical and Biomolecular Engineering
Matthew J. Lazzara, Assistant Professor, Department of Chemical and Biomolecular
Engineering

MICROFLUIDIC APPROACHES TO THROMBOSIS
AND HEMOSTASIS: TOWARDS A PATIENT-SPECIFIC
TEST OF ANTIPLATELET THERAPEUTICS AND THE
ASSESSMENT OF COAGULOPATHY IN
HEMOPHILIC AND TRAUMA PATIENTS
COPYRIGHT
2016
Ruizhi Li

ACKNOWLEDGEMENTS
First and foremost I would like to thank my thesis advisor, Dr. Scott L. Diamond, without
your guidance and mentorship this dissertation would not have been possible. The research
experience, problem-solving abilities, project management skills, and written and oral
communication skills I learned during my degree will forever shape by my professional
career as an engineer and scientist. They are a testament to the exceptional learning
opportunities afforded to me while in Scott's lab and his ability to bring the best out of his
PhD students. I would also like to extend thanks to the other members of my thesis
committee, Dr. Lawrence Brass, Dr. Matthew Lazzara, and Dr. Talid Sinno. Your
suggestions and thoughtful insights during my proposal and along the progression of my
dissertation helped me think critically about my work. Furthermore, I would like to
acknowledge all of my collaborators around Penn, without your resources and support this
work could not have been possible either. Special thanks to Professor Tilo Grosser, Dr.
Xuanwen Li, Dr. Adam Cuker, Dr. Patrick Forgarty, Karen Panckeri, Dr. Thomas Diacovo,
Dr. Carrie Sims, and Ryan Walters, all of whom have provided me with opportunities I
could have never imagined. Additionally, I want to express my gratitude towards the past
and current members of the Diamond lab: Xinren Yu, Brad Herbig, Shu Zhu, John Welsh,
Dr. Ryan Muthard, Dr. Viraj Kamat, Dr. Melissa Myint, Dr. Thomas Colace, Dr. Andrew
Dolan, Dr. Roman Woronov, and Huiyan Jing. I am especially grateful to Tom and Ryan for
being ever so helpful with my work and bringing me under their tutelage. I would also like to
thank the many friends outside of lab, those that stayed in Sansom (Neil, Keith, etc.), those I
met at Pottruck (Jeff, Paul, Andrea, etc.), members of GCC (Brian, Chris, Minna, Shirley
iii

etc.). I'm also thankful for Katlin, whose happiness, exuberance, kindness, and compassion
has brightened me ever since the day we met. I can always count on you to support me, to
listen, and to be there for me through the best of times and worst of times. I would also like
to thank my Lord and savior for loving me, protecting me, and blessing me all five years in
Philadelphia. Finally and most importantly, I would like to thank my parents, whose love and
support has always been there through the countless hours, days, and years. The love and
dedication you have shown me in both my personal and professional life is unfathomable.
The lessons the two of you have taught me have made me into the man I am today.
Without my parents, I could have never accomplished so much and would have never
learned the values of love, hard work, responsibility, respect, and perseverance in this
lifetime. Your unwavering support and faith in me have gotten me this far and will
undoubtedly carry me even further into the future. For this I dedicate the entirety of this
PhD dissertation to my parents.

iv

ABSTRACT
MICROFLUIDIC APPROACHES TO THROMBOSIS AND HEMOSTASIS: A
GLOBAL INVESTIGATION OF ANTIPLATELET THERAPEUTICS AND THE
ASSESSMENT OF BLEEDING AND COAGULOPATHY IN HEMOPHILIC AND
TRAUMA PATIENTS
Ruizhi (Richard) Li
Scott L. Diamond
Current in vitro or ex vivo models of hemostasis and thrombosis fail to recapitulate the
hemodynamic conditions and biorheologic phenomena found throughout the vasculature.
Microfluidic technology enables physiologic hemodynamics for the study of platelet
deposition and coagulation using minimum volumes of human whole blood. This
dissertation describes the application of microfluidic assays, the manipulation of surfacepatterned procoagulant and sub-endothelial proteins, anti-coagulation, and flow conditions
to investigate platelet function and coagulation under flow. First, we demonstrate a novel
method to assess the in vivo or in vitro therapeutic efficacy of anti-platelet therapies on
platelet aggregates adhering to collagen type I surfaces. We phenotyped individual healthy
donor platelet function responses to in vivo or in vitro aspirin, a common antiplatelet
therapy over collagen type I surfaces at venous shear rates. Utilizing the same flow assay, we
also characterized mechanism-based resistance to aspirin conferred by non-steroidal antiinflammatory drugs. Furthermore, we have also developed a new model to assess the
intrinsic pathway of coagulation under flow on collagen type I surfaces and investigated the
role of the intrinsic pathway in recombinant coagulation factor VIIa (rFVIIa) therapeutic
efficacy. We then extended this mechanistic investigation of rFVIIa to flow assays where
clotting is initiated by collagen and immobilized lipidated tissue factor to evaluate the role of
the intrinsic tenase in conjunction with exogenous rFVIIa when surface-triggered extrinsic
v

pathway is present. Finally, we continued to assess coagulopathic patients by first mimicking
resuscitation-driven hemodilution, hyperfibrinolysis, and plasmin-inhibitor therapy under
flow. We then evaluated downregulation of platelet function in whole blood from trauma
patients during the acute phase of trauma-induced coagulopathy. The development of
microfluidics, microfabrication, and its applications in hemostasis and thrombosis is essential
in advancing our knowledge of clinical and pathological disorders such as myocardial
infracts, hemophilia, and deep vein thrombosis. Beyond this work, microfluidic platforms in
hemostasis and thrombosis can potentially be used as drug screening platforms for
antiplatelet or clotting factor therapies, or a point of care diagnostic test for bleeding and
pin-pointing the therapeutic index of novel biopharmaceutics.
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INTRODUCTION TO PLATELETS, BLOOD COAGULATION,
AND MICROFLUIDICS

1.1

Hemostasis and the Role of Platelets
Human blood is primarily comprised of plasma proteins, platelets, red blood cells,

and white blood cells. In human whole blood, platelets are the primary anucleate cells that
are responsible for hemostasis, more commonly described as the physiologic balance
between bleeding and excessive blood clotting (thrombosis). Healthy whole blood on
average contains 150,000 – 400,000 platelets per microliter[1]. These anucleate cells stay in a
quiescent state circulating the blood vasculature patrolling the human body for vessel wall
damage and exposure of the subendothelium. Once damage occurs to the vessel wall, tissue
factor (TF) is exposed and the coagulation cascade (to be described in detail later) is
triggered. This cascade produces a potent serine protease thrombin (IIa) which activates
platelets[2]. The final downstream product of the cascade is fibrin, which is a fibrous
biopolymer network that stabilizes and seals a blood clot[3].
Platelets are able to remain in a quiescent state as they are inhibited by chemical
mediators from the endothelium, prostacyclin (PGI2) and nitric oxide (NO2)[4]. Additionally,
platelets have numerous receptors and respond to activating stimuli such as collagen, von
Willebrand Factor (vWF), epinephrine, and histamine[4]. In the presence of these agonists,
platelet become activated through a series of transmembrane receptors on their surface. This
then results in an increase in intracellular calcium that cause changes in platelet morphology
and the platelet cytoskeleton[5]. In addition to platelet shape change, platelet activation also
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results in the secretion of additional agonists from platelet alpha and dense granules. These
granules are packaged prior to platelet release by megakaryocytes during
megakaryopoiesis[6]. Secretion of these agonists [Adenosine Diphosphate (ADP),
Thromboxane A2 (TXA2)] results in both autocrine and paracrine signaling which are
biochemical signaling processes important for the recruitment of additional platelets to the
site of injury and the stabilization of previously deposited platelets during blood clotting.

1.2 Thrombosis
Once the delicate balance of blood clotting is perturbed, excessive clot growth or
thrombosis then occurs. Thrombosis is the cessation of blood flow through a vessel due to
an occlusive blood clot. Two clinically-relevant types of thrombosis are clots that emanate
from the venous circulation or clots that emanate from the arterial circulation of the
vasculature. The most prevalent venous thrombosis is deep vein thrombosis (DVT). Deep
vein thrombosis usually occurs due to continuous immobilization, surgery, or heart
failure[7]. Medical treatment for DVT consists of anticoagulant drugs such as heparin or
vitamin K antagonists[7]. Arterial thrombosis is pathologically different from venous
thrombosis and occurs within arterioles[8]. A prime example of arterial thrombosis is
myocardial infarction (MI), otherwise commonly known as a heart attack. This sudden
occlusive event prevents blood flow to the heart. The major causes of MI are usually genetic
risk factors, atherosclerotic plaque build-up and rupture, or a combination of high blood
pressure, cholesterol and obesity[8]. Common treatment for arterial thrombosis includes
antiplatelet therapies, drug-eluting stents, and bypass surgery. A major concern with venous
and arterial thrombosis is the risk of thromboembolism. Thromboembolism is a scenario
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where an occlusive clot dislodges from the injury site and eventually travels downstream and
becomes lodged in another vascular bed. Thromboembolism is a major concern with
patients who have DVT or have experienced acute MI. Thrombus dislodgement followed by
adherence either in the lungs or brain could put an individual at risk for pulmonary
embolism or stroke. The investigation of the biophysical and biochemical characteristics of
venous and arterial thrombi is on-going and much additional research is still needed[9].

1.3 Hemostatic clot growth under flow: platelet adhesion biology &
receptor interactions
Hemostastic clot growth under physiologic flow environments occurs in three stages,
initial platelet adherence to subendothelial proteins, growth of the clot through autocrine
and paracrine signaling, and stabilization of the platelet aggregate (Figure 1-1). Platelets
initially adhere to either collagen or vWF at the site of injury. This initial adhesion is
mediated through platelet receptors α2β1 and glycoprotein VI (GPVI) for collagen and
glycoprotein IB (GPIB) for vWF respectively[10]. Beyond this initial monolayer of platelets
adhered to collagen and vWF, local platelet secretion of agonists ADP and TXA2 help
activate more platelets and recruits those additional platelets to the site of injury[11].
Furthermore, platelet calcium levels Ca2+ rise due to its release from intracellular stores.
Rising Ca2+ levels results in platelet integrin αIIbβ3 activation. Platelet integrin αIIbβ3 is a major
integrin involved in platelet aggregation, it undergoes a conformational change which then
facilitates its binding to fibrinogen, a major plasma protein in blood and vWF[12]. The high
copy number of platelet αIIbβ3 and multiple binding sites on fibrinogen and vWF for αIIbβ3
then ensure platelet aggregation, extension of the hemostatic blood clot and the cessation of
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bleeding. This is further supported by platelet mechanosensing as increases in platelet
activation and changes in the local flow environment results in single platelet and platelet
aggregate contraction that secures the clot against the vessel wall and stops bleeding[13,14].

Figure 1-1 Hemostatic Plug Formation, Aggregation, and Contraction
(a) Circulating platelets are kept quiescent by PGI2 and NO released from endothelial cells. (b & c) At sites of
vessel injury, platelets adhere to proteins of the exposed subendothelium through interactions with collagen,
vWF through their receptors integrin α2β1 and GPIb respectively. Agonists, ADP and thrombin then cause
platelet shape change. (d) Activated platelets release ADP and fibrinogen from their intracellular granules. ADP
and TXA2 recruits additional platelets to the site of injury through autocrine and paracrine signaling. (e) Platelet
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αIIbβ3 becomes engaged and activated platelets bind fibrinogen or vWF resulting in platelet aggregation. (f) Clot
contraction then leads to a stable thrombus under flow.

A final important role of platelets during blood clotting is the ability of their
phospholipid membrane surfaces to support coagulation. The surface of activated platelets
becomes negatively charged due to phosphatidylserine (PS) and phosphatidycholine (PC)
exposure as these phospholipids are transferred from the inner leaflet of the platelet
membrane to the outer leaflet of the platelet membrane[15]. This negatively charged surface
then provides a surface for the adherence of plasma proteins which then can support the
coagulation cascade[16].

1.4 Coagulation
Blood coagulation is a series of biochemical, enzymatic pathways that is governed by
zymogens, serine proteases, and enzymes. This serious of reactions results in generation of a
master enzyme, thrombin and the formation of a biopolymer network, fibrin, which then
stabilizes the clot. The coagulation cascade is divided into two pathways, the contact
(intrinsic) pathway and the tissue factor (extrinsic) pathway. These two pathways converge to
the formation of clotting factor Xa (FXa). The subsequent steps following FXa generation
are known as the “common pathway”. This leads to the formation of thrombin. Thrombin
then acts on fibrinogen to convert fibrinogen into fibrin monomer which then polymerize
into fibrin. Fibrin fibers stabilize the loose platelet aggregate. These pathways occur in the
presence of serine protease inhibitors that limit the activity of active proteases. The
coagulation cascade is schematically depicted in.
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Figure 1-2 Schematic Depiction of the Coagulation Cascade
The coagulation cascade involves a series of sequential plasma reactions that lead to the generation of
thrombin. The cascade is triggered either by exposure of TF at the site of injury (extrinsic pathway) or by
exposure to negatively charged surfaces and activation of FXII (intrinsic pathway). Both pathways lead to
thrombin formation and then fibrin production.

In in vivo scenarios, the extrinsic pathway is the predominant trigger of the
coagulation cascade. This involves the exposure of TF at the site of vascular injury. TF is
commonly expressed by smooth muscle cells and fibroblasts. TF exposure to flowing blood
in vivo then allows binding of activated soluble clotting factor seven (FVIIa). FVII is a
member of the vitamin K-dependent clotting factors, the others are FIX, FIX, and proteins
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C and S[18]. Most coagulation factors have gamma-carboxyglutamic acid residues in the Nterminal region (Gla-domain) of their protein structure which then enables them to bind
calcium and assemble on the phospholipid surfaces of platelets. Once the TF/FVIIa
complex forms it can activate FIX via limited proteolysis. However, TF/FVIIa complex can
directly activate FX and this is a heavily favored pathway in vivo. Once FIX is activated, it
can also activate FX as long as FVIIIa is present. Factor VIIIa is the cofactor for FIXa and
the assembly of these two active factors together to promote FXa generation is known as the
‘intrinsic tenase’ complex’. As all serine proteases and clotting cofactors in the coagulation
cascade exist as zymogens in the plasma component of whole blood, it is surprising how
such potent biocatalytic reactions can be triggered via the ensemble of these inert precursors.
However, previous studies have shown that sub-nanomolar concentrations of FVIIa does
exist in circulation while active forms of other clotting factors are even more miniscule in
comparison. Exposure of TF to this small but nevertheless potent amount of FVIIa then
sets up autocatalytic feedback where VII bound to TF is activated. Furthermore, other
clotting enzymes can also activate FVII which thus makes the coagulation cascade a network
of self-amplifying, feedforward, and feedback reactions.
In a traditional sense, the other arm of the coagulation cascade is the ‘intrinsic’
pathway. Its name is derived from the ‘intrinsic’ ability of blood to clot when placed in a
glass tube. Specifically speaking, blood derived from the human blood tends to clot in vitro
when in direct contact with negatively charged surfaces. Non-physiologic surfaces for
contact activation of blood include glass, clay, and kaolin, while physiologic substrates for
contact activation include DNA, RNA, and histones. The contact pathway has been viewed
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previously as non-physiologic as severe deficiencies in the most upstream source of this
pathway(FXII) causes no severe bleeding defect[19]. In fact, studies have shown inadequate
levels of FXII may actually result in increased risk of thrombosis[20]. However, recent in
vivo models have shown that mice deficient in FXII have a tendency to form unstable
thrombi, thus suggesting that this previously overlooked part of the coagulation cascade may
have an important physiologic role. The intrinsic pathway is activated once zymogen FXII
comes into contact with negatively charged surfaces. The heavy chain of FXII is the portion
that binds to negatively charged surfaces which then leads to increases in local enzyme
concentration, autoactivation, and activation of FXI. Then FIX is activated by dimerized
FXIa.
Nevertheless both the intrinsic and extrinsic pathway converge to FXa generation.
Factor Xa along with its cofactor FVa converts prothrombin into thrombin. Factor Xa
assembly with FVa in the presence of calcium on a phospholipid surface results in a 300,000
fold increase in thrombin generation as compared to FXa alone. Thrombin is central to the
formation of the haemostatic blood clot as it controls its own generation and inhibition by
acting on numerous substrates such as fibrinogen, FV, FVIII, FIX, platelet receptors,
protein S, and protein C. One major role of thrombin is its cleavage of fibrinogen, a heavily
abundant protein in both plasma and platelet granules. Thrombin cleavage of fibrinopeptide
A and B of fibrinogen results in a self-association and restructuring of fibrin monomers[21].
The progressive lengthening of initial fibrin monomers into dimers and beyond occurs
initially through half overlap of fibrin monomers which then forms long, thin fibrin strands.

8

Factor XIIIa can then crosslink these loose fibrin strands and confers degradation by
plasmin.

1.5 Anticoagulation for in vitro and ex vivo research
1.5.1

Citrate or Ethylenediaminetetraacetic acid (EDTA)
Citrate or EDTA are potent calcium chelators that can completely inhibit thrombin

production and platelet adhesion under flow. Thus these reagents are ideally used for pure
biorheological studies of platelet/red blood cell interaction under flow. The addition of
exogenous Ca2+ for recalcification can recover extracellular calcium levels, however EDTA
tends to destroy αIIbβ3 function and citrate also significantly impairs αIIbβ3 after
recalcification[22]. Basic scientific and clinical studies of TF or contact pathway triggered
coagulation predominantly uses citrate as an anticoagulant. However, it is important to note
that FXIIa can be generated in the absence of calcium.
1.5.2

Corn Trypsin Inhibitor (CTI)
CTI is an intrinsic pathway inhibitor which when used in the 20-120 µg/ml range

can inhibit the activity of βFXIIa, the soluble cleavage product formed from surface-bound
αFXIIa. As CTI does not inhibit αFXIIa, it can provide approximately 30-60 min of
inhibition of the contact pathway without interfering with the cation levels required for
extrinsic pathway medicated coagulation. Thus high exogenous concentrations of CTI are
commonly used to test TF-initiated coagulation under flow given that blood can be tested in
vitro immediately following phlebotomy. Furthermore, recent studies have shown that a low
level of CTI (4 µg/ml) can partially delay the contact pathway allowing study of FXIIa and
its subsequent reactions ex vivo provided that blood is perfused ex vivo within 5-15 minutes
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of phlebotomy[23,24]. Other reagents have also been used to control in vitro contact
activation. Monoclonal function-blocking antibodies have been used against FXIIa and
FXIa[25]. Infestin-4 has been used to antagonize FXIIa, while domains from protease nexin2 have been used to inhibit FXIa[26–28].
1.5.3

FPR-Chloromethylketone (PPACK), Direct FXa inhibitors, Heparin
PPACK is a small molecule inhibitor of thrombin. PPACK (100 µM) provides strong

and irreversible inhibition of thrombin for in vitro studies of platelet function. This
approach is useful to solely examine platelet activation, adhesion, aggregation, and function
in the absence of thrombin and fibrin. Furthermore, with the advent of novel oral direct
FXa inhibitors (apixaban), these new anticoagulants can be used in vitro for direct inhibition
of FXa. The use of apixaban (0.25 – 1 µM) becomes particularly useful when examining the
effect of exogenously added thrombin on platelet activation and intracellular calcium
signaling[29].

1.6 Microfluidic Technology
1.6.1

Motivation
Microfluidic technology was invented due to a need in industrial applications and

academic laboratories to minimize reagent usage, evaluate novel drug therapeutic efficacy
and toxicity, and increase throughput while maintaining the physiologic conditions in which
most biological systems exist. Since blood flow occurs in a closed, high pressure,
continuously circulating system, in vitro or ex vivo models that can capture the
hemodynamics and flow characteristics offer better opportunities to accurately investigate
the biological phenomena that occurs in vivo during thrombus formation. Furthermore,
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current in vivo animal models of hemostatic and vascular injury are still not well-understood
and the small volumes of blood collected from difficult to breed genetically modified
animals mandates a low volume test of hemostasis and thrombosis[30,31].
Several previous technologies have been used to study the hemostatic process under
flow ex vivo. Such technologies include parallel plate flow chambers, capillary flow
chambers, and cone and plate viscometers. These technologies all have their own pitfalls
with respect to volume requirements, experimental control and physiologic hemodynamics.
By coupling very well-established micropatterning techniques with soft photolithography,
microfluidic assays can be developed for whole blood perfusion over well-defined
biomimetic injuries. With control over flow conditions, micropatterned protein/enzyme
surface composition and inlet blood biochemistry, thrombi can be formed in vitro and
examined with real time epifluorescence microscopy by a host of monoclonal antibodies,
novel biosensors, and fluorescently conjugated peptides or proteins. Finally, the ability to
measure multiple outputs in real-time with various fluorescent probes from a single blood
sample over the course of an experiment provides control and reproducibility critical to the
variable nature of hemostatic studies. This could serve as a basis for future automated
preclinical diagnostic platforms.
A thorough discussion of PDMS and microcontact printing techniques is out of the
scope of this dissertation and extensive reviews can be found elsewhere[32]. Generally
speaking, microfluidic devices are made out of polydimethylsiloxane (PDMS) that was cured
over master molds fabricated by photolithographic techniques. In brief, a photoresistive
substrate is spin-coated onto a silicon wafer in a process known as spin-coating. This process
11

enables substrate adherence to the wafer to a height that will represent the microfluidic
channel depth. The spin-coated wafer is then brought into close contact with a highresolution transparency of the desired microfluidic geometry and channel device. UV light is
then shun on the sample which then cross-links the photo-resistive substrate. Unexposed
photoresist is then removed with a developing solution. This master mold can then be used
to make PDMS casts of the microfluidic devices.
1.6.2

Microfluidic open systems for the study of hemostasis and thrombosis: Focal
Injury Models, High Throughput Testing
Open microfluidic systems allow for exchange with the outside environment and

offer excellent spatial and temporal control of the flow regime, surface protein/enzyme
concentration, and perfused blood biochemistry. Such flow systems allow for high replicate
testing of clotting events in vitro and utilizes low volumes of blood (< 1 ml). Microfluidic
assays provide control of local flow environments by perfusion of whole blood over welldefined geometries and excellent command of sample flow rates via pre-programed syringe
pumps that can also be automated via external LABVIEW interface[13]. Physiological
venous (100-800 s-1) and arterial shear rates (1000-2000 s-1) can be used in microfluidic
devices, and pathological shear rates (10,000-200,000 s-1) have also been investigated too.
Most microfluidic devices set-ups are single path perfusions and for square rectangular
channels, the x-directed velocity field for steady flow over a domain of –w/2 y w/2 and 0 z
h is given by
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PDMS allows for the creation of rectangular flow channels with microscopic features down
to approximately 3 µm. Microcontact stamping has also allowed microprinting of proteins or
lipids on various substrates down to a spatial resolution of < 1 µm. Neeves et al. have
previously demonstrated the use of micropatterned collagen surfaces in a PDMS
microchannel[33]. Collagen Type I was patterned onto a glass slide using a single channel
device that was then removed to allow placement of a second 13 channel flow device[33].
The resulting protocol was an assay of thrombi formed over 13 individual flow paths each
with a precisely patterned injury site where collagen was exposed to the flowing blood.
Maloney et al. further advanced this design by making an 8-channel device through which
blood was perfused by withdrawal through a single outlet[34]. Furthermore, Colace et al. also
improved the biological complexity of the surface trigger in this model 8-channel
microfluidic system. With regards to micropatterning, microchannels are usually filled with a
protein of interest and rinsed with physiologic buffer before sample perfusion. Colace et al.
used this technique to generate thrombogenic surfaces of collagen and immobilized TF in
PDMS microchannels[35]. Briefly, Colace et al. modified the TF-bearing liposomes
described by Smith et al. to produce TF-bearing biotinylated liposomal constructs which
then could be bound to a collagen surface via biotinylated anti-collagen antibody and
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streptavidin[36]. Such techniques are vital to study the simultaneous effect of platelet
deposition and thrombin production under flow and characterize the roles of thrombin in
platelet adhesion and fibrin generation in platelet plug formation[37]. Finally, it is important
to note that the use of external syringe pumps only generates constant flow rate
environments. Under these flow conditions, growing thrombi only obstruct the flow as large
pressure drops develop eventually leading the partial and complete embolism of clots as even
occlusive structures under flow cannot stop a syringe pump. Thus Colace et al. used the 8channel device previously described to create a constant pressure drop flow regime by
developing thrombi in four of eight channels which then diverted flow to the other four
bifurcated channels due to the unreactive EDTA-treated blood that was being perfused
simultaneously[37]. This was verified computationally with fluid dynamics simulations
showing a drastic difference between clots formed in the presence or absence of fibrin.
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2

MICROFLUIDIC ASSAY OF PLATELET DEPOSITION ON
COLLAGEN BY PERFUSION OF WHOLE BLOOD FROM
HEALTHY INDIVIDUALS TAKING ASPIRIN

2.1 Introduction
Antiplatelet therapies are commonly used in the acute treatment of coronary diseases
and long-term prevention of cardiovascular events[38]. Inhibition of platelet cyclooxygenase1 (COX-1) by aspirin (acetylsalicylic acid, ASA) and the subsequent attenuation of
thromboxane A2 (TXA2) production causes a decrease in secondary platelet aggregation and
reduces excessive thrombus formation[39]. ASA does not severely reduce the primary
platelet response to the damaged vessel wall needed for homeostasis. Currently, about 50
million patients in the United States take ASA at typical doses of 81 or 325-mg per day to
reduce cardiovascular risks[40].
Aspirin reduces the activation of platelets by irreversibly acetylating serine 529 of
cycloxygenase-1 and therefore reducing TXA2 production[39]. The inhibition of COX-1 is
irreversible and permanent for the lifetime of platelets because platelets lack the synthetic
machinery to produce new protein[41]. Recently, the bleeding risks associated with aspirin
led to the development of anti-inflammatory drugs selective for COX-2. Several COX-2
selective inhibitors cause less gastrointestinal side effects than traditional non-steroidal antiinflammatory drugs[42], but they cause cardiovascular risks via inhibition of COX-2
dependent endothelial prostacyclin. All approved COX-2 inhibitors have either been
withdrawn or their prescription restricted[43].
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However, with regards to COX-1 inhibitors, patients show a marked variability in
laboratory responses to aspirin. Depending on the platelet function test, aspirin resistance
has been reported in 5-60% of patients[44–46]. Failure to actually take the pill is a welldocumented cause of apparent “aspirin resistance”[47,48]. Mutations in the thromboxane
receptor would also cause aspirin insensitivity, but such mutations result in a modest
bleeding phenotype that would be a contraindication for aspirin therapy[49]. Patients may
also fail to benefit from aspirin therapy owing to increased platelet turnover, increased
sensitivity to ADP and collagen[41], or increased COX-1 synthesis. However, an association
between aspirin resistance detected by a laboratory test in patients and a higher vascular
event rate in a group of resistant individuals has yet to be convincingly shown[50,51].
Determination of the anti-platelet effectiveness of pharmacological agents often
occurs in closed systems, with or without flow. Measurement of platelet calcium
mobilization upon TP stimulation is an example of a closed system with no flow[5]. Platelet
aggregometry is a closed system with a poorly defined flow field. The efficacy of
pharmacological agents in closed systems may not always predict anti-platelet therapeutic
benefits under flow conditions. For example, apyrase is a potent inhibitor in a tube but can
potentiate thrombosis under flow due to the dynamics of local levels of ATP and ADP in a
concentration boundary layer[34]. During platelet deposition under flow conditions, the
platelet deposit can reach platelet densities that are 50 to 200-fold greater than that of
platelet rich plasma. Because of this dense platelet deposit, the potency of pharmacological
agents may depend on the local concentration of platelet release products that occur under
flow conditions[52]. The advent of microfluidic technology has enabled such platelet
16

deposits to be built under flow[34,53].Microfluidic patterning techniques allow for spatially
confined injury models distinct from current technologies such as perfusion of whole blood
through coated glass capillary flow chambers or parallel plate flow chambers. Furthermore,
microfluidic devices recreate the progression of signaling and thrombotic pathways as they
progress from a surface trigger, i.e. collagen and/or thrombin produced at the wall to
secondary aggregation processes driven by ADP and TXA2[37,52]. Here we investigated the
utility of an 8-channel microfluidic device in assessing ASA phenotype using fluorescently
labeled platelets with ASA added to whole blood in vitro, either before ASA intake or at 24 h
after ASA intake by healthy individuals. We show a novel method to measure residual COX1 function and evaluation of the COX-1 mediated thromboxane A2 pathway in a
microfluidic platelet function test under venous flow conditions.

2.2 Materials and Methods
2.2.1

Blood Collection, Labeling, and Drug Administration
Blood was collected at 0 h and 26 h by venipuncture from 28 healthy subjects (18-55

years), who self-reported non-smoking, free from oral medication and abstained from,
caffeine, alcohol, and high fat food for 24 h prior to the study and throughout the duration
of the study. All volunteers received a 325-mg loading dose of aspirin by mouth at 2 h.
Subjects returned after a 2 week washout period for a third blood draw (Figure 2-1A). For
arterial flow studies, blood was collected by venipuncture from 4 healthy individuals who
were free of oral medication for 10 days and self-reported free from disease or bleeding
disorders. All blood samples were drawn into H-D-Phe-Pro-Arg-chloromethylketone (100
17

µM PPACK final concentration, Haematologic Technologies). PPACK is a potent active site
inhibitor of thrombin that irreversibly and specifically inactivates thrombin. All volunteers
provided informed consent in accordance with IRB approval and the Declaration of
Helsinki. The blood was treated with PE Mouse Anti-Human CD61 (αIIbβ3) antibody (BD
Biosciences) in a ratio of 1:50. PPACK-treated whole blood was perfused through the
microfluidic device within 1 h of phlebotomy. For in vitro additions to whole blood,
acetylsalicylic acid (Sigma Aldrich) was dissolved in DMSO at 500 mM. Dilutions of ASA
were then made to the desired final concentration in HBS within 1 h of the test. Final ASA
concentrations used were: 0 µM, 0.05 µM, 0.5 µM, 1 µM, 5 µM, 10 µM, 50 µM, 500 µM (final
0.1 % DMSO in all samples). Blood was incubated for 30 min in ASA before initiation of
the assay.
2.2.2

Fabrication of microfluidic devices, platelet deposition, and real-time imaging
Microfluidic devices were fabricated in poly(dimethylsioxane) (PDMS, Sylgard 184,

Ellsworth Adhesives) according to previously described techniques[34]. The device was fed
by 8 distinct wells, with perfusion by withdrawal into a syringe pump (Harvard Apparatus)
from a single outlet (Figure 2-1B). The channels were spaced in close proximity to allow all
channels to be imaged simultaneously with a 2X objective lens using an inverted microscope
(IX81, Olympus America) equipped with a charge-coupled camera (Hamamatsu). A custom
stage insert held 3 microfluidic devices allowing 24 simultaneous clotting events to be
imaged in 15 sec intervals. A micropatterning device with a single channel (5 cm x 250 µm x
50 µm) was used for patterning collagen. Equine fibrillar collagen type 1 (Chronopar,
Chronolog) was diluted to 250 µg/mL in isotonic glucose solution (Chronopar, Chronolog).
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Prior to perfusion, channels were blocked with 0.5% bovine serum albumin (BSA) in 2-[4(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES) buffered saline (HBS, 20
mmol/L HEPES, 160 mmol/L NaCl, pH 7.5) for 30 min. Samples were perfused at an
initial venous wall shear rate of 200 s-1 (2 µL/min per channel) for 5 min. For arterial studies,
an initial wall shear rate of 1000 s-1 (10 µL/min per channel) was used for 5 min. The
respective shear rates for venous and arterial studies were established previously in other
assays with the same microfluidic device[34,37].
2.2.3

IC50 Calculation and ASA Sensitivity
Background-corrected fluorescence values were fit with a four parameter dose-

response curve ((Equation 2-1):
(Equation 2-1)
𝑭𝑰 = 𝑨 +

𝑨−𝑩
𝟏+𝟏𝟎[(𝑳𝒐𝒈 𝑰𝑪𝟓𝟎 −𝑪)∙𝑫]

with C representing the ASA concentration, FI the background corrected fluorescence of the
corresponding region of interest, A and B the minimum and maximum intensities,
respectively, and D the Hill coefficient. The data were fit using a log(inhibitor) vs. response
routine by GraphPad Prism 5.00 (GraphPad Software). Analysis of platelet deposition and
total platelet accumulation on collagen was also calculated using the change in the
background-corrected fluorescence values over time between time intervals 60 to 150 sec for
collagen deposition and 150 to 300 sec for TXA2-dependent secondary aggregation (F’ = ∆
F/∆ t between 60-150 sec or 150-300 sec). A ratio of these two slopes (R-value) was then
taken as an internally normalized value for each subject with R > 1 when secondary
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aggregation was prominent and R < 1 when secondary aggregation was attenuated relative to
the primary response to collagen (primary deposition) (Figure 8-2, Table 6).

Figure 2-1 ASA phenotyping protocol and quantification of ASA concentrationresponse
(A), Study protocol. Blood samples were taken at t = 0 h and t = 26 h with ASA administration to each healthy
donor at t = 2 h, followed by a second blood draw 2 weeks later. For each blood sample, increasing amounts of
in vitro ASA was added to PPACK-inhibited WB prior to microfluidic testing (3 replicate tests per blood
sample). (B), Photograph of the 8-channel microfluidic device with the micropatterned collagen strip digitally
indicated. (C & D), Epifluoresence images of fluorescently labeled platelet accumulation on the collagen and
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platelet interaction zone with various in vitro ASA concentrations, either in randomized positions (C) or ordered
by ASA concentration (D). (E), Platelet fluorescence values over time for each in vitro ASA concentration. (F),
Schematic summary of secondary platelet aggregation and definition of R value on the basis of platelet
deposition rates (F’).

2.3 Results
A protocol was established (Figure 2-1A) for the recruitment of healthy
donors (n = 28, Table 1) to obtain 3 venous blood samples. Relevant characteristics of the
subjects are reported (Table 1). The first blood sample was collected at t = 0 h, followed by
ASA ingestion at t = 2 h, and collection of a second sample at t = 26 h, 24 h after in vivo
ingestion of 325-mg of ASA by all subjects (Period 1). A third venous sample was collected
after a 2 week washout period at t = 0 h (Period 2). With each of the 3 blood samples
obtained from each donor during Period 1 and 2, ASA was added in vitro at increasing doses
from 0 to 500 µM ASA prior to running the 300 sec microfluidic test (8 doses run in
triplicate per blood draw at an initial wall shear rate of 200 s-1), for a total of 2304 individual
clotting events. All results shown are an average of triplicate measurements.
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Subject
ID

Age

BMI

Gender

Platelet Count
Period 1
(x1000
platelets/µL)

Platelet Count
Period 2
(x1000
platelets/µL)

%
Hematocrit

217

25

27.08

M

190

187

43

246

30

24.28

F

183

171

36

272

22

21.65

F

280

275

39

259

43

20.14

M

220

247

39

262

37

24.18

M

274

233

41

225

31

24.47

F

216

217

36

250

44

24.77

F

227

216

38

241

26

19.47

F

204

227

40

283

37

28.28

F

206

176

38

268

31

27.59

M

293

262

44

203

33

29.71

M

216

226

44

248

33

20.84

F

300

288

38

239

52

24.58

F

225

301

37

216

27

24.98

F

182

195

36

226

51

23.51

F

226

222

34

235

21

20.73

F

189

216

36

238

26

17.54

F

150

183

37

240

48

31.79

M

182

149

40

255

25

20.02

F

183

181

44

212

29

23.92

M

272

191

44

231

35

27.33

M

209

209

45

243

23

19.46

F

235

230

40

278

22

20.37

F

261

258

36

293

37

20.59

F

283

285

39

253

44

26.18

M

224

245

46

256

29

19.12

M

176

176

40

277

25

20.34

F

196

182

36

282

44

M

243

234

45

Average

33 ±
9

28.52
23.62
±
3.70

11M/17F

223 ± 40

220 ± 39

40 ± 3.5

Table 1. Donor Attributes
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Healthy subject age, BMI, gender, platelet count for period 1 and 2, and %Hematocrit were measured and data
is presented above.

2.3.1

IC50 for ASA during thrombosis under flow
Ex vivo addition of ASA to whole blood was tested in the device in a concentration-

dependent manner to calculate IC50 values for collagen induced platelet deposition (Figure
2-1). In each experiment, a total of 24 simultaneously forming thrombi were imaged in real
time. Fluorescently labeled platelets aggregated only at the site of micropatterned collagen,
with no platelet deposition upstream or downstream of the micropatterned collagen (Figure
2-1C,D). Platelet adhesion due to collagen occurred within 60 sec and secondary platelet
accumulation/aggregation continued after 150 sec of perfusion (Figure 2-1E, Figure 8-2).
Inhibition of secondary platelet adhesion by ASA was measured through the R-value
(Figure 2-1F). Determination of platelet surface fluorescence at 300 sec (FI300s) allowed a
measurement of an IC50 of 22 µM ASA (Figure 2-2AFigure 2-1) for an in vitro ASA
incubation time of 30 min for Subject 272. The collagen-induced platelet activation was
temporally separated and preceded the ASA-sensitive deposition regime. A dose-dependent
decrease in platelet deposition rate (F’ from 150 to 300 sec) was observed with increasing
ASA concentration while the initial platelet deposition rate (F’ between 60 and 150 s) was
ASA insensitive (Figure 2-2B). Finally, internal normalization (Figure 2-2C) of late stage
F'150-300s divided by early stage F'60-150s provides a R-value of 1.0 near the ASA IC50 of 10 µM.
This R value showed more dynamic range and sensitivity related to secondary platelet
aggregation due to TXA2 release causing a minor left shift in the IC50 value to 10 µM. The
ASA dose-response was also obtained by in vitro addition of ASA to whole blood 24 h after a
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single 325-mg dose was ingested by subjects. Representative subject 255 lacked response to
in vitro addition of ASA demonstrating strong inhibition of platelet COX-1 activity by the
325 mg dose (Figure 2-2D).

Figure 2-2 Platelet deposition from PPACK-inhibited WB treated with increasing in

vitro ASA at 200 s-1 initial wall shear rate over fibrillar collagen for period 1 (t= 0 h, no
ASA ingestion).
(A), Representative IC50 curve for in vitro ASA dose-response. (B), In order to separate COX-1 mediated
TXA2 production from the platelet-collagen response, F’ = ΔF/Δt was calculated for the initial time interval of
60 to 150 sec and secondary aggregation platelet deposition rate was calculated during the time interval of 150
to 300 sec. Initial platelet deposition rate from 60 to 150 sec was ASA-insensitive. (C), Normalization of
subject response to in vitro ASA using the R-value. (D), In vitro addition of ASA at 26 h (open circle) had no
efficacy after donors took ASA (325mg) at 2 h
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2.3.2

Microfluidic ASA Phenotyping and in vitro addition of aspirin after oral
administration
Microfluidic phenotyping of whole blood 24-h after a single 325-mg dose was

ingested showed that 27 of 28 subjects had some reduction in total platelet accumulation
relative to total platelet accumulation measured in blood prior to ASA ingestion (Figure
2-3A). Only Donor 253 displayed a slight increase in platelet deposit size, which was not
statistically significant. Marked inter-subject variation in the amount of baseline platelet
deposition was observed, with FI300s values ranging from below 4000 to above 12000 FI.
However, the microfluidic assay detected the decrease in total platelet accumulation
following in vivo ASA ingestion. Platelet deposition from blood obtained 24 h after ASA
ingestion (no additional in vitro ASA added) was inhibited relative to the platelet deposition
measured for blood prior to ASA ingestion (Figure 2-3B). The degree of inhibition of
platelet deposition for these 28 subjects at 24 h after ASA dosage ranged from 10 to 90 %
(45 % ± 23%; P < 0.001, n = 28) (Figure 2-3B). When comparing each subject at 26 h to
their response at 0 h, subjects with ≥ 25 % inhibition (16 of 28 subjects) displayed
statistically significant inhibition (Figure 2-3B, P < 0.05). In comparing platelet deposition
(FI300s) in response to in vitro 500 µM ASA addition relative to in vitro 0 µM ASA addition, the
in vitro addition of high dose ASA was very potent in blood obtained from subjects prior to
ASA ingestion where 24 of 28 subjects responded to in vitro ASA addition (Figure 2-3C, solid
bar). Only 4 of 28 subjects (Donors 217, 250, 240, 253) lacked significant inhibition with in
vitro ASA addition to blood obtained prior to in vivo ASA ingestion. In contrast, only 7
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subjects of 28 displayed sensitivity to in vitro 500 µM ASA addition 24 h after ASA ingestion
(Figure 2-3C, open bar).

Figure 2-3 Microfluidic ASA Phenotyping of donors
(A), Ingestion of ASA at t = 2 h resulted in smaller platelet deposits compared to the response obtained from
blood prior to ASA ingestion at t = 0 h (28 donors). *P < 0.05, relative to each donor at t = 0 h. Percent
inhibition of platelet deposition as a measure of in vivo ASA efficacy at 26 h, as assessed by 8-channel
microfluidic assay. *P < 0.05, relative to each donor at t = 0 h. (B). Comparison of high dose in vitro addition
of 500 µM ASA measured for whole blood obtained before (t = 0 h) or 26 h after oral ASA administration (t =
2 h) (C). Data are mean ± SD (3 replicates).
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2.3.3

Microfluidic Assay for measuring platelet deposition in the presence of aspirin
For the 28 healthy donors with platelet counts in the normal range, no correlation

between the extent of platelet deposition on collagen and platelet count was observed
(Figure 2-4A). Subject platelet counts were highly correlated between period 1 and period 2,
indicating the ability of the body to tightly regulate total platelet count (Figure 2-4B). Total
platelet deposition (FI300s) showed a weak but positive correlation between period 1 and
period 2 (Figure 2-4C).
Using the R-value as a normalized metric of secondary aggregation for each subject,
22 of 28 subjects had R > 1 in Period 1 and 23 of 28 subjects had R > 1 in Period 2 (Figure
2-4D). Interestingly, only 2 of 28 subjects had R < 1 in both trial periods (Figure 2-4D,
lower left quadrant), suggesting that almost all donors have a secondary aggregation response
(i.e. R > 1) that was detectable in a microfluidic assay when aspirin was absent. All 28
cohorts as a group had an average R = 1.21 ± 0.34 and 1.16 ± 0.22 in period 1, 0 h and
period 2, 0 h respectively from 168 determinations of this metric displaying sensitivity and
specificity to score secondary aggregation upon no in vitro ASA treatment in this microfluidic
assay (P < 0.05, n = 28). In contrast, with 500 µM ASA added in vitro, only 3 of 28 donors
displayed R(500 µM ASA) > 1 in both Period 1 and 2 (Figure 2-4E) demonstrating that
almost all subjects had platelet function that were sensitive to inhibition by ASA. With
respect to the in vivo activity of ASA, 21 out of 28 subjects had R < 1 at 24 h after ingestion
of a 325-mg dose (no ASA added in vitro) (Figure 2-4F). In these subjects, the addition of
500 µM ASA in vitro did not further inhibit platelet function since the platelets had already
been inhibited by ASA in vivo. Interestingly, the 7 of 28 subjects who had R>1 following
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ASA ingestion also displayed insensitivity following in vitro ASA addition (upper right quadrant,
Figure 2-4F).
A detailed Receiver-Operator Curve (ROC) analysis (Figure 8-3, Figure 8-4Figure
8-3) indicated that an R-value = 1 cut-off resulted in a true positive rate of 71 % (sensitivity)
and a false positive rate of 36 % (or 64 % specificity) when comparing donors pre and postASA ingestion. Similarly, when comparing donors pre and post in vitro ASA addition, the Rvalue = 1 cut-off resulted in a true positive rate of 75 % (sensitivity) and a false positive rate
of 33 % (or 67 % specificity).

Figure 2-4 Microfluidic assay characterization of in vitro ASA response: R value
(A), Final thrombus size measured by final platelet fluorescence without in vitro ASA at t = 300 sec vs. donor
platelet count in period 1 (no ASA ingestion). (B), Donor platelet count in period 1 vs. donor platelet count in
period 2 after 2-week ASA washout period. (C), Final thrombus size without in vitro ASA addition at t = 300
sec in period 1 vs. final thrombus size without in vitro ASA addition at t = 300 sec in period 2. (D), R value for
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secondary platelet aggregation (no ASA ingestion; no in vitro ASA added) in both periods. (E), R value for highdose in vitro ASA inhibition of secondary platelet aggregation in both periods 1 and 2 (no ASA ingestion) (F), R
value for high-dose in vitro ASA addition vs zero in vitro ASA addition in period 1 in blood exposed in vivo to
ASA (ASA ingestion at 2 h).

2.3.4

Effect of in vitro ASA at arterial flow conditions
ASA is used to reduce the incidence of arterial thrombosis. In these microfluidic

assays, we have observed that arterial shear rates of 1000 to 2000 sec-1 cause unstable
thrombi with pronounced embolism, especially when thrombin or fibrin is absent (19). This
is especially relevant for experiments conducted at constant flow rate (as opposed to
constant pressure drop) where clot growth can cause high shear stresses to occur as the clot
partially occludes the flow path. To investigate the pharmacological potency of ASA at
arterial shear rates, IC50 curves were calculated using the same microfluidic assay by
measuring platelet accumulation on collagen under the influence of in vitro ASA addition at
1000 s-1. Comparison of the same 4 donors who did not participate in the study protocol
previously mentioned at both venous (Figure 2-5A) and arterial (Figure 2-5B) shear rates
indicate the efficacy of ASA under both flow conditions. The slightly lower IC50 at 1000 s-1,
although not significantly different, compared to the value found at venous shear rate may
be due to the reduced levels of TXA2 in the boundary layer at higher shear rates[34]. Further
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work will be necessary to determine if the IC50 depends on wall shear rate.

Figure 2-5 Response to in vitro ASA dosing: a comparison of venous vs. arterial
initial wall shear rate
Representative IC50 curves for ASA at venous (A) and arterial (B) wall shear rates (4 donors). A total of 9
microfluidic assays were run at each initial wall shear rate for the 4 donors.

2.4 Discussion
We demonstrated that whole blood microfluidic assays and the data generated from
these assays can produce an aspirin dose-response curve under flow conditions based upon:
final platelet fluorescence (FI300s in Figure 2-2A), platelet deposition rate between 150 and
300 sec (F'300-150s in Figure 2-2B), or the R-value which is a normalized metric of secondary
platelet aggregation (Figure 2-2C). For each of these metrics, the IC50 of aspirin was
between 10 and 20 µM which is quite consistent with the known Kd = 4.5 µM of ASA
against COX-1 [54]. The effect of COX-1 inhibition on donor platelet function after 150 sec
in this flow assay is consistent with previous findings in the same microfluidic device and a
multi-scale neural network and Monte Carlo simulation of platelet deposition under flow
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[52]. Furthermore, this onset of action of ASA is consistent with aggregometry results
showing action of COX-1 inhibitors at the later stages after primary aggregation [55]. The
assay partially detected the in vivo efficacy of ASA ingestion on platelet COX-1 when whole
blood was tested ex vivo (Figure 2-3). Lack of statistical significance of in vivo modulation of
platelet COX-1 activity due to ASA ingestion in 12 of the 28 subjects tested could be
attributed to varying interdonor functionality of TP, P2Y1, and P2Y12 receptors. Interdonor
changes in P2Y1 and P2Y12 receptor response modulate ADP flux from the growing
thrombus under flow conditions hence causing variations in total platelet accumulation and
the R value. Healthy subjects who ingested 325-mg ASA displayed 45 % smaller platelet
deposits on average when the blood was tested 24 h after dosing (Figure 2-3B). Whereas
healthy donors have platelets that display thromboxane-dependent secondary aggregation in
the flow assay (only 2 of 28 donors had R < 1; Figure 2-4D), healthy donors have platelets
that respond to ASA administered ex vivo (only 3 of 28 donors had R > 1 in duplicate tests of
500 µM ASA added ex vivo; Figure 2-4E).
These microfluidic assays bring together contributions from platelet collagen signaling,
granule release, ADP signaling, thromboxane synthesis, and adhesion strength under flow
conditions. Thus, the pharmacological effects of COX-1 inhibition were investigated under
far more complex conditions than an assay that measures thromboxane synthesis. While the
effects of aspirin ingestion or in vitro aspirin addition are clearly detectable in our assay, the
capabilities of this microfluidic assay to detect "aspirin resistance" for patients with
cardiovascular diseases remains unknown, as this study was limited to healthy subjects.
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Several platelet function tests currently exist, however these technologies that assess
aspirin sensitivity in whole blood have limitations, especially with regards to running a doseresponse assay requiring multiple tests. Dose-response assays are fundamental
pharmacological tools to quantify drug potency or remaining enzyme activity. The Platelet
Function Analyzer (PFA-100) and VerifyNow are tests used to assess inhibition of platelet
function by aspirin using whole blood. PFA-100 deploys a cartridge to create flow and
measure puncture closure time with an activating coating of collagen/ADP or
collagen/epinephrine [56]. The assay is highly dependent on plasma vWF, high shear stress,
and epinephrine thus presenting difficulties in isolating the inhibitory effects of aspirin [57].
VerifyNow Aspirin is a point of care assay utilizing whole blood in standard cartridges
containing a preparation of human fibrinogen-coated beads and arachidonic acid as agonists
[56]. VerifyNow Aspirin is an assay based on light transmittance but lacks a hemodynamic
flow field. Most recently development of a perfusion chamber allows for study of ASA
dependent changes in platelet deposition [58]. Our methodology is distinct from Stephens et
al. where whole blood was perfused through an entire glass capillary coated with human type
III fibrillar collagen at 1000 or 1500 sec-1. A collagen-coated capillary creates a long distance
of many centimeters of collagen for platelets to activate, adhere, embolize, and recapture on
the surface. Platelet deposition is a function of distance from the entrance in this assay due
to boundary layer depletion of platelets over the long length of collagen. Since only one
capillary is run at a time, dose-response testing is particularly cumbersome. In contrast, our
8-channel microfluidic perfusion of whole blood over fibrillar collagen exposes platelets to a
spatially-confined 250 µm long "injury" site where all the data is collected with no
32

dependence on distance down the microfluidic channel. The 8-channel microfluidic device
facilitated the ex vivo testing of anti-platelet drugs in a dose-dependent manner over a large
cohort of healthy donors.
The biology of thrombosis includes the interaction of platelets with potent vessel wallderived stimuli including collagen and thrombin. As a layer of platelets becomes activated
on collagen, they recruit additional platelets via release of ADP and TXA2. By targeting the
secondary wave of platelet recruitment with P2Y12 antagonists and/or cyclooxgenase-1
inhibitors, an anti-thrombotic effect is achieved with reduced risk of bleeding in comparison
to other antithrombotic therapies that target biologically active clotting factors like warfarin.
Few assays recreate the sequential process of collagen adhesion followed by the release of
autocrine factors. Since platelet recruitment, adhesion, and the convective-diffusion of
autocrine agents are dictated by prevailing hemodynamic conditions [34], microfluidic assays
partially recreate the disease environment in which anti-platelet agents must act. We
demonstrate the use of microfluidic assays to evaluate healthy subject response to aspirin.
Supplemental discussion about this chapter, including additional discussion topics and data,
is presented in the appendix of this dissertation.
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3

DETECTION OF PLATELET SENSITIVITY TO INHIBITORS
OF COX-1, P2Y1, and P2Y12 USING A WHOLE BLOOD
MICROFLUIDIC ASSAY

3.1 Introduction
Antiplatelet therapies are used in a variety of clinical settings from management of
unstable angina to risk reduction of myocardial infarction or stroke. Aspirin is used by over
50 million patients in the United States to reduce the risk of cardiovascular events[40].
Aspirin irreversibly acetylates serine 529 of cyclooxygenase-1 (COX-1), blocking the enzyme
active site for arachidonic acid and inhibiting the generation of prostaglandin H2 and thus
thromboxane A2 (TXA2) production from platelets[59]. Inhibition of platelet TXA2 synthesis
prevents platelet activation through the platelet TXA2 receptor (TP), a receptor encoded by
the TBXA2R gene.
In addition to TXA2, adenosine disphosphate (ADP) receptors are another target of
antiplatelet therapies. The platelet plasma membrane contains two ADP receptors, P2Y1 and
P2Y12, which are purinergic G protein coupled receptors. P2Y1 is linked to Gq and ADP
signaling through this pathway results in rapid Ca2+ mobilization and platelet shape change
[11,60]. P2Y12 is linked to a Gi protein. ADP binding to P2Y12 inhibits adenylate cyclase and
stabilizes secondary platelet aggregation. Current therapies that target the P2Y12 receptor
range from prodrugs that irreversibly antagonize the P2Y12 receptor to direct, reversible
antagonists[60,61]. The thienopyridines clopidogrel and prasugrel are examples of the
former, while ticagrelor is an example of the latter. Currently, no P2Y1 antagonists are on
the United States drug market, however, combined P2Y1 and P2Y12 antagonists are in
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development[62]. To mimic the action of P2Y1 and P2Y12 antiplatelet therapies ex vivo, 2'deoxy-N6-methyl adenosine 3',5'-diphosphate (MRS 2179) and 2-methylthioadenosine 5monophosphate (2MeSAMP) are used in this study as highly selective P2Y1 and P2Y12
antagonists, respectively.
Targeting signaling pathways such as TXA2 production and ADP/P2Y12 signaling
reduces secondary platelet aggregation while not severely altering primary hemostasis.
However, the delicate balance between preventing excessive clotting and increasing bleeding
risks requires careful monitoring of antiplatelet therapies. The evaluation of the effect of
pharmacological agents on platelet function often rely on tests with poorly defined fluid
mechanics and flow fields (eg. aggregometry) that fail to replicate platelet adhesive
mechanisms under realistic and well geometrically-defined hemodynamic conditions. Under
flow conditions, the efficacy of pharmacological agents greatly depend on granule release,
platelet-platelet contacts, and convective removal of autocrinic agonists from the injury site.
Microfluidic devices can recreate the hemodynamic conditions required to study anti-platelet
agents. These devices offer spatially controlled focal injuries with collagen or collagen with
tissue factor bearing surfaces[35,37]. Microfluidic devices have also been used to study clot
contraction and clot permeability with precise control of wall shear stress and transthrombus
pressure gradients [13,63]. In fact, the core-shell hierarchy of clots observed in vivo
following laser injury [9] can be replicated in vitro with such devices[63].
Here we continue the development of microfluidic assay metrics found previously[64]
and extend these metrics to examine two ADP antagonists and validate this assay for
detection of anti-platelet therapies through Receiver-Operator Characteristic (ROC) analysis.
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For flow assays to become a relevant clinical tool a large cohort of healthy donors must be
tested with respect to response to antiplatelet agents. Toward that goal, we tested healthy
subject platelet function with 38 donors and 66 independent blood draws (2 combined
studies) following ex vivo addition of ASA. While coagulation assays can rely on stable
pooled plasma for calibration, live platelet function assays have no available standard to
calibrate the assay. We sought to define a self-normalized parameter, the R-value, to score
platelet accumulation on collagen surfaces from a single blood sample test without reference
to a prior test value or calibration fluid.

3.2 Materials and Methods
3.2.1

Blood collection, labeling, and antiplatelet agents
Blood was collected via venipuncture from 11 healthy subjects who self-reported as

non-smoking, free of oral medication, and abstained from alcohol 48 h prior to donation. All
subjects were free from illness and bleeding disorders. Blood samples were drawn into H-DPhe-Pro-Arg-chloromethylketone (100 µM PPACK final concentration, Haematologic
Technologies). All volunteers provided informed consent in accordance with IRB approval
and the Declaration of Helsinki. Whole blood was treated with Phycoerythrin (PE) Mouse
Anti-Human CD61 (αIIbβ3) antibody (BD Biosciences) in a ratio of (1:50) 7 min prior to
perfusion. This antibody has no effect on platelet αIIbβ3 function in this microfluidic flow
assay. PPACK-treated whole blood was perfused through the device within 25 min of
phlebotomy. Blood was incubated with vehicle (0.1% DMSO final concentration) or
indicated concentrations of ASA, 2MeSAMP, MRS 2179, or combined 2MeSAMP and MRS
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2179 20 min prior to the assay. This time scale is consistent with previous studies done with
these compounds[34,52,64]. Acetylsalicylic acid (ASA, Sigma Aldrich) was dissolved in
DMSO at 500 mM, 2-methylthioadenosine 5′-monophosphate triethylammonium salt
hydrate (2MeSAMP, Sigma Aldrich) was dissolved in HEPES buffered saline (HBS, 20 mM
HEPES, 160 mM NaCl, pH 7.5) at 1 mM/L, and 2'-deoxy-N6-methyladenosine 3', 5'bisphosphate ammonium salt (MRS 2179, Tocris Bioscience) at 0.1 mM in HBS. A dilution
of ASA was then made to the desired final concentration in HBS within 1 h of the test. Final
concentrations of antiplatelet therapies used were: 500 µM ASA, 100 µM 2MeSAMP, and 10
µM MRS 2179, well in excess of their IC50s in the assay of 10-20 µM ASA, 2.56 µM
2MeSAMP, and 0.23 µM MRS 2179 respectively[34,64]. Antiplatelet agent concentrations
were used well in excess of their respective IC50 values to completely antagonize ADP
receptors or abate COX-1 derived TXA2.
3.2.2

Microfluidic devices and real time platelet deposition imaging
Microfluidic devices were fabricated in polydimethylsiloxane (PDMS, Sylgard 184,

Ellsworth Adhesives) according to previously described techniques [34,64]. The microfluidic
device has 8 parallel channels (250 µm wide by 60 µm high) that converge to a common
outlet(Figure 3-1A). The device was fed by 8 distinct wells, with perfusion achieved by
withdrawal into a single syringe pump (Harvard Apparatus). The channels run
perpendicularly over a 250 µm long stripe of patterned equine fibrillar collagen type 1
(Chronopar, Chronolog). Channels were spaced in close proximity to image all 8 eight
channels simultaneously with a 2X objective lens using an inverted microscope (IX81,
Olympus America Inc.) equipped with a CCD camera (ORCA-ER, Hamamatsu). A custom
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stage insert held 3 microfluidic devices allowing formation of 24 simultaneous thrombi to be
imaged in 15 sec intervals. Prior to microfluidic assay, all channels were blocked with 0.5%
bovine serum albumin (BSA) in HBS buffer. Blood samples were perfused at an initial
venous wall shear rate of 200 s-1 for 5 min (2 L/min per channel).
3.2.3

Platelet accumulation analysis
Background corrected fluorescence values were measured using MATLAB

(MathWorks) as previously described [34]. Briefly, all eight platelet deposits on a single
microfluidic device were identified and corrected with their corresponding background
regions downstream of each platelet deposit by a custom MATLAB script. To calculate
overall percent inhibition after a 300 s perfusion, platelet fluorescence values were
normalized to each donor's baseline platelet adhesion to collagen (FI300s(Drug)/FI300s).
Additionally, a R-value for ASA (RCOX) was defined as a ratio of platelet deposition rates that
normalized the late stage platelet deposition rate (F'300-150s) to early stage deposition rate (F'150) for all ex vivo ASA additions, as previously established[64]. The RCOX value is an internal
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intradonor standard to score secondary aggregation due to TXA2 secretion, with values of
RCOX > 1 indicating when secondary platelet aggregation was prominent and RCOX < 1 when
secondary aggregation was attenuated by ex vivo ASA treatment (Figure 3-1C). In a
previous work, a dose-dependent decrease in the rate of secondary platelet aggregation was
found with increasing ex vivo ASA concentrations whereas the initial platelet deposition rate
on collagen was unaffected by ASA. We now define an additional intradonor normalization
metric RP2Y as a ratio of platelet deposition rates normalizing late stage secondary platelet
aggregation rate due to ADP release (F'300-105s) to earlier stage platelet deposition rate (F'105-60s)
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(Figure 3-1D). The temporal onset for RP2Y was based on previous work[52] establishing
that the effect of ADP antagonism occurred after 100 sec, as was later confirmed in platelet
dynamic traces for ADP antagonists for the 11 donors in this present study (Figure 3-1B).
Finally, sensitivity and specificity for detection of ASA, 2MeSAMP, or MRS 2179
was found through Receiver Operator Characteristic (ROC) analysis[65]. ROC curves were
generated to detect the presence of each drug in the microfluidic assay through evaluation of
the true positive and false positive fractions and the area under the curve (AUC) [65]. In this
analysis, for each antiplatelet therapy tested, ROC curves were generated comparing 10
average R-values, one from each of the 10 healthy subjects with no ex vivo inhibition to 10
average measurements of the R-value for each anti-platelet drug tested.
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Figure 3-1 Eight-channel device, measured platelet fluorescence dynamics, and RCOX,
RP2Y schematic summaries.
(A), Photograph of the 8-channel microfluidic device, the device is fed by 8 wells converging into a single
outlet. (B), Platelet fluorescence values over time in the presence of aspirin, 2MeSAMP, and MRS 2179. Error
bars indicate standard deviation from 6 measurements at each time point. (C), Graphic representation of RCOX
based on a ratio of platelet deposition rates (F') of secondary platelet aggregation to initial platelet deposition
on collagen. (D), Graphic representation of RP2Y.

3.3 Results
Ex vivo testing of anti-platelet agents occurred in duplicate on 3 separate microfluidic
devices run simultaneously. For 11 subjects, a total of 432 individual thrombi were formed
under flow on collagen, resulting in 108 events each for 3 individual conditions (control,
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2MeSAMP, and MRS 2179), 60 events for ex vivo ASA addition, and 48 events for ex vivo
addition of 2MeSAMP and MRS 2179. Statistical analysis was conducted to evaluate
intradonor variations for duplicate control conditions on a single microfluidic device or 3
devices run simultaneously (6 conditions). Total platelet accumulation (FI300s) and secondary
aggregation [RCOX(0)] values for whole blood perfusion with vehicle buffer were tabulated
from 11 blood samples and the coefficient of variation for each donor defined as standard
deviation divided by the mean was found (Table 7, Table 8). Coefficients of variation for
FI300s ranged from 5.3% to 35.8% (mean = 13.1%) for replicate channels on a single device
while values varied from 5.3% to 24.4% for triplicate microfluidic testing (mean = 16.3%).
For RCOX (0), coefficient of variation values were all < 20% for a single microfluidic device
or triplicate device testing with the exception of donor 4 and donor 10. In 3 comparisons
evaluating ex vivo ASA efficacy (Figure 3-5), prior supplementary data for 28 individuals
[64] obtained in the same manner as this study was combined with data from 10 subjects
from this work. Only 1 subject partook in both studies.
Platelets adhere substantially to the localized collagen surface within 1 minute and
subsequent secondary platelet accumulation via platelet-platelet interactions over the 300 s
perfusion time has been well-established in previous studies [34,52]. Growth in platelet
coverage occurs in two dimensions on the collagen surface between 60 -105 sec. After 105
sec, thrombus growth continues in the third dimension and thrombus height under flow
increases significantly due to secondary platelet-platelet aggregation mediated by soluble
agonists such as ADP and TXA2 at approximately 105 s and 150 s, respectively.
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3.3.1

Platelet inhibition by ASA, 2MeSAMP, and MRS 2179
Platelet adhesion and subsequent secondary platelet aggregation were significantly

reduced upon ex vivo addition of ASA, 2MeSAMP, or MRS 2179 (Figure 3-1B). Using RCOX
or RP2Y (Figure 3-1C, D), 8 out of 10 subjects displayed significant secondary platelet
aggregation [R(0 drug) > 1] before ex vivo drug addition (Figure 3-2A-C). In contrast, 9
out of 10 subjects had RCOX < 1 upon ex vivo treatment with ASA (Figure 3-2A).
Furthermore, 9 out of 10 subjects had RP2Y < 1 with ex vivo 2MeSAMP addition,
demonstrating that most subjects had secondary platelet aggregation and primary platelet
deposition that was sensitive to P2Y12 antagonism (Figure 3-2B). RP2Y was less reliable in
scoring MRS 2179 inhibition of P2Y1 with only 6 out of 10 subjects having RP2Y < 1 (Figure
3-2C), in part (ironically) due to the high potency of MRS 2179 in reducing Ca2+
mobilization through P2Y1 signaling. Hence MRS 2179 drastically reduces primary platelet
deposition in comparison to 2MeSAMP, thus the associated difficulty of taking a ratio of
two small numbers as both primary platelet deposition and secondary platelet aggregation
rate were inhibited by MRS 2179.
ROC curves were generated to examine the inhibitory effects of ASA, 2MeSAMP,
and MRS 2179 in this assay (Figure 3-2D-F). In comparing 10 measurements of RCOX(0)
(true full COX-1 activity, true full P2Y12 and P2Y1 function) to 10 measurements of RCOX
(500 µM ASA) (true full COX-1 inhibition), the ROC curve had an AUC of 0.874 (Figure
3-2D). Comparison of 10 RP2Y values at baseline to 10 RP2Y(100 µM 2MeSAMP) (true full
P2Y12 antagonism) gave an ROC curve AUC of 0.966 (Figure 3-2E). Finally, in comparing
the same 10 baseline RP2Y values to RP2Y(10 µM MRS 2179) an ROC curve AUC of 0.889 was
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obtained. Calculated ROC AUC values indicate excellent diagnostic discrimination between
populations upon ex vivo treatment with ASA, 2MeSAMP, or MRS 2179. ASA, 2MeSAMP,
or MRS 2179 all decreased total platelet accumulation at 300 sec when normalized against
baseline collagen response reaching statistical significance for the entire cohort (p < 0.01, n
= 10 subjects) and each antiplatelet agent (Figure 3-3). The % inhibition of platelet function
was much greater for 2MeSAMP and MRS 2179 than ASA. However, the effect of ex vivo
2MeSAMP and MRS 2179 were not statistically different from each other. While the %
inhibition is very useful for measuring drug potency following ex vivo drug addition, it
requires reference to a separate untreated blood sample which may not necessarily be
available clinically with patients. In contrast, the R-value is self-normalized and can be used
for a single blood sample obtained from a patient without the need to reference to a prior
blood test to obtain % inhibition.
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Figure 3-2 Microfluidic assay sensitivity and specificity of RCOX and RP2Y to detect
inhibition of primary platelet adhesion to collagen or secondary platelet aggregation
(A), Rcox for ex vivo ASA addition. (B), RP2Y for ex vivo 2MeSAMP addition. (C), RP2Y for ex vivo MRS 2179
addition. (D) ROC curve for detection of ex vivo ASA addition. (E), ROC curve for detection of ex vivo
2MeSAMP addition. (F), ROC curve for detection of ex vivo MRS 2179 addition. Error bars indicate standard
deviation from 6 measurements of RCOX or RP2Y for each donor. Dashed lines are 95% confidence intervals.
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Figure 3-3 Effect of ex vivo ASA, 2MeSAMP, or MRS2179 on final platelet aggregate
size normalized by baseline platelet aggregate size formed on collagen.
Ex vivo addition of ASA, 2MeSAMP, or MRS2179 resulted in smaller final platelet aggregate size compared to
response measured with no drug (p < 0.01, n = 10 donors)

3.3.2

Platelet inhibition by combined 2MeSAMP and MRS 2179 ex vivo addition
To investigate the effects of combined P2Y1 and P2Y12 inhibition by MRS 2179 and

2MeSAMP respectively, 7 of the 10 subjects from the above study of ex vivo addition of
either P2Y1, P2Y12, or COX-1 inhibitor alone were re-enrolled along with new subject #11.
Platelet fluorescence traces over time representing thrombus buildup during the microfluidic
assay were reduced in the case of combined P2Y1 and P2Y12 inhibition of platelet function in
comparison to ex vivo P2Y1 or P2Y12 inhibition alone (Figure 3-4A). Using MRS 2179 and
2MeSAMP together, both primary deposition rate and secondary platelet aggregation rates
were strongly reduced when compared to control or when MRS 2179 or 2MeSAMP were
used individually to inhibit platelet function (Figure 3-4A).
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Combined ex vivo addition of 2MeSAMP and MRS 2179 dramatically reduced total platelet
accumulation at 300 sec when normalized against control platelet response to collagen
(Figure 3-4B). The platelet mass at the end of 300 sec due to combined P2Y1 and P2Y12
inhibition was significantly smaller than the platelet masses due to single P2Y1 or P2Y12
inhibition (p < 0.001, n = 8 subjects) (Figure 3-4B). Because the primary deposition rate
was so strongly attenuated, RP2Y was not suited to score combined P2Y1 and P2Y12 inhibition
(Figure 3-4C). This is due to the high efficacy of combined MRS 2179 and 2MeSAMP
treatment on the primary platelet deposition rate on collagen in this microfluidic thrombosis
model. The primary deposition rate becomes exceedingly low once ADP is completely
attenuated under flow conditions through inhibiting both P2Y12 and P2Y1 signaling
pathways. ADP is a potent modulator of platelet recruitment to the initial monolayer of
platelets adherent to collagen. The R-value was originally intended to score secondary
aggregation, hence the difficulties in using RP2Y to detect a ratio of platelet deposition rates
over the two temporal ranges.

Figure 3-4 Effect of combined ex vivo addition of 2MeSAMP and MRS2179 on
platelet function in comparison to ex vivo addition of 2MeSAMP or MRS2179 alone.
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(A) Platelet fluorescence dynamics over time in the presence of ex vivo 2MeSAMP, MRS 2179, or combined
2MeSAMP and MRS 2179. (B) Ex vivo addition of 2MeSAMP and MRS 2179 reduced final thrombus size
more significantly than 2MeSAMP or MRS 2179 treatment alone when normalized against final control
thrombus size over collagen (p < 0.01, n = 8 donors). (C) RP2Y for combined ex vivo 2MeSAMP and MRS
2179 addition. Error bars indicate standard deviation for 6 measurements of RP2Y for each donor.

3.3.3

Statistics of platelet phenotyping with microfluidics using ASA
Finally, we incorporate and quantify historical supplementary data from a previous

work [64] into this study with intent to show the full distribution of microfluidic platelet
function metrics (total platelet accumulation, primary and secondary platelet deposition rates,
RCOX). Distribution of these metrics is optimal with maximum data in assessing the
capabilities of this microfluidic assay to detect the inhibitory effects of ex vivo ASA on
platelet function.
Microfluidic phenotyping of 37 donors, 10 from the current study and 28 from a
previous study [64] showed a broad distribution of primary platelet deposition rates on
collagen with no ex vivo ASA treatment (Figure 3-5A). Late stage secondary platelet
aggregation also distributed broadly (Figure 3-5A). Binning of total platelet accumulation
showed varied inter-subject platelet function response to collagen with FI300s values ranging
from 2,000 to 16,000 (Figure 3-5B). Interestingly, the 10 healthy subjects from this study
exhibited FI300s values all below 6000 while the larger unique subset of 28 subjects from the
previous study showed a wider range of FI300s values. The stochastic Gaussian-like
distribution of RCOX(0) values centered above 1 indicated that RCOX was a robust
measurement of secondary platelet aggregation response in untreated whole blood (Figure
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3-5C). The use of RCOX = 1 as the decision value was previously reported as the microfluidic
assay for detection of in vivo and ex vivo ASA had high discrimination (high true positive
rate with low false positive rate) at this anchoring point [64]. In a total of 66 determinations
of RCOX(0), 52 measurements were above the RCOX = 1 cutoff demonstrating a majority of
donors had a strong secondary platelet aggregation response in the assay. Observation of 14
values of RCOX < 1 indicate some donors lack detectable secondary aggregation by this assay,
a phenomena potentially attributable to low levels of released ADP and TXA2 in the
boundary layer formed above the platelet deposit [52]. In contrast, with 500 µM ASA added
ex vivo, 49 of 66 determinations of RCOX < 1 demonstrated that most subjects had platelets
that were sensitive to ASA inhibition of platelet TXA2 production (Figure 3-5C). The 17
determinations of RCOX where RCOX > 1 with 500 µM ASA added ex vivo could be due to
non COX-1 mediated ASA effects on platelets when they are activated by collagen with
autocrinic ADP present [66]. Such blood samples may be worthy of further study with
respect to the phenotype of functional insensitivity to ASA despite COX-1 acetylation. A
notable left shift of the distribution away from RCOX(0) was evident for the 66
determinations of RCOX(500 µM ASA) (Figure 3-5C).
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Figure 3-5 Distribution of microfluidic metrics in the assessment of platelet adhesion
to collagen and ASA’s inhibition of platelet function under flow.
(A), Binning of primary and secondary platelet deposition rates. (B), Binning of final platelet accumulation as
measured by platelet fluorescence at t = 300s (FI300s). (C), Binning of RCOX values in assessment of the effect of
ASA on secondary platelet aggregation in the microfluidic perfusion assay.
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3.4 Discussion
We demonstrated the utility of whole blood microfluidic assays run on an 8-channel
microfluidic device to assess the effect of various anti-platelet agents on platelet function
under flow. We extended from a previous study [64] the RCOX value, a normalized metric to
detect reduction in secondary platelet aggregation due to ex vivo ASA addition (Figure
3-1C). We now define RP2Y a ratio of secondary platelet aggregation rate to primary platelet
deposition rate (with a different temporal profile than RCOX) to quantify P2Y1 and P2Y12
antagonists (Figure 3-2). Examination of RP2Y and ROC curve testing establish 2MeSAMP
and MRS 2179 as potent anti-platelet drugs that target both initial platelet adhesion to
collagen and secondary platelet aggregation by attenuating the autocrine ADP pathway
(Figure 3-6).

Figure 3-6 Effect of P2Y1, P2Y12 antagonists and ASA on primary platelet adhesion to
collagen and secondary platelet aggregation due to ADP and thromboxane autocrine
and paracrine signaling.
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COX-1 inhibitor ASA reduced secondary aggregation between 150 and 300 s without an effect on primary
platelet deposition to collagen from 60 to 150 s. 2MeSAMP and MRS 2179 reduced primary deposition
between 60 and 105 s and secondary platelet aggregation between 105 and 300 s. Time intervals marked are
indicators for RCOX and RP2Y, 60- 150 sec & 150 sec-300 sec and 60-105 sec & 105 sec-300 sec respectively. Xaxis is not to scale.

The effect of ASA on secondary platelet-platelet interactions has been wellcharacterized in platelet aggregometry [55]. Under flow, ADP and TXA2 are complex and
interacting modulators since both can become elevated in a concentration boundary layer
[52]. Additionally, RP2Y was shown to be unsuited to score the potency of combined P2Y1
and P2Y12 antagonism of platelet function because primary deposition rate was so strongly
inhibited in this microfluidic thrombosis model. Measured platelet fluorescence dynamics
and normalization of final platelet mass against control platelet masses formed over collagen
for 8 healthy donors showed ex vivo dual treatment with P2Y12 and P2Y1 inhibitors to be
significantly more potent than single ex vivo P2Y1 or P2Y12 antagonism (Figure 3-4B).
We report findings with some similarities and differences to the prior flow studies of
Lucitt et al. [67] and Mendolicchio et al. [68]. Lucitt et al. found no effect on the rate of
platelet coverage of the collagen surface with in vitro ASA addition at 1500 s-1. However,
percent surface coverage may be a less sensitive measure of secondary aggregation which
also increases the height of platelet deposits. Menolicchio et al. also reported a limited
reduction of platelet aggregate growth above the layer of platelets adherent to collagen with
in vitro addition ASA at 1500 s-1. Since there was no thrombin/fibrin generation allowed in
Lucitt [67] who used 300 ATU hirudin or Menolicchio [68] who used 68 USP heparin,
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arterial shear rates of 1500 s-1 may limit the detection of ASA action because thrombin/fibrin
dramatically stabilize the platelet deposit at arterial conditions[37]. As a platelet deposit
grows in height in a flow channel, the shear rates become exceedingly high during a constant
flow rate perfusion and embolization is likely, especially at an initial arterial wall shear rates,
with or without fibrin present[37]. At the venous shear rate used with antiplatelet agents in
the present study, partially occlusive deposits formed in the absence of thrombin/fibrin are
more reliably measured since there is no embolization, even under constant flow conditions.
In prior work, we have shown that the IC50 of ASA measured at venous shear rates was quite
similar to that measured at arterial shear rates [64]. In addition, the IC50 of 2MeSAMP and
MRS 2179 at venous wall shear rates were also on the same order of magnitude to that
found at arterial shear rates (1000s-1) (Figure 8-5).
Lucitt et al. also reported an effect of in vitro 2MeSAMP on initial platelet
recruitment on collagen surfaces delaying the time to reach 2.5% platelet surface coverage to
56 sec as compared to 33 sec for the control case in an 8 min assay at 1500 s-1. Lucitt et al.
found that in vitro ASA had no effect on this initial stage of platelet adhesion. We report
findings consistent with Lucitt et al. but at 200 s-1. We found that ASA does not affect
primary platelet deposition to collagen (F'150-60s), while 2MeSAMP and MRS 2179 inhibit
primary platelet response to collagen (F'105-60s) but more significantly affects secondary
platelet aggregation (F'300-105s) requiring RP2Y as a new internally normalized metric to
characterize platelet response to ADP antagonists under flow. ADP antagonists were found
to inhibit platelet function by ~ 105 sec as compared to ~ 150 sec due to ASA inhibition of
TXA2 release. Also, Lucitt et al. determined 2MeSAMP significantly reduced the rate of
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platelet aggregate formation on collagen by impairing recruitment of additional platelets.
Menolicchio et al. reported marked reduction of platelet aggregation above the initial platelet
surface on collagen due to in vitro addition of 2MeSAMP. Both report these results at 1500s1

. This is consistent with our findings at 200s-1 with RP2Y and ROC curves detecting

significant impairment of secondary platelet aggregation due to either 2MeSAMP or MRS
2179.
Monitoring of P2Y12 inhibition by clopidogrel or other P2Y12 antagonists can be
achieved through assays such as vasodilator-stimulated phosphoprotein phosphorylation
(VASP), turbidometric platelet aggregometry, or the VerifyNow P2Y12 test. Although
platelet aggregometry remains the gold standard for platelet function testing, several
disadvantages exist such as poor reproducibility, high sample volume, and complex sample
preparation[44]. Turbidometric platelet aggregometry testing uses ADP induced platelet
aggregation to measure the effect of clopidogrel. However, ADP can illicit platelet
aggregation through P2Y1 while VASP requires flow cytometry and an experienced
technician[44]. Point of care assays are especially advantageous in clinical settings as they
enable immediate decision making for dosing of antiplatelet drugs. The VerifyNOW P2Y12
is the only device that meets the various constraints to be considered a point of care assay.
Interestingly, in comparing the clinical utility of this microfluidic assay to the VerifyNow
P2Y12 system, ROC curve AUC values were strikingly similar. A ROC curve value of 0.929
was found in the assessment of the VerifyNow P2Y12 assay to detect antiplatelet effects
during clopidogrel therapy, comparable to the 0.966 value found for 2MeSAMP in this
study[69].
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With regards to microfluidic flow assays, microfluidic chambers often utilize a single
flow path comprised of a millimeter length collagen coated cover slip or capillary tube
enabling platelets to tether, activate, and re-adhere along the entire length[67]. With such
long zones available for adhesion, the platelet coverage is often a function of distance along
the collagen. The current microfluidic injury model exposes platelets to a narrow 250 µm
long collagen strip with no dependency on distance down the "injury" site as the image
capture zone is the entire prothrombotic surface. Furthermore, the type of collagen used as
the adhesive substrate impacts platelet-surface interactions. Previous reports utilize bovine
soluble collagen type I, porcine type I collagen, or equine tendon fibrillar type I
collagen[13,37]. The equine fibrillar type I collagen used in this study is a thoroughly
established prothrombogenic surface as a recent study examined sources of variability over
this collagen type in microfluidic flow assays for n = 104 healthy donors[70].
Several previous flow systems have been examined for the detection of P2Y1, P2Y12
antagonists and COX-1 effects under various shear rates[67,68,71]. However, distinct in our
studies are the eight channels comprising this single microfluidic device capable of
performing dose-response experiments for 8 different concentrations on a single antiplatelet
agent or high throughput testing of three antiplatelet agents in duplicate with simultaneous
testing across three devices. Single channel platelet function measurements make dose
response testing and high replicate testing of multiple drugs cumbersome. Dose dependent
testing of the inhibitory effects of antiplatelet therapies on platelet function is crucial in
narrowing the therapeutic window for these drugs. This would be an additional step towards
personalized medicine in a clinical setting.
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While antiplatelet agents are used for the prevention of arterial thrombosis, the
monitoring of antiplatelet agents in anticoagulated whole blood (that lacks fibrin
stabilization) is perhaps most precisely detected at venous shear rate, especially when
constant flowrate perfusion is used. The action of antiplatelet agents on thrombus build-up
in the presence of fibrin generation at arterial shear rates remains an area of active
investigation. Such arterial thrombosis studies will be best conducted under microfluidic
conditions of constant pressure drop (not constant flow rate) where channel occlusion is a
natural and important endpoint to the experiment [37]. Further work would be required to
examine whether the presence of thrombin and fibrin in this microfluidic thrombosis model
affects the inhibitory capabilities of 2MeSAMP and MRS 2179 on platelet function and as
well as the compounds' respective IC50 values at venous and arterial wall shear rates. A
constant pressure drop microfluidic thrombosis model at initial arterial wall shear rates
would be more physiologically relevant. This could be a future avenue to investigate the
efficacy of P2Y1 and P2Y12 inhibitors over increasingly complex surface triggered
prothrombogenic surfaces such as lipidated recombinant tissue factor on collagen[35].
The 8-channel microfluidic phenotyping of healthy subject response to anti-platelet
therapies in this study was able to reproduce the biochemical signaling pathways and
transport processes under which antiplatelet therapies must act. Quantification through
platelet deposition rates, total platelet fluorescence and the all encompassing R value selfnormalizes donors without requiring donor specific measurements of vWF levels, platelet
count, and hemoatocrit. However, quantification of secondary platelet aggregation using RP2Y
or RCOX has not been tested with patients on clopidogrel or combined clopidogrel and
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aspirin regiments. Translation of these values to quantify patients treated for coronary heart
disease remains an area of future study. This work represents another step towards a
functional high throughput point of care platelet function assay to detect patient-specific
response to various antiplatelet therapies.
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4

MICROFLUIDIC ASSAY OF HEMOPHILIC BLOOD
CLOTTING: DEFICITS IN PLATELET AND FIBRIN
DEPOSITION AT LOW FACTOR LEVELS AND
POTENTIATION OF rFVIIa-INDUCED FIBRIN DEPOSITION
BY THE CONTACT PATHWAY

4.1 Introduction
Hemophilia A and B are X-linked genetic disorders resulting in deficiencies of
coagulation factor VIII (FVIII) or FIX, respectively[72]. The inheritance of FXI deficiency,
also known as hemophilia C, is autosomal, and mostly leads to a bleeding risk during
trauma[73]. Bypass therapies are used when neutralizing antibodies develop against FVIII,
FIX, or less commonly FXI in hemophilic patients. Bypass therapies, including activated
prothrombin complex concentrates (aPCC) and recombinant factor FVIIa (rFVIIa) supplant
FXa generation from the intrinsic tenase (FIXa/FVIIIa) by increasing prothrombinase levels
or activating FX on the platelet surface that then leads to thrombin generation[74].
Evaluations of responses to infused rFVIIa in hemophilia A and B patients reveal
phenotypic differences in the drug's capacity to restore hemostasis[75]. Previous studies
show that addition of rFVIIa to washed platelets increases platelet adhesion and aggregation
to collagen at arterial shear rates attributable to the binding of rFVIIa to activated
platelets[76]. Others showed a significant decrease in lag time and an increase in total fibrin
deposition[77]. However, the effect of rFVIIa on fibrin generation under flow conditions
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and the potential role of the contact pathway in rFVIIa efficacy has not yet been
investigated.
Recent developments in microfluidics have allowed low volume, high-throughput
hemostatic assessment of platelet function[23,64,78]. We have previously described a
microfluidic model evaluating contact pathway-driven coagulation using whole blood (WB)
from patients with congenital bleeding disorders perfused over collagen without exogenously
added tissue factor[23]. Platelet and fibrin deposition in WB from patients with FVIII and
FIX-deficiencies displayed deficits in both platelet and fibrin deposition at <1% critical
factor level activity[23].
In the current study, the efficacy of rFVIIa was tested in high and low corn trypsin
inhibitor (CTI, 4 or 40 µg/ml) inhibited WB from healthy or clotting factor-deficient
hemophilia patients. CTI is a potent and selective inhibitor of βFXIIa[79]. Normal or
hemophilic WB was perfused over collagen type I surfaces at an initial venous wall shear rate
of 100s-1. We observed rFVIIa potentiation of platelet adhesion to collagen in hemophilic
patients and healthy donors independent of CTI. However, with strong inhibition of the
contact pathway (high CTI), exogenous rFVIIa was unable to rescue fibrin generation in
cases of severe or moderate factor-deficiencies. The low levels of thrombin generated by
rFVIIa alone indicate a novel role for the contact pathway in potentiating platelet-rFVIIa
function. Thus in the absence of exogenous tissue factor, rFVIIa promotes platelet
deposition on collagen by production of "signaling" levels of thrombin, but does not rescue
fibrin deposition to normal levels unless the contact pathway participates.
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4.2 Materials and Methods
4.2.1

Blood collection, labelling, rFVIIa addition and patient recruitment
Blood was drawn from healthy donors (n = 10) and coagulopathic patients (n = 8)

under Internal Review Board approval of the University of Pennsylvania. Information
regarding patient sex, age, bleeding phenotype, and recent therapy was collected(Table 2).
Laboratory testing of hemophilic patients included a platelet count, residual coagulation
factor activity, prothrombin time (PT), and activated partial thromboplastin time (aPTT).
Residual FVIII, FIX, or FXI activity were measured in Hemophilia A and VWD disease,
Hemophilia B, and Hemophilia C diagnoses respectively. The aPTT test assesses contact
pathway function by measuring the time to clot formation in platelet-poor plasma in the
presence of contact activators. aPTT values (reference range: 20.9-34.4 sec) were negatively
correlated with residual factor activity levels as previously established[23]. Healthy donors
were self-reported free of oral medication for 7 days and abstained from alcohol 48 h prior
to blood donations.

Patient
ID#

Platelets
(103/µL)

Timing
of Most
Recent
Therapy

Replacement
Therapy Dosage

58.7

274

None

N/A

Residual
Coagulation
Factor %*

aPTT
(Sec)

3%

50

Diagnosis
Moderate
Hemophilia C

51

Severe Hemophilia A

<1%

78.6

233

1 wk

35 IU/kg rFVIII

52

Severe Hemophilia A

15%

43.5

204

20 hr

26 IU/kg rFVIII
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Severe Hemophilia A
Moderate Hemophilia
B

15%

39.9

239

24 hr

30 IU/kg rFVIII

5%

48.2

250

30 hr

50 IU/kg rFIX

3%

51.8

201

4 days

30 IU/kg rFVIII
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Severe Hemophilia A
Moderate Hemophilia
A

10%

46

333

4 wk

51 IU/kg rFVIII

57

Severe Hemophilia A

9

57.1

145

3 days

27 IU/kg rFVIII
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Table 2. Eight patients were examined with respect to ex vivo rFVIIa addition in the
microfluidic hemostasis model with high or low CTI-inhibited WB.
59

Time since last hemostatic therapy, % residual coagulation factor activity, PTT, and platelet count are as
reported. *Reflects in some cases recent administration of factor concentrate.

WB was drawn into 4 µg/ml and 40 µg/ml CTI (Haematologic Technologies, Essex
Junction, VT) containing polypropylene test tubes, a material which minimally activates the
contact pathway. A low 4 µg/ml CTI is a concentration sufficient to prevent visible clotting
in the test tube for approximately 30 min but insufficient to completely inhibit contact
pathway activation at the micropatterned microfluidic injury site[23]. A high 40 µg/ml CTI
concentration, while not perfect in abolishing contact activation, will prevent visible clotting
for 60 to 120 min allowing studies of TF-dependent extrinsic pathway with minimal
participation of the contact pathway[35,37,80]. Both concentrations of CTI allow sufficient
time for completion of all assays with no clotting in the 35 µL entrance reservoirs of the
microfluidic devices.
Blood samples were treated with 0.125 µg/ml fluorescently conjugated non-function
blocking anti-CD41a antibody (clone VI-PL2, Becton Dickson, Franklin Lakes, NJ, 0.125
µg/ml final concentration) to label platelets and fluorescently conjugated anti-fibrin antibody
(clone T2G1, Dr. Mortimer Poncz laboratory, Children's Hospital of Philadelphia, 0.5 µg/ml
final concentration) to label fibrin. WB samples were also treated with vehicle HEPES
buffered saline (HBS, 20 mM HEPES, 160 mM NaCl, pH 7.5) or indicated concentrations
of rFVIIa. Recombinant FVIIa (NovonSeven, Novo Nordisk, Plainsboro NJ, 1 mg/ml final
concentration) was reconstituted in histidine diluent. A dilution of rFVIIa was made to the
final desired concentration in HBS within 1 hr of the assays. Whole blood perfusion in
microfluidic devices started within 15 min of venipuncture.
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4.2.2

Microfluidic haemostasis model
Microfluidic devices were fabricated in polydimethylsiloxane (PDMS, Sylgard 184,

Ellsworth Adhesives) according to previously described techniques[33,34]. The 8-channel
microfluidic device has 8 channels fed by 8 wells with perfusion by withdrawal from a single
outlet into a syringe pump (PHD 2000, Harvard Apparatus, Holliston, MA). The channels
(250 µm by 60 µm) run perpendicularly over a 250 µm wide strip of patterned equine fibrillar
collagen type I (Chronopar, Chronolog). A custom stage insert held two microfluidic devices
allowing replicate testing of 4 conditions at each concentration of CTI in 60 sec intervals.
Microfluidic devices were mounted on an inverted microscope (IX81, Olympus, Center
Valley, PA). Microfluidic channels were spaced in close proximity to allow two channels to
be imaged simultaneously with a 10X objective lens equipped with a CCD camera (ORCAER, Hamamatsu, Bridgewater, NJ). Prior to initiation of the flow assay, all channels were
blocked with 0.5% bovine serum albumin (BSA) in HBS buffer. Blood samples were
perfused at an initial local wall shear rate of 100s-1 (1 µL/min per channel) for 15 min. In
constant flow rate mode, the local wall shear rate monotonically increases as thrombi grow
to the channel height[37].
4.2.3

Platelet and fibrin accumulation analysis
Platelet and fibrin fluorescence intensities, which are proportional to the total platelet

and fibrin masses respectively were measured in 60 sec intervals for 15 min through Image J
software (Image J, NIH, Bethesda, MD). The initial image was taken as background and
subsequent images were background corrected. Platelet and fibrin masses were measured in
an area comprising of 70% center zone of the 250 µm by 250 µm collagen surface due to the
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slightly non-uniform shear profiles along the side of the microfludic channels[33]. Platelet
adhesion and fibrin formation was not observed upstream or downstream of the collagen
strip prior to full channel occlusion. Statistical significance was assessed using a two tailed
Student's t test.

4.3 Results
4.3.1

Exogenous rFVIIa enhances platelet adhesion to collagen, but does not restore
fibrin generation in a moderately FXI-deficient patient
The hemostatic effect of rFVIIa was evaluated by ex vivo addition to the WB of

hemophilic patients. High or low CTI-treated WB from a moderately FXI-deficient patient
(#50) with 3% FXI activity produced no detectable levels of fibrin (Figure 4-1B,D). As
expected, high or low CTI had little effect on fibrin generation, which was already strongly
attenuated in this patient because of the FXI deficiency. In the flow assay over collagen,
fibrin generation is dependent on contact pathway engagement (FXIIa→FXIa) which is
nearly absent in this patient. Fibrin generation due to the contact pathway was confirmed
with perfusion of low CTI-treated recalcified healthy pooled plasma or factor-deficient
plasma over collagen (Figure 8-6).
Exogenous rFVIIa addition increased platelet deposition on collagen at high and low
CTI (Figure 4-1A,C). However, ex vivo supplementation with rFVIIa failed to rescue fibrin
formation at either CTI concentration (Figure 4-1B,D). Without contact pathway
engagement (high CTI and FXI deficiency), rFVIIa strongly promoted platelet deposition
with little effect on fibrin production. To rule out inhibition of rFVIIa function by CTI, a
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fluorogenic substrate for FVIIa was tested with rFVIIa and high or low CTI showing no
effect of CTI on rFVIIa function (Figure 8-7).

Figure 4-1 Moderately FXI-deficient (3%) patient #50 response to exogenous rFVIIa
(A & B), Platelet and fibrin fluorescence at various exogenous rFVIIa concentrations in high CTI (40 µg/ml).
(C & D), Platelet and fibrin fluorescence with ex vivo rFVIIa addition in low CTI (4 µg/ml). Shaded traces are
the standard deviation of two clotting events measured in 60 sec intervals over 15 min. Insert: 8-channel
microfluidic device with location of the collagen strip as indicated.
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4.3.2

Exogenous rFVIIa enhances platelet adhesion to collagen, but does not restore
fibrin generation in a severely FVIII-deficient patient

WB from a severely FVIII-deficient patient (#51; <1% FVIII) tested at one week following
administration of FVIII concentrate, showed a deficit in fibrin production that was not
rescued by rFVIIa at either CTI concentration. Recombinant FVIIa enhanced platelet
deposition but had no effect on fibrin production (Figure 4-2). Despite FXa generation due
to rFVIIa binding to activated platelets, insufficient thrombin was produced to cause robust
fibrin formation. Robust fibrin formation, especially in the absence of exogenous tissue
factor, requires intrinsic tenase formation (FIXa/FVIIIa) which clearly did not occur with
<1% FVIII levels. The level of CTI had no effect since the contact pathway can proceed
downstream from FXIIa to FIXa but will not result in sufficient intrinsic tenase.
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Figure 4-2 Severely FVIII-deficient (<1%) patient #51 response to exogenous rFVIIa
(A & B), Platelet and fibrin fluorescence over time in high CTI at indicated concentrations of ex vivo rFVIIa.
(C & D), Platelet and fibrin fluorescence over time in low CTI at indicated concentrations of ex vivo rFVIIa.
Timing of recent hemostatic therapy is as indicated. Shaded traces are the standard deviation of two clotting
events measured in 60 sec intervals over 15 min.

4.3.3

Moderate deficiency of FVIII or FIX allows rFVIIa to enhance platelet and
fibrin generation when the contact pathway is available
In high CTI, rFVIIa augmented platelet deposition in a severely FVIII-deficient

patient (#55; 3% FVIII) who was treated with FVIII concentrate 4 days prior to testing
(Figure 4-3A, upper left). However, ex vivo rFVIIa addition again did not produce
substantial fibrin accumulation with strong inhibition of the contact pathway (Figure 4-3A,
65

lower left). In contrast, fibrin generation occurred upon addition of rFVIIa at low CTI
(Figure 4-3A, lower right). Contact pathway engagement (FXIIa→FXIa→FIXa) and
intrinsic tenase assembly was productive enough to make sufficient thrombin to generate
fibrin when rFVIIa was used at a 3% FVIII deficiency.
Similarly, a moderately FIX-deficient patient (#54; 5%) displayed nearly identical
results as patient (#55) (Figure 4-3B). Recombinant FVIIa potently amplified platelet
deposition in either CTI concentration (Figure 4-3, upper panels) whereas fibrin formation
was highly dependent on contact pathway activity (low versus high CTI; Figure 4-3, lower
panels). A similar role for the contact pathway was discovered when two additional severely
FVIII-deficient patients treated with FVIII concentrate were tested (#57 & 56) (Figure 8-8).
In three of these patients a peak in platelet deposition as measured by platelet fluorescence
with contact pathway engagement and rFVIIa was found at 7-11 min followed by a drastic
dip in the signal(Patient #54,57,56). This is due to downstream movement of the plateletfibrin aggregates past the collagen surface as the clots formed under a constant flow regime
cannot stop flow driven by a syringe pump.
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Figure 4-3 Effect of ex vivo rFVIIa in severely FVIII-deficient patient #55 and
moderately FIX-deficient patient #54 after recovery of critical factor levels to 3 and
5% respectively
(A), Platelet and fibrin fluorescence over time in high or low CTI-inhibited WB for patient #55. (B), Platelet
and fibrin fluorescence in high or low CTI-inhibited WB for patient #54. Timing of recent hemostatic therapy
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is as indicated. Shaded traces are the standard deviation of two clotting events measured in 60 sec intervals over
15 min. Dashed lines indicate full channel occlusion.

4.3.4

Recovery of FVIII levels to 15% in patients allows rFVIIa to potentiate both
platelet and fibrin deposition with less requirement for the contact pathway
When severely FVIII-deficient patients (#53 and #52) were recently treated (<24 hr)

with therapy to increase their FVIII levels to 15%, exogenous rFVIIa addition caused
substantial increases in platelet deposition and fibrin generation. The two FVIII-deficient
patients displayed identical responses to rFVIIa. Increases in platelet deposition, fibrin
initiation, and fibrin generation were measured in both patients; concentration dependent
increases in platelet and fibrin accumulation were statistically significant at 4 nM rFVIIa
(Figure 4-4). As residual clotting factor levels reach 15%, a level clinically considered as a
mild deficiency, the influence of FXIIa was less prominent. However, the effects of FXIIa
were still detectable as fibrin was generated faster and more abundantly in low CTI
compared to high CTI in both patients (Figure 4-4A, B, lower panels).
In examining total platelet accumulation at 15 min (or prior to full channel
occlusion), rFVIIa increased final platelet accumulation independent of CTI in all 8 patients
(#50-57) (Figure 4-5A). Recombinant FVIIa showed robust effects on total fibrin
accumulation with contact pathway-initiated coagulation at low CTI and >3% factor levels
and minimum effect with strong inhibition of the contact pathway (high CTI) or at <3%
factor levels (Figure 4-5B). The levels of fibrin production in FVIII or FIX-deficient
patients in low CTI and the lack of fibrin generation in high CTI with rFVIIa indicate a
novel role for contact pathway potentiation of platelet-rFVIIa function.
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Figure 4-4 Effect of ex vivo rFVIIa in 2 severely FVIII-deficient patients after
recovery of FVIII activity to 15%
(A), Platelet and fibrin fluorescence dynamics in high or low CTI-inhibited WB for severely FVIII deficient
patient #53. (B), Platelet and fibrin fluorescence dynamics in low or high CTI inhibited WB for severely
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FVIII-deficient patient #52. Timing of recent hemostatic therapy is indicated. Shaded traces are the standard
deviation of two clotting events measured in 60 sec intervals over 15 min.

Figure 4-5 rFVIIa response in CTI-inhibited WB from 8 factor-deficient patients
(#50-57; Table 2. Eight patients were examined with respect to ex vivo rFVIIa
addition in the microfluidic hemostasis model with high or low CTI-inhibited WB.):
Platelet and fibrin accumulation at t = 15 min or just prior to full channel occlusion
sorted by residual factor activity and aPTT results
(A), Average final platelet mass as measured by platelet surface fluorescence at 0 or 4 nM rFVIIa in 8 intrinsic
clotting factor deficient patients. Error bars are standard deviation of a minimum of 4 clotting events. (B),
Average final fibrin mass as measured by surface fibrin fluorescence at 0 or 4 nM rFVIIa in 8 intrinsic clotting
factor deficient patients. Error bars are standard deviation of a minimum of 4 clotting events. (*p<0.05,
**p<0.01, ns: non-significant)
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4.3.5

Contact activation and rFVIIa enhance platelet and fibrin deposition in healthy
blood
Eight healthy donors were subsequently tested in the same manner as the

coagulopathic patients to further investigate the role of the contact pathway in exogenous
rFVIIa function. Consistent with the platelet response to rFVIIa in hemophilic patients,
healthy donor platelet deposition increased due to rFVIIa addition independent of the
contact pathway (high or low CTI) (Figure 4-6A, upper panels). However, the contact
pathway (low CTI) was required to generate sufficient levels of thrombin for robust fibrin
formation (Figure 4-6A, lower panels). Similar to some hemophilic patients (#54, 56, 57), a
combination of the contact pathway and ex vivo rFVIIa resulted in peak platelet deposition
at 7 min followed by a drastic drop in signal. This is indicative of increasing shear stresses on
the clots which eventually causes them to tear from the collagen surface, restructure, and
embolize downstream.
Recombinant FVIIa significantly increased total platelet accumulation at 15 min or
prior to full channel occlusion in low CTI, showing efficacy in enhancing platelet deposition
independent of the contact pathway (Figure 4-6B; p<0.01). Total fibrin accumulation
increased by three fold with rFVIIa when FXIIa was engaged (Figure 4-6C; p<0.01), while
no increase was observed when FXIIa was strongly inhibited.
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Figure 4-6 Healthy donor WB (n = 8 donors) platelet and fibrin accumulation
response to rFVIIa
(A), Platelet and fibrin fluorescence over time as a function of rFVIIa concentrations in high or low CTI.
Dashed line indicates full channel occlusion (B), Average final platelet mass at t = 15 min or just prior to full
channel occlusion in the presence or absence of ex vivo rFVIIa in high or low CTI-inhibited WB. (C), Average
final fibrin mass at t = 15 min in the presence or absence of ex vivo rFVIIa in high or low CTI-inhibited WB.
Bars are average and standard deviation from n = 8 healthy donors and 16 clotting events. (*p<0.05,
**p<0.01, ns: non-significant)
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4.4 Discussion
Microfluidic models of hemostasis comprised of high or low CTI anti-coagulated WB
perfused over collagen at venous shear rates were used to assess platelet and fibrin
deposition in response to exogenous rFVIIa. Under these conditions, we investigated the
role of rFVIIa under flow. We observed significantly increased platelet adhesion in the
presence of rFVIIa but an inability of rFVIIa to potentiate fibrin formation unless the
contact pathway was engaged.
Results from hemophilic patients (#50,51,54,55,56,57) indicate that rFVIIa function
on platelets generate low "signaling" levels of thrombin to amplify platelet deposition but
these levels were insufficient to generate fibrin. If contact engagement was blunted in the
case of severe FXI or FVIII-deficiency (Figure 4-1,Figure 4-2) or at high CTI in FVIII or
FIX-deficient patients (Figure 4-3A, B, lower left), rFVIIa did not lead to ample fibrin
formation. However, with engagement of the contact pathway (low CTI), rFVIIa may
crosstalk with the contact pathway to facilitate strong fibrin production in FVIII or FIXdeficient patients (Figure 4-3A, B lower right).
In addition, rFVIIa can generate FXa on the platelet surface and to a very minimal
extent in solution[81]. In severely FVIII-deficient WB (< 1%), thrombin made distally from
platelet-bound rFVIIa (4 nM added) is sufficient to promote greater platelet activation but is
insufficient to generate fibrin (Figure 4-2). In moderately hemophiliac blood (3% FVIII or
5% FIX), strong inhibition of the contact pathway prevented fibrin formation although
platelet deposition was still enhanced by rFVIIa (Figure 4-3). The initiation of the contact
pathway in low CTI dramatically enhanced fibrin formation in moderate hemophiliac blood
73

(3% FVII or 5% FIX) treated with rFVIIa (Figure 4-3). Similar results were found in mild
hemophilic blood (15% FVIII) (Figure 4-3) and even in healthy WB (Figure 4-6) where
strong inhibition of the contact pathway significantly blunted fibrin production following
exogenous rFVIIa treatment.
Recombinant FVIIa can enhance FXa generation at the site of bleeding by a variety of
pathways. If TF is exposed to WB, formation of the extrinsic tenase TF/rFVIIa would be
extremely procoagulant. Furthermore, the heterogeneous response to rFVIIa amongst
hemophiliacs can also be potentially attributable to variable quantities of circulating lipids or
procoagulant TF-containing microparticles, two variables known to put hemophiliacs at risk
for cardiovascular diseases as they age[82,83]. However, hemophiliacs bleed into joints,
which are presumably sites of low cellularity and low TF[84]. The results derived from FXIdeficient blood (Figure 4-1) argue against bloodborne TF as a kinetically significant trigger
that produces detectable changes in our intrinsically driven microfluidic hemostasis model.
In contrast to the present study, prior work by Onasoga-Jarvis et al. perfused rFVIIasupplemented hemophiliac blood over TF-containing collagen to drive thrombin and fibrin
production [77].
We predict that for in vivo situations where wall-derived TF and contact activation are
both minimal, rFVIIa can promote hemostasis in severe hemophilia via platelet activation by
low levels of thrombin (distal of platelet bound rFVIIa) in the absence of substantial fibrin
generation. When the contact pathway is engaged through FXII[85], collagen[86], activated
platelets[87], or nucleic acid[88], it can promote the efficacy of rFVIIa by providing
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additional FXa or by inactivation of an inhibitor, such as recently reported FXIa-mediated
cleavage of tissue factor pathway inhibitor (TFPI)[89].
A level of 4 nM rFVIIa enhanced platelet deposition under flow by 2 to 3-fold in all
patients tested (Figure 4-5A; p<0.05). At <10% factor level (aPTT > 45 sec), the contact
pathway alone (no rFVIIa) at either high or low CTI produced essentially no fibrin (Figure
4-5B). However, for <10% factor level, low CTI inhibition of WB potentiated the ability of
rFVIIa to promote fibrin formation. Distinct from hemophilia, conditions of trauma that
promote contact activation may enhance the ability of rFVIIa to cause fibrin generation.
Furthermore, while incidences of venous thrombosis are rare in factor-deficient patients[90],
we quantified partial movement and remodeling of clots at low CTI with ex vivo rFVIIa in 3
hemophilic patients. As embolized thrombi are clinically significant, future work should
assess the risk of venous thromboembolism with rFVIIa under a pressure relief flow regime
in this microfluidic device[37]. In pressure relief mode, full channel occlusion is a natural
endpoint as flow diversion to open channels allows thrombi to grow to full occlusion.
This work highlights the ability of rFVIIa to generate low levels of FXa on platelets to drive
platelet deposition via thrombin even when that thrombin is sufficient to drive fibrin
deposition under flow. If the contact pathway is not engaged and TF is absent, rFVIIa may
display its efficacy in severe hemophiliacs (<1%) by enhancing only platelet function.
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5

RECOMBINANT FACTOR VIIA ADDITION TO SEVERE
HEMOPHILIC BLOOD PERFUSED OVER
COLLAGEN/TISSUE FACTOR CAN SUFFICIENTLY BYPASS
THE FACTOR IXA/VIIIA DEFECT IN ORDER TO RESCUE
FIBRIN

5.1 Introduction
Hemophilia A and B are X-linked genetic disorders resulting in deficiencies in
coagulation factor VIII (FVIII) or factor IX (FIX), respectively[72]. These deficiencies cause
a wide range of bleeding phenotypes depending on severity [75,91–93]. Current treatment
strategies for hemophilic patients include recombinant clotting factors or bypass therapies.
Bypass therapies such as activated prothrombin complex concentrates (aPCC) or
recombinant factor VIIa (rFVIIa) were developed to treat hemophilic patients who develop
inhibitors[74]. Bypass therapies can supplant FXa generation from the intrinsic tenase
(FIXa/FVIIIa) by increasing prothrombinase levels or by activating FX on the platelet
surface via rFVIIa. Though rFVIIa is approved for treating hemophilia patients with
antibodies to FIX or FVIII, its mechanism of action is complex[94]. Past work has indicated
that rFVIIa requires tissue factor to function and its requisite high doses are due to its
competition with endogenous FVII for TF[95,96]. Other studies indicate that rFVIIa can
also bind monocytes and activated platelets to generate FXa independent of TF[97–99].
Thus, further studies can help elucidate the roles of intrinsic tenase, extrinsic tenase,
and rFVIIa in platelet rich thrombus formation and fibrin generation in hemophilic patients
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under the hemodynamics conditions found in vivo. In hemophilia, deficits in thrombin
generation impact platelet activation[100], fibrin formation[101], and clot stabilization[102].
In vitro flow models with perfusion of human blood deficient in FVIII or with inhibition of
FVIII resulted in decreased platelet aggregation and fibrin formation at low shear
conditions[103–105]. With in vivo models of vascular injury (ferric chloride or laser injury),
mice deficient in FVIII or FIX produce unstable thrombi that fail to reach full vessel
occlusion[106–108]. While the extrinsic pathway is classically thought of as the arm of the
coagulation cascade that mitigates deficits in hemophilia A and B, TF expression varies
greatly in human tissues[109,110]. High TF levels may compensate for a lack of FVIII or
FIX in some but not all subendothelial vascular beds. Studies have shown bleeding in
hemophilia is common in the joints where TF expression is considered to be low[110]. The
contribution of FXa and thrombin stemming from residual intrinsic tenase in various TFladen backgrounds has not been studied extensively using hemophilic blood. Previous
studies only assessed the most severe cases of human FVIII or FIX deficiency (<1%) often
with FXIIa function uncontrolled or utilized blood from mice deficient in FVIII or
FIX[104,105,111]. Few have examined how mild or moderate deficiencies in FVIII or FIX
levels affect platelet adherence, clot stability, and fibrin formation under flow in the presence
or absence of bypass therapy[77] and surface TF.
Previously we have developed a contact pathway-driven microfluidic model that
evaluated the role FVIII and FIX in patients with congenital bleeding disorders[23,24].
Platelet adhesion and fibrin formation under flow was significantly reduced in whole blood
from these patients at <1% critical factor level activity[23]. Furthermore, in a second study
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we concluded that rFVIIa generates low levels of ‘signaling’ thrombin sufficient to enhance
platelet deposition on collagen, but is insufficient to drive fibrin polymerization unless the
contact pathway is engaged. In this present study, we aimed to unify our previous two
studies and firmly establish the role of the intrinsic tenase and rFVIIa in the regulation of
platelet-fibrin thrombus development under flow. We measured healthy or hemophilic WB
perfusion over collagen type I surfaces bearing well-controlled low or high concentrations of
lipidated tissue factor at an initial venous wall shear rate of 100 s-1. We also measured the
differential effect of exogenously added rFVIIa on platelet deposition, fibrin initiation, and
fibrin accumulation. This study confirms that FIXa/FVIIIa is required for fibrin generation
under healthy WB flow, even when TF is abundant at the wall. In severe hemophilic blood
with CTI-inhibited FXIIa, high levels of rFVIIa are required to rescue fibrin formation
through the combined generation of FXa via TF/rFVIIa and platelet/rFVIIa function.

5.2 Materials and Methods
Blood was drawn from healthy donors (n = 5) and hemophilic patients (n = 10) under
Internal Review Board approval of the University of Pennsylvania. Data regarding patient
bleeding phenotype and recent therapy was collected (Table 3)
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Patient
ID#

PT

Platelets
(103/µL)

Timing
of Most
Recent
Therapy

56.1

13.3

172

3 days

32

32.7

12.9

291

5 hrs

14

34.4

13.7

252

96 hrs

6

51.2

14.9

200

3 days
None in
past 5
years
None in
past 10
months
None
since
2012

Residual
Coagulation
Factor %*

aPTT
(Sec)

3

65

Diagnosis
Severe
Hemophilia A
Severe
Hemophilia A
Severe
Hemophilia B
Severe
Hemophilia B
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Mild Hemophilia
A

18

37.4

12.9

244

68

Moderate
Hemophilia A

6

50.8

14.1

173

2

53.5

12.5

217

24

40.1

12.8

273

5

51.1

15.9

208

26 hrs
None in
past 5
years

**<1

133.6

14.5

125

8 hrs

62
63
64

69
70

71
29

Moderate
Hemophilia A
Severe
Hemophilia A
Moderate
Hemophilia B
Severe
Hemophilia B

Replacement
Therapy
Dosage
rFVIII (35
IU/kg)
rVIII (25
IU/kg)
rFIX
(unknown)
rFIX (47
IU/kg)
rFVIII
(unknown)

N/A

N/A
rFVIII (50
IU/kg)

N/A
rFIX (50
IU/kg)

Table 3. 10 patients were examined with respect to exogenous rFVIIa efficacy by
perfusion of high CTI inhibited WB on TFlow and TFhigh collagen surfaces.
Time since last hemostatic therapy, % residual coagulation factor activity, PTT, and platelet count are as
reported. *Reflects in some cases recent administration of factor concentrate.

Laboratory testing of hemophilic patients included a platelet count, residual coagulation
factor activity, prothrombin time (PT), and activated partial thromboplastin time (aPTT).
Residual FVIII, FIX, or FXI activity were measured in Hemophilia A and VWD disease,
Hemophilia B, or Hemophilia C diagnoses respectively. The aPTT test assesses intrinsic
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pathway function by measuring the time to clot formation in platelet-poor plasma in the
presence of exogenous intrinsic pathway activators such as kaolin[112]. aPTT values
(reference range: 20.9-34.4 sec) were negatively correlated with residual factor activity levels
as previously established[23]. Healthy donors were self-reported free of oral medication for 7
days and abstained from alcohol 48 h prior to blood donations.
WB was drawn into 40 µg/ml CTI (Haematologic Technologies, Essex Junction,
VT) containing polypropylene plastic syringes, a material which activates the contact
pathway minimally. At 40 µg/ml, CTI will almost completely abolish contact pathway
activation and prevent visible clotting for 30 to 45 min allowing studies of surface-trigged
TF-dependent coagulation under flow with minimal participation of FXIIa[80]. This
concentration of CTI allows sufficient time for completion of all assays with no clotting in
the 35 µL entrance reservoirs of the microfluidic devices.
Preparation of TF bearing collagen surfaces
Glass slides were first functionalized with Sigmacote (Sigma, St. Louis, MO) to create
a hydrophobic surface. Acid-insoluble equine type I collagen fibrils (Chrono-Par, Chronolog, Havertown, PA) were introduced into a previously described single channel microfluidic
patterning device (250 µm by 1 cm) [33,34]. This patterning device was then filled with 5 µL
of Dade Innovin PT reagent (Siemens Healthcare USA, Malvern, PA. 20 nM stock
concentration) diluted 300 or 5 fold with 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic
acid (HEPES)-buffered saline (HBS, 20 mM HEPES, 160 mM NaCl, pH 7.4) to obtain low
or high TF surface concentrations. TF surface concentrations were measured by the staining
of TF vesicles with fluorescein isothiocynate labeled annexin V as previously described[113].
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In all microfluidic experiments TF bearing collagen surfaces were incubated for 30 minutes
in the absence of flow and then washed with 5 µl of 0.5% bovine serum albumin (BSA) in
HBS. Nominal low and high TF surface concentrations ([TF]wall) were ~0.1 and ~2
molecules per µm2, respectively, as previously reported[113]. This single channel patterning
device was then removed to allow placement of microfluidic flow devices onto the
micropatterned TF bearing collagen strip.
Extrinsic pathway triggered microfluidic flow assay on TF bearing collagen surfaces
An 8-channel microfluidic device was fabricated in polydimethylsiloxane (PDMS,
Sylgard 184, Ellsworth Adhesives) according to previously described techniques[33,64]. The
device has 8 channels fed by 8 wells with perfusion by withdrawal from a single outlet into a
syringe pump (PHD 2000, Harvard Apparatus, Holliston, MA). This 8-channel device was
placed over TF bearing collagen surfaces and reversibly sealed by house vacuum. The
channels (250 µm by 60 µm) of the device run perpendicularly over a 250 µm wide strip of
patterned equine fibrillar collagen type I bearing TF. This forms platelet and prothrombotic
protein interaction zones measuring 250 µm by 250 µm. A customized stage insert held two
microfluidic devices allowing replicate testing of 4 conditions in 60 sec intervals. Microfluidic
devices were mounted on an inverted microscope (IX81, Olympus, Center Valley, PA).
Microfluidic channels were spaced in close proximity to allow two channels to be imaged
simultaneously with a 10X objective lens equipped with a charged-coupled device (ORCAER, Hamamatsu, Bridgewater, NJ). Prior to initiation of the flow assay, all channels were
blocked with 0.5% bovine serum albumin (BSA) in HBS.
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Blood samples were treated with fluorescently conjugated non-function blocking
anti-CD41a antibody (clone VI-PL2, Becton Dickson, Franklin Lakes, NJ, 0.125 µg/ml final
concentration) to label platelets and fluorescently conjugated anti-fibrin antibody (clone
T2G1, Dr. Mortimer Poncz laboratory, Children's Hospital of Philadelphia, 0.5 µg/ml final
concentration) to label fibrin. WB samples were also treated with vehicle HBS or indicated
concentrations of rFVIIa. Recombinant FVIIa (NovonSeven, Novo Nordisk, Plainsboro NJ,
1 mg/ml final concentration) was reconstituted in histidine diluent. WB samples were treated
with detection antibodies and rFVIIa 5 min prior to initiation of flow assays. A dilution of
rFVIIa was made to the final desired concentration in HBS within 1 hr of the tests. Whole
blood perfusion in microfluidic devices started within 15 min of venipuncture. Blood
samples were perfused at an initial local wall shear rate of 100s-1 (1 µL/min per channel) for
15 min. In constant flow rate mode the local wall shear rate monotonically increases as
thrombi grow to the channel height[37].
Platelet and fibrin accumulation analysis
Platelet and fibrin fluorescence intensities, which are proportional to the total platelet
and fibrin masses respectively were measured in 60 sec intervals for 15 min through ImageJ
software (ImageJ, National Institute of Health, Bethesda, MD). The initial image was taken
as background and subsequent images were background-corrected. Platelet and fibrin masses
were measured in an area comprising of 70% center zone of the 250 µm by 250 µm TF
collagen surface due to the slightly non-uniform shear profiles along the side of the
microfluidic channels[33,34]. Platelet adhesion and fibrin formation was not observed
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upstream or downstream of the TF collagen strip prior to full channel occlusion. Statistical
significance was assessed using a two tailed Student's t test.

5.3 Results
5.3.1

Surface-triggered extrinsic pathway under flow does not rescue platelet
adherence or fibrin generation at <3% factor activity.
The hemostatic potential of surface-triggered TF under flow to rescue deficits in

FVIII or FIX was evaluated through perfusion of hemophilic or healthy WB over collagen
bearing TFlow or TFhigh surfaces.

Figure 5-1 Comparison of severely and moderately factor-deficient (1-3%) patients
against healthy donor response to TFlow or TFhigh bearing collagen surfaces
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(A & B), Platelet adherence and fibrin deposition dynamics measured by platelet and fibrin fluorescence
respectively. WB inhibited with 40 µg/ml CTI was perfused over TF low bearing collagen surfaces at 100 s-1. (B
& C), Platelet adherence and fibrin deposition dynamics over time. WB inhibited with 40 µg/ml CTI was
perfused over TFhigh bearing collagen surfaces at 100 s-1. Lines with shaded traces and points are the mean and
standard deviation of 6 clotting events measured in 60 sec intervals over 15 min for three distinct hemophilic
patients (red) or 10 clotting events measured in 60 sec intervals over 15 min for five distinct healthy subjects
(black).

High CTI-inhibited WB from two severely factor-deficient patients and one
moderately factor-deficient patient (#62, 69, 29) with 3, 2, and <1 % factor activity
respectively produced no detectable levels of fibrin (Figure 5-1B,D, red lines) as opposed
to healthy controls where robust platelet deposition and fibrin generation was measured
regardless of surface TF concentration (Figure 5-1B, D: black lines). Fully consistent with
TF/FVIIa as the primary trigger of coagulation in this microfluidic model, time to fibrin
initiation in healthy donors decreased when surface TF concentration increased (Figure
5-1B, D: black lines). Platelet deposition over time was also elevated on TFhigh collagen
surfaces indicating that thrombin generation was occurring at a concentration sufficient to
drive platelet deposition and facilitate fibrin formation (Figure 5-1C,D: black line).
Interestingly, at < 3% factor activity, hemophilic patient platelet deposition was reduced
compared to healthy blood independent of surface TF concentration (Figure 5-1A, C: red
lines).
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Figure 5-2 Comparison of 3-14% clotting factor activity patients against healthy
donor response to TFlow or TFhigh bearing collagen surfaces
(A & B), Platelet adherence and fibrin deposition dynamics measured by platelet and fibrin fluorescence
respectively. WB inhibited with 40 µg/ml CTI was perfused over TF low bearing collagen surfaces at 100 s-1. (B
& C), Platelet adherence and fibrin deposition dynamics over time. WB inhibited with 40 µg/ml CTI was
perfused over TFhigh bearing collagen surfaces at 100 s-1. Lines with shaded traces and points are the mean and
standard deviation of 6 clotting events measured in 60 sec intervals over 15 min for three distinct hemophilic
patients (red) or 10 clotting events measured in 60 sec intervals over 15 min for five distinct healthy subjects
(black).

5.3.2

Extrinsic pathway triggered coagulation under flow partially restores platelet
adhesion and fibrin generation at 3-14% factor activity.

Perfusion of moderately and mildly FVIII or FIX-deficient patient WB (#64, 65, 68, 71)
resulted in poorly detectable or low levels of fibrin accumulation under flow on TFlow or
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TFhigh surfaces, respectively (Figure 5-2C,D: red lines). Additionally, significant decreases in
platelet adhesion on TF collagen surfaces were again observed in these patients independent
of surface TF concentration (Figure 5-2A, B: red lines). However, these levels of platelet
adhesion were higher than those observed with the 1-3% factor activity group (Figure 5-1A,
C: red lines). These results indicate that engagement of the intrinsic tense (FIXa/FVIIIa 
FXa) in combination with FXa production from TF/FVIIa under flow on TFhigh collagen
surfaces was sufficient to initiate some fibrin formation and produce low amounts of fibrin
accumulation (Figure 5-1D: red lines).

Figure 5-3 Comparison of >14% clotting factor activity against healthy donor
response to TFlow or TFhigh bearing collagen surfaces
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(A & B), Platelet adherence and fibrin deposition dynamics measured by platelet and fibrin fluorescence
respectively. WB inhibited with 40 µg/ml CTI was perfused over TF low bearing collagen surfaces at 100 s-1. (B
& C), Platelet adherence and fibrin deposition dynamics over time. WB inhibited with 40 µg/ml CTI was
perfused over TFhigh bearing collagen surfaces at 100 s-1. Lines with shaded traces and points are the mean and
standard deviation of 6 clotting events measured in 60 sec intervals over 15 min for three distinct hemophilic
patients (red) or 10 clotting events measured in 60 sec intervals over 15 min for five distinct healthy subjects
(black).

Figure 5-4 Total platelet or fibrin accumulation for different clinical severities of
hemophilia
(A & B), Maximum platelet or fibrin accumulation on TF low bearing collagen surfaces at 100 s-1 measured by
platelet or fibrin fluorescence at t = 15 min or just prior to full channel occlusion. Data is ordered by severity

87

of factor deficiency (1-3%, 3-14% & >14%) and compared to mean healthy subject maximum platelet or fibrin
accumulation. (C & D), Maximum platelet or fibrin accumulation on TFhigh bearing collagen surfaces at 100s-1
measured by platelet or fibrin fluorescence at t = 15 min or just prior to full channel occlusion. Data is ordered
by severity of factor deficiency (1-3%, 3-14% & > 14%) compared to mean healthy subject maximum platelet
or fibrin accumulation. Error bars are the standard deviation of 6 clotting events for each clinical severity of
hemophilia and 10 clotting events for five healthy subjects. (** p < 0.01, * p < 0.05, ns: non-significant)

5.3.3

Platelet adhesion is partially rescued by the extrinsic pathway independent of
TF concentration while fibrin formation is fully restored on TFhigh collagen
surfaces at >14% factor activity
Platelet deposition from WB of mildly FVIII or FIX-deficient patients (#63, 67, 70)

remained attenuated in comparison to the platelet deposition from healthy controls although
it was not statistically significant with low surface TF concentrations (Figure 5-3A, C).
Interestingly, we observed residual defect in fibrin production at >14% factor activity in the
presence of TFlow collagen surfaces (Figure 5-3B: red line). Time to fibrin initiation and
total fibrin accumulation under flow was fully restored with TFhigh collagen surfaces (Figure
5-3: red line). The influence of FVIIIa and FIXa become more prominent as residual
clotting factor levels reach >14%.
In examining total platelet and fibrin accumulation under flow at 15 min for all
cohorts, platelet and fibrin accumulation on TFlow and TFhigh surfaces was highly defective
for blood from patients with 1-3% normal factor level when compared to healthy blood
(Figure 5-4A-D). High levels of TF do not rescue clotting in severely factor-deficient
patients (Figure 5-4D) whose blood generated essentially no fibrin.
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Figure 5-5 Effect of in vitro rFVIIa (0-20 nM) in severely FVIII-deficient patient
(A & B), Platelet adherence and fibrin deposition in the presence or absence of exogenous rFVIIa measured by
platelet and fibrin fluorescence at t = 15 min or just prior to full channel occlusion. WB treated with exogenous
rFVIIa (0-20 nM) and inhibited with 40 µg/ml CTI was perfused over TFlow bearing collagen surfaces at 100 s1.

(C & D), Platelet adherence and fibrin deposition in the presence or absence of exogenous rFVIIa

measured by platelet and fibrin fluorescence. WB treated with exogenous rFVIIa (0-20 nM) and inhibited with
40 µg/ml CTI was perfused over TFhigh bearing collagen surfaces at 100 s-1. Lines with shaded traces and points
are the mean and standard deviation of 2 clotting events measured in 60 sec intervals over 15 min for each
concentration of rFVIIa (colored) or 10 clotting events measured in 60 sec intervals over 15 min for five
distinct healthy subjects (gray).
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Figure 5-6 Total platelet or fibrin accumulation in response to in vitro rFVIIa (0-20
nM) for different clinical severities of hemophilia
(A & B), Maximum platelet or fibrin accumulation in the presence or absence of exogenous rFVIIa measured
by platelet or fibrin fluorescence. WB treated with exogenous rFVIIa (0-20 nM) and inhibited with 40 µg/ml
CTI was perfused over TFlow bearing collagen surfaces at 100s-1. Data is ordered by severity of factor deficiency
(1-3%, 3-14% & >14%) and compared to mean healthy subject maximum platelet or fibrin accumulation. (C
& D), Maximum platelet or fibrin accumulation in the presence or absence of exogenous rFVIIa measured by
platelet or fibrin fluorescence. WB treated with exogenous rFVIIa (0-20 nM) and inhibited with 40 µg/ml CTI
was perfused on TFhigh bearing collagen surfaces at 100s-1. Data is ordered by severity of factor deficiency (13%, 3-14% & >14%) and compared to mean healthy subject maximum platelet or fibrin accumulation. Data is
ordered by severity of factor deficiency (1-3%, 3-14% & > 14%) compared to mean healthy subject maximum
platelet or fibrin accumulation. Error bars are the standard deviation of 6 clotting events for each clinical
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severity of hemophilia and 10 clotting events for five healthy subjects. (** p < 0.01, * p < 0.05, ns: nonsignificant)

5.3.4

Exogenous rFVIIa enhances platelet deposition on collagen with TFlow and
TFhigh, but only fully restores fibrin accumulation at 20 nM on TFhigh collagen
in a severely FIX-deficient patient
Perfusion of WB from a severely FIX-deficient patient (#29; <1% FIX) showed

negligible fibrin accumulation that was only partially rescued by even 20 nM rFVIIa on
TFlow/collagen (Figure 5-5B). Addition of rFVIIa strongly enhanced platelet deposition at
either TF concentration (Figure 5-5. 5A,C). The combination of high exogenous rFVIIa
(20 nM) and TFhigh/collagen was able to fully restore fibrin initiation and accumulation under
flow (Figure 5-5D).
The effect of exogenously added rFVIIa was tested on patients with a range of
hemophilic severity using TFlow and TFhigh surfaces. A level of 20 nM rFVIIa significantly
increased final platelet and fibrin accumulation at 1-3% factor activity (Figure 5-6) to levels
commensurate with that observed with untreated healthy blood. With increasing rFVIIa
supplementation, healthy whole blood also displayed increased platelet and fibrin deposition
on TFlow and TFhigh(Figure 5-6).
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Figure 5-7 Signaling pathways of hemophilic blood when triggered by surface
TF/collagen in the presence or absence of rFVIIa.
In hemophilic blood clotting under flow conditions over TF, most FXa comes from the intrinsic tenase
(FIX/FVIIIa) even when some FXa can be initially generated by the extrinsic tenase TF wall/FVIIa and
platelet/rFVIIa.
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Phenotype

Severe

Condition
Surface

Collagen

(< 3%)

Moderate

Collagen

(3-10%)

Contact
pathway

rFVIIa

No (high
CTI)

0

low

none

No (high
CTI)

+

modest
rescue

none

Yes (low
CTI)
Yes (low
CTI)
No (high
CTI)

0

Low

none

+

slight rescue

~none

0

modest

none

No (high
CTI)

+

rescue

none

Yes (low
CTI)

0

modest

very low

Yes (low
CTI)

+

rescue

rescue

0

very low

none

+

rescue

rescue

0

very low

none

Collagen +
[TF]low
Severe

Collagen +
[TF]low

(<3 %)

Collagen +
[TF]high

Clotting at 100 s-1
Platelets
Fibrin

No (high
CTI)

[ref.]
[24]

[24]

*
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Collagen +
[TF]high

+

rescue

rescue

Collagen +
[TF]low

0

modest

modest

*

No (high
CTI)

Moderate

Collagen +
[TF]low

+

modest

modest

(3-10%)

Collagen +
[TF]high

0

moderate

moderate

moderate
moderate
Collagen +
+
[TF]high
Table 4. Clotting potential of severe or moderate hemophilic A or B blood when

triggered by the low or high levels of contact activation or extrinsic activation in the
presence and absence of rFVIIa.
Rescue indicates return to response levels of healthy blood. Low CTI: 4 µg/mL corn trypsin inhibitor; High CTI:
40 µg/mL corn trypsin inhibitor. Mild hemophilic blood (>14-15%) preforms without large functional deficit
when compared to healthy blood in this assay under conditions of contact or extrinsic activation with reduced
sensitivity to added rFVIIa. *, this study.

5.4 Discussion and Conclusion
Microfluidic assays consisting of high CTI (40 µg/ml)-inhibited WB perfusion on
TFlow or TFhigh /collagen surfaces at venous wall shear rates were used to evaluate platelet
deposition and fibrin formation in hemophilic patients. A broad cohort of patients were
tested representing a large spectrum of clinical phenotypes of hemophilia A or B (severe,
moderate, and mild(Table 3). Under these ex vivo hemodynamic conditions, we observed
significantly decreased platelet deposition and fibrin formation on TFlow and TFhigh collagen
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surfaces in severe hemophilic samples. Taken together, these results indicate that in healthy
blood clotting under flow conditions over TF, most Factor Xa comes from the intrinsic
tenase (FIXa/FVIIIa) even when some FXa can be initially generated by the extrinsic tenase
TF/FVIIa (Figure 5-7).
With respect to factor-deficient patients at 1-3% factor activity (Figure 5-1), we
observed severe deficits in platelet adherence and fibrin formation that was not rescued by
perfusion on TFhigh collagen surfaces. With the intrinsic tenase severely blunted as in the case
of severe FVIII or FIX-deficiency, surface TF-triggered coagulation failed to produce
adequate levels of thrombin for detectable fibrin formation (Figure 5-1B,D). At high
surface TF concentrations of ~ 2 TF molecules/µm2 as measured in a prior study [113], the
extrinsic tenase could not support fibrin formation when critical residual clotting factor
activity was <3% (Figure 5-1D). Interestingly, we did not observe similar trends when we
tried to recreate the conditions of acquired severe hemophilia in these microfluidic assays
through the use of function-blocking antibodies against FVIII or FIX (data not shown)
added to healthy blood. Under flow conditions on TFlow or TFhigh collagen surfaces, normal
blood treated with function-blocking antibodies against FVIII or FIX only displayed
decreases in fibrin formation on TFlow collagen surfaces while no effect was seen on platelet
deposition. This suggests large functional differences between true factor deficiencies, factor
deficiencies plus inhibitors, and laboratory experiments with antibodies added to healthy
blood.
At 3-14% factor activity, TF collagen surfaces were able to partially restore platelet
adhesion and fibrin formation under flow, yet these levels were still significantly below
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healthy WB controls (Figure 5-2). This restoration of platelet adhesion and fibrin generation
was likely due to sufficient intrinsic tenase (FVIIIa/FIXa) functioning on platelets to
generate sufficient FXa for thrombin and fibrin production. Finally, at >14% factor activity,
platelet adhesion was moderately suppressed while TFhigh/collagen fully restored fibrin
formation (Figure 5-3). This is consistent with previous studies which report adequate local
thrombin concentrations that support fibrin formation under flow in the case of mild FVIII
deficiencies and high surface TF concentrations[77]. These findings are also consistent with
previous studies that report FVIII/FIX dependent enhancement of platelet procoagulant
activity as a limiting step in fibrin formation under flow[111].
We also assessed the role of rFVIIa in platelet deposition and fibrin formation under
flow in hemophilic and healthy WB samples. Results from a severe hemophilic patient
indicate that rFVIIa amplifies platelet deposition but was not fully sufficient to support
fibrin generation if the contact pathway was inhibited (Figure 5-5) [24]. However, a
combination of 20 nM exogenous rFVIIa and TFhigh/collagen facilitated strong fibrin
production in the severely FVIII-deficient patient (Figure 5-5D). A consideration of final
platelet and fibrin deposit size in the presence of exogenous rFVIIa indicates enhancement
of platelet and fibrin accumulation in the severely factor-deficient hemophilic patients tested
(Figure 5-6). A similar trend was observed when rFVIIa was exogenously added to the WB
of healthy donors followed by perfusion on TFlow and TFhigh collagen surfaces (Figure 5-6).
In summary, we took a systems approach by modulating the following inputs: contact
pathway engagement, the procoagulant surface trigger, and exogenous concentrations of
rFVIIa. We then explored the impact of these inputs and found distinct changes in platelet
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deposition and fibrin generation under flow as a function of these inputs (Table 4). Based
on this study and our earlier study[24], rFVIIa cannot rescue fibrin deposition via the cellular
pathway alone, unless FXIIa or TF is participating.
Distinct from the studies of Swieringa et al. who added TF directly into blood prior to
perfusion, the micropatterning of TF-rich collagen surfaces generates localized regions of
thrombosis in microfluidic channels which ensures that blood does not come into contact
with extraneous prothrombogenic surfaces prior to the region of interest. This enables study
of platelet deposition in conjunction with surface-triggered coagulation akin to the laser
cremaster injury[114–116]. In contrast, addition of exogenous TF into blood fails to recreate
the hemodynamic aspects of thrombosis which are highly dependent on surface presentation
of TF to the flowing blood[35]. Furthermore, the present work extends previous studies by
directly examining the contribution of platelet bound rFVIIa on platelet and fibrin formation
under flow in a wide range of hemophilic patients[77].
In conclusion, our microfluidic assay results from WB of FVIII or FIX-deficient
patients indicate a critical role of the intrinsic tenase in driving platelet adhesion and fibrin
formation on TF-laden collagen substrates at venous shear rates (Figure 5-7). FVIII/FIX
dependent thrombin production on the platelet surface and the subsequent thrombin
activation of platelets along with fibrin formation are potent, key pathways in thrombus
formation under flow.
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6

EX VIVO RECAPITULATION OF TRAUMA-INDUCED
COAGULOPATHY UNDER FLOW AND PRELIMINARY
ASSESSMENT OF PLATELET FUNCTION FOLLOWING
TRAUMA USING MICROFLUIDIC TECHNOLOGY

6.1 Introduction
Trauma is the leading cause of death in people under the age of 36 years old[117].
Many severely injured patients exhibit trauma induced coagulopathy (TIC), a hemorrhagic
state that accounts for 40% of trauma deaths[117]. TIC is multifactorial and associated with
tissue injury, inflammation, shock, hemodilution, acidosis, hypoxia, and hypothermia[117].
Tissue injury and shock result in hyperfibrinolysis due to the acute release of tissue
plasminogen activator (tPA) from endothelial cells. Systemic fibrinolysis results in fibrinogen
consumption and limits clot formation and stability at the site of vascular injury, resulting in
increased bleeding risk[118]. Furthermore, blood loss followed by resuscitation with colloids
or packed red blood cells (PRBCs) leads to the hemodilution of clotting factors.
Current research in TIC has focused on coagulation factors and proteases, with the
role of platelet function during trauma not as well-defined[119,120]. Platelet function studies
of trauma patients have been difficult to implement due to the technical complexities of
current platelet function tests. Although recent advances in platelet aggregometry and
thromboelastography (TEG) have enabled important studies of platelet function and clot
strength in trauma patients [121–125]. These techniques, however, are closed systems lacking
flow or are comprised of poorly defined flow fields.
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Microfluidic systems are open systems where blood flows over a zone of defined
procoagulant surface, thereby recreating the unique spatial and compositional attributes of
blood clotting found in vivo [23]. Microfluidic technology in conjunction with
micropatterning techniques enable low volume and high throughput testing of platelet
function and fibrin generation over a range of physiological shear stresses [34,37,126–128].
Microfluidic whole blood assays have been previously used to evaluate platelet and clotting
function in hemophiliacs and healthy donors taking antiplatelet therapeutics [23,24,77,129].
In regards to current resuscitation strategies, the administration of PRBCs with or
without fresh frozen plasma (FFP) and the optimal FFP:PRBCs ratio remain active areas of
investigation [130]. Prospective studies have shown that platelets may serve as the third
component of resuscitation strategy [130–133]. PRBC administration not only increases
hemoglobin, but also contributes biorheologically by driving platelet margination towards
the vessel wall.
In this study, we applied microfluidic technology to investigate resuscitation-driven
hemodilution, hyperfibrinolysis, and plasmin-inhibitor therapy, all topics relevant to TIC risk
and treatment. Additionally, we evaluated platelet function under flow using whole blood
from trauma patients during the acute phase of TIC.

6.2 Methods
6.2.1

Microfluidic evaluation of hemodilution and hyperfibrinolysis
Following approval from the Internal Review Board approval at the University of

Pennsylvania, healthy donors (n = 15) were recruited to donate whole blood using standard
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phlebotomy techniques. Donors were required to refrain from all oral medications for 7 days
and abstain from alcohol for 48 h prior to donation. Blood was drawn into corn trypsin
inhibitor (CTI, Haematologic Technologies, Essex Junction, VT, 40 µg/ml final
concentration) or FPR-chloromethylketone (PPACK, Haematologic Technologies, Essex
Junction, VT, 100 µM final concentration). CTI inhibits the contact pathway for studies of
surface-triggered coagulation while PPACK inhibits thrombin generation in order to
examine platelet function in the absence of thrombin in vitro. Blood samples were treated
with fluorescently conjugated anti-CD61a antibody (clone VI-PL2, Becton Dickson,
Franklin Lakes, NJ, 0.125 µg/ml final concentration) to label platelets and fluorescently
conjugated fibrinogen (Invitrogen, Life Technologies, Carlsbad, CA, 75 µg/ml) to label
fibrin(ogen) 5 min prior to initiation of flow assays. All healthy donor microfluidic
experiments were completed within 45 min of phlebotomy.
Microfluidic fabrication methods and device specifications were previously described
[24,33,34]. Microfluidic channels ran perpendicularly over a 250 µm wide strip of patterned
equine fibrillar collagen type I (Chronopar, Chronolog) or Tissue Factor (TF) bearing
collagen type I surfaces (Dade Innovin, Siemens Healthcare USA, Malvern, PA).
Epifluorescent microscopy and image acquisition were performed in real-time as previously
described [23,24]. Dilution of the hematocrit to simulate resuscitation-induced hemodilution
was achieved with exogenous addition of HEPES buffered saline (HBS, 20 mM HEPES,
160 mM NaCl, pH 7.5), donor specific platelet poor plasma (PPP) or platelet rich plasma
(PRP). Isolation of PRP or PPP was previously described [24,80]. HBS, PPP or PRP was
added in 1:3, 1:1, 3:1 ratio to whole blood to obtain Hct levels of 30%, 20%, 10%
100

respectively 5 min prior to initiation of the flow assay. Fibrinolysis was promoted by
exogenously adding 10X stock solutions of tPA (abcam, Cambridge, MA, 0-50 nM). Blood
samples were perfused at an initial venous wall shear rate of 200 s-1 or an initial arterial wall
shear rate of 1222 s-1 in a previously designed pressure relief mode for 20 min [37]. Platelet
and fibrin accumulation were analyzed as previously described [24].
6.2.2

Microfluidic Assessment of Trauma patient platelet function
Following Institutional Review Board approval, blood was collected from trauma

patients (n = 20) who had sustained injuries requiring evaluation at the Hospital of
University of Pennsylvania (HUP) Level 1 Trauma Center. Exclusion criteria included failure
to obtain an initial blood draw and death within 24 h of admission. Patient demographics,
clinical laboratory test results, and outcomes were recorded (Table 5). All trauma patients
had Hct levels and platelet counts within physiologic ranges (Table 5). All clinical laboratory
tests were obtained at the same time as the microfluidic assessment of trauma patient platelet
function. All trauma patient samples were collected within one hour of injury. A blood
sample was drawn upon patient arrival using 21-guage or larger needle into a 10 ml plastic
syringe (Becton Dickson, Franklin Lakes, NJ) containing no anticoagulant. Blood samples
were aliquoted into vacationers for clinical assays and residual blood was transferred into a
single vacutainer containing 100 µM PPACK. The effects of this collection method and the
delay between phlebotomy and inhibition by PPACK (average ~ 3 min) were assessed and
found to have negligible effects on platelet activation and thrombin generation (Figure 8-16,
Figure 8-17).
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Table 5. Twenty trauma patient characteristics and clinical data
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Twenty trauma patients were examined in WB microfluidic assays with PPACK-inhibited WB perfusion over
collagen. Trauma patient characteristics and clinical data are as reported, blood products post microfluidic testing
were administered within the first hour of evaluation by Hospital of University of Pennsylvania (HUP) Level 1
Trauma Center. Medications altering coagulation, blood product use, pre-existing conditions, Hct, platelet count,
Injury Severity Score (ISS), diagnosis of traumatic brain injury (TBI), PT, PTT, INR, blood alcohol level, and
blood products post microfluidic testing are as reported. (MCC, motorcycle crash; MVC, motor vehicle crash;
GSW: gun shot wound; SW, stab wound.)

PPACK anticoagulated blood samples were treated with fluorescently conjugated antiCD61a antibody (clone VI-PL2, Becton Dickson, Franklin Lakes, NJ, 0.125 µg/ml final
concentration) to label platelets and anti-human CD62P (P-Selectin) antibody (BioLegend,
San Diego, CA, 4 µg/ml final concentration) to stain for P-Selectin. Blood samples were
subsequently treated with either HBS or 100X stock solutions of the indicated antagonists.
MRS 2179 (2'-deoxy-N6-methyladenosine 3', 5'-bisphosphate ammonium salt (MRS 2179,
Tocris Bioscience, Minneapolis, MN), S-Nitrosoglutathione (GSNO, Santa Cruz
Biotechnology, Dallas TX), and iloprost (Tocris Bioscience) were the antagonists used and
dissolved at 0.1 mM, 10 mM, 0.2 mM in HBS respectively. Whole blood perfusion in
microfluidic devices started within 10 min of blood collection in constant flow mode at 100
s-1.
6.2.3

Statistical significance analysis
Statistical significance was assessed using a two-tailed unpaired Student's t-test. Data

sets were considered significantly different from each other if the calculated p-value < 0.05.
Exact p-values are reported in the results where p > 0.001, otherwise p < 0.001 is denoted.
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6.3 Results
6.3.1

Hemotocrit reduction: dilution reduces platelet deposition on collagen (no
thrombin) and platelet-fibrin accumulation on TF/collagen
Our healthy volunteer study population had a mean age 26.2 ± 1.52y (10M/5F). The

effect of hematocrit dilution on platelet deposition was evaluated by ex vivo dilution of
healthy whole blood with either saline, PPP, or PRP (Figure 8-11). In the absence of
thrombin with PPACK-inhibited whole blood at 200 s-1, platelet deposition was strongly
inhibited by hemodilution with saline (p < 0.001), PPP (p < 0.001), or PRP (p < 0.001: 10 &
20% Hct, p = 0.01: 30% Hct) (Figure 6-1A,C,E). As expected in the microfluidic flow
assay over collagen, fibrin generation was dependent on thrombin production and was
negligible in PPACK-inhibited whole blood in the absence of surface-patterned TF on
collagen (Figure 6-1B, D, F).
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Figure 6-1 Platelet accumulation on collagen in healthy donors following Hct
dilution in the absence of thrombin.
(A & B), Platelet and fibrin fluorescence intensities vs. time with saline dilution of Hct. (C & D), Platelet and
fibrin fluorescence vs. time with PPP dilution of Hct. (E & F), Platelet and fibrin fluorescence intensities vs.
time with PRP dilution of Hct. Shaded traces are the mean and standard deviation of 10 clotting events from 5
donors.
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Similarly, in the presence of surface-triggered coagulation (Figure 6-2), we detected
significant decreases in platelet accumulation for all lowered Hct levels when whole blood
was diluted with saline (p < 0.001: 10 & 20% Hct, p = 0.0154: 30% Hct), PPP (p < 0.001: 10
& 20% Hct, p = 0.002: 30% Hct or PRP (p < 0.001: 10% Hct, p = 0.0035: 20% Hct, p =
0.0316: 30% Hct) (Figure 6-2A, C, E). Total fibrin accumulation at lower Hct levels was
also significantly reduced when whole blood was supplemented with saline (p < 0.001: 10, 20
& 30% Hct) or PPP (p < 0.001: 10% Hct, p = 0.005: 20% Hct, p = 0.0064: 30% Hct) or
PRP (p < 0.001: 10% & 20% Hct, p = 0.3576: 30% Hct) to reduce Hct (Figure 6-2B, D).
The reduced fibrin accumulation observed with reduced Hct cannot be due to a reduction in
coagulation factors since the concentration of coagulation proteins remains constant when
whole blood is diluted with PPP or PRP (as opposed to saline dilution). In this experiment,
reduced platelet deposition was highly correlated with reduced fibrin production as Hct was
reduced, regardless of how Hct was lowered (Figure 6-2).
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Figure 6-2 Platelet and fibrin accumulation on TF bearing collagen in healthy donors
following Hct dilution
(A & B), Platelet and fibrin fluorescence intensities vs. time with saline dilution of Hct. (C & D), Platelet and
fibrin fluorescence intensities vs. time with PPP dilution of Hct. (E & F), Platelet and fibrin fluorescence
intensities vs. time with PRP dilution of Hct. Shaded traces are the mean and standard deviation of 10 clotting
events from 5 donors.
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6.3.2

Exogenous tPA activates the lytic state at venous and arterial shear rates and
promotes hyperfibrinolysis
Following severe trauma and shock, injured endothelial cells release tPA systemically

leading to hyperfibrinolysis [117]. To mimic this pathological mechanism, tPA was
exogenously added to whole blood (Figure 8-11). At venous shear rates (200 s-1), exogenous
addition of tPA to whole blood had negligible effects on platelet deposition on TF bearing
collagen surfaces under flow (Figure 6-3A, B; ns). However, the rapid production of
plasmin at the surface-patterned injury site in conjunction with fibrin formation at 200 s-1
induced a 'lytic state' with 50 nM ex vivo tPA added. Total fibrin accumulation decreased
63.9 % by 10 min (Figure 6-3C; p = 0.0044). To reverse the 'lytic state' and stop fibrinolytic
activity under flow, we added the lysine analogue ε-aminocaproic acid (εACA) to inhibit
plasmin activity. The inhibition of plasmin by εACA restored total fibrin accumulation to
levels comparable to control conditions but resulted in delayed fibrin initiation (Figure
6-4C). At arterial shear rates (1222s-1), embolization occurred with tPA as indicated by a
significant drop in the platelet signal by 12 min (Figure 6-4). The platelet signal continued to
decrease approaching zero by the end of the 20 min assay (Figure 6-4B). Exogenous tPA
addition minimized total fibrin accumulation while treatment with εACA non-significantly
increased platelet deposition (p = 0.1024) and total fibrin accumulation (p = 0.1132) (Figure
6-4B, C). Interestingly, in a few channels of the microfluidic assay at either venous or
arterial wall shear rates, tPA-mediated fibrinolysis was followed by destabilization of platelet
deposits which then embolized downstream. This disruption of platelet rich thrombi from
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the patterned injury site was followed a second round of platelet deposition and renewed
fibrin generation (Figure 8-14, Figure 8-15).

Figure 6-3 Platelet and fibrin accumulation in response to exogenous tPA ± εACA at
venous shear rates
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 200 s -1 over the time course of
the 20 min assay. (B), Platelet fluorescence intensities vs. time with exogenous tPA ± εACA. (C), Fibrin
fluorescence intensities vs. time with exogenous tPA ± εACA. Shaded traces are the mean and standard
deviation of 12 clotting events from 3 donors.
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Figure 6-4 Platelet and fibrin accumulation in response to exogenous tPA ± εACA at
arterial shear rates
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 1222 s -1 over the time course of
the 20 min assay. (B), Platelet fluorescence intensities vs. time with exogenous tPA ± εACA. (C), Fibrin
fluorescence intensities vs. time with exogenous tPA ± εACA. Shaded traces are the mean and standard deviation
of 8 clotting events from 2 donors.
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6.3.3

Trauma patient platelet function tests: delayed platelet recruitment to collagen
and attenuated secondary aggregation
Our 20 trauma patient population had a mean age of 50.2 ± 22.84 and a median

injury severity score (ISS) of 7.5 with an interquartile range of 25. There were 15%
penetrating injuries and 25% brain injuries. Rapid platelet function testing of PPACKinhibited whole blood from trauma patients (n = 20) revealed a subpopulation of patients
(14/20) with reduced platelet function upon arrival to a Level 1 Trauma Center (Figure 6-5,
Figure 8-18). When compared to 7 healthy donors, 14 trauma patients were found to have
significantly decreased total platelet accumulation measured at 900 sec (Figure 8-19; p <
0.001). We categorized these subset of patients as 'loss of function'. Patients with statistically
significant increased total platelet accumulation measured at 900 sec when compared to
healthy donors were categorized as 'gain of function' (Figure 6-5, Figure 8-19) Visual
inspection of platelet aggregates formed on collagen surfaces indicate two loss of function
phenotypes in trauma patients. The first loss of function phenotype in trauma patients was
characterized by platelets failing to adhere to the collagen surface indicative of dysfunctional
platelet glycoprotein VI (GPVI) (Figure 6-5B, C, E, K). In a second observed loss of
function phenotype, platelet aggregate growth beyond the initial monolayer of platelets was
minimal or completely missing (Figure 6-5D, F-N). Platelet aggregates tended to form
above the initial monolayer of collagen-adherent platelets but were subsequently washed
downstream. Clots formed from these patients did not grow to full channel occlusion during
the duration of the 900 sec assay (Figure 6-5, black arrow). This failure of secondary
aggregation in these patients may be due to a lack of ADP or thromboxane A2 mediated clot
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growth. Interestingly, 3 patients exhibited hyper-responsive platelet function in this
microfluidic assay with two patients forming occlusive clots within the first 400 seconds
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(Figure 6-5R-T).
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Figure 6-5 Trauma patient thrombi morphology at 900 sec and platelet deposition
dynamics at venous shear rates (100 s-1)
(A & A'), Platelet fluorescence intensities vs. time for representative healthy donor and representative image of
final platelet accumulation at 900 sec. (B-N & B'-N', blue line), Platelet fluorescence intensities vs. time and
representative image of final platelet accumulation at 900 sec for trauma patients exhibiting loss of platelet
function. (O-Q & O'-Q', yellow line), Platelet fluorescence intensities vs. time and representative images of
final platelet accumulation at 900 sec for trauma patients exhibiting normal platelet function. (R-T & R'-T',
green line), Platelet fluorescence intensities vs. time and representative images of final platelet accumulation at
900 sec for trauma patients exhibiting gain of platelet function. Shaded traces are the mean and standard
deviation of 4 clotting evens from each patient. (MCC: Motorcycle Crash, MVC: Motor Vehicle Crash, SW:
Stab wound, GSW: Gun Shot Wound)

6.3.4

Trauma patient platelets respond less to antagonism by MRS2179 and iloprost
but increased sensitivity to inhibition by GSNO
To assess the various pathways that affect trauma platelet signaling under flow, we

antagonized platelet function in three different manners (Figure 8-12). MRS 2179 was used
to potently inhibit the platelet ADP receptor, P2Y1. The addition of GSNO was used to
stimulate nitric oxide production ex vivo and iloprost was used to raise cyclic adenosine
monophosphate (cAMP) levels in order to reduce platelet aggregation. On average, trauma
patients with detectable baseline platelet function measured by platelet fluorescence
responded to all three forms of antagonism (Figure 8-12C). Total platelet accumulation at
900 sec was reduced 58.8%, 43.83% and 73.80 % by MRS2179, GSNO, and iloprost
respectively in trauma patients (n = 17, 68 clots, p < 0.001) as compared to 79.2%, 15.2%,
and 91.81% in healthy donors (n = 6, 24 clots, p < 0.001) (Figure 8-20). Interestingly,
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trauma patient platelet function responded less to the addition of MRS 2179 or iloprost but
was more strongly inhibited by production of nitric oxide ex vivo (Figure 8-20; MRS 2179:
p = 0.003, Iloprost or GSNO: p < 0.001).
6.3.5

A subpopulation of trauma patient platelets displayed decreased p-selectin
expression under flow
P-selectin surface expression was also used as a marker for α-granule secretion and

irreversible platelet activation in our microfluidic assay (Figure 8-13). A population of
trauma patients (9/21) exhibited low p-selectin expression in the flow assay (data not shown)
however, when normalized against the platelet fluorescence signal, a single patient displayed
a severe deficit in p-selectin expression on a per platelet basis (Figure 8-13B-D). The lack of
p-selectin expression in patient #9 may be indicative of low levels of platelet activation and
potential previous degranulation of platelets prior to microfluidic testing.

6.4 Discussion
Trauma induced coagulopathy is a multi-faceted phenomenon that occurs in a setting
of shock, hemodilution, hypothermia, and tissue injury. With the use of microfluidic
technology we evaluated hemodilution and hyperfibrinolysis, two common mechanisms of
TIC, in order to understand how derangements in platelet deposition and fibrin formation
contribute to altered hemostasis. Hemodilution of healthy whole blood with saline, PPP, or
PRP significantly reduced platelet adhesion to collagen in the absence of surface-triggered
coagulation at all lowered Hct levels (Figure 6-1). Platelet deposition was also significantly
decreased with this dilution scheme on TF-bearing collagen surfaces (Figure 6-2). RBCs
115

strongly influences platelet margination and enhances platelet accumulation at the collagen
or collagen/TF micropatterned injury site in these assays. These results indicate a significant
role for RBCs in mediating the rapid platelet response required to seal vessel injuries.
Furthermore, RBCs have also been shown to release ADP thus promoting platelet
aggregation and can potentially sustain thrombin generation [134]. This is could be another
role in which RBCs support platelet function and coagulation in our microfluidic assays.
However, ADP release from RBC is expected to be minimal under the venous flow
conditions tested (Figure 6-2).
Furthermore, a second mechanism associated with TIC is increased fibrinolytic
activity. Excessive fibrinolysis impairs clot integrity and causes bleeding. We recapitulated
this mechanism and rapidly detected changes in fibrin accumulation and clot stability in
microfluidic assays with exogenous addition of tPA. We promoted a 'lytic state' under flow
inducing fibrin lysis at venous shear rates that was rescued with ex vivo εACA addition
(Figure 6-3). At arterial shear rates, the 'lytic state' induced embolism as clots tore from the
TF bearing collagen surfaces and washed downstream (Figure 6-4). In rare cases, the 'lytic
state' induced a consumptive coagulopathy with complete fibrin lysis and disintegration of
platelet aggregates followed by platelet re-adherence and fibrin regeneration on the TF
bearing collagen surface. This observed process depletes platelets, clotting factors, and other
plasma proteins in the flowing blood. The deranged hemostasis during hyperfibrinolysis we
have recreated in the microfluidic assays mimics the coagulopathy of traumatic brain injuries
[135]. Our results suggest that hyperfibrinolysis and excessive consumption of clotting
factors work synergistically during TIC. (Figure 8-14, Figure 8-15). Finally, we were able to
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detect and quantify changes in fibrin generation and clot stability during this 'lytic state' in <6
min, a time scale much faster than what is currently capable with TEG.
In clinical settings, conventional plasma-based assays are used to assess TIC instead of
microfluidic-based assays. The prothrombin time (PT), partial thromboplastin time (PTT),
platelet count, and fibrinogen levels are the most commonly used tests for monitoring
coagulopathy following trauma. These tests, however, examine only a single component of
the hemostatic process and fail to measure clot strength, fibrinolytic activity or platelet
function. Furthermore, while TEG with or without platelet mapping is more indicative of
global hemostasis, the use of FXII activator kaolin and citrated samples are major drawbacks
with this technology. Kaolin activation of coagulation is non-physiologic as kaolin is not
found in the body and citrate is known to affect platelet αIIβIIIa integrin function. The fluid
mechanics of TEG also fail to replicate the hemodynamics of the vasculature. The
oscillatory movement of a cup in a closed system cannot generate the extraordinary platelet
concentrations in a clot on the vessel wall. Furthermore, in TEG, the moving cup is a closed
system where platelet releasates and coagulation factors can accumulate unhindered due to
the lack of transport-induced washout of these components. Microfluidic assessment of
trauma patient function detected platelet function defects in < 5 min while a complete TEG
test may take upward to 60 min [136].
In whole blood microfluidic assays, on the other hand, platelet deposition and fibrin
generation must occur under well-controlled hemodynamic conditions and in the presence
of convective dilution of thrombin, soluble agonists, and plasma proteins. During these
assays, the biorhelogic phenomena present can either limit or augment local enzyme
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concentrations. In addition to changes in the local enzyme concentrations, platelet receptorligand bonds must withstand the hydrodynamic shear stress imparted by the following
blood. Thus whole blood microfluidic assays provide a much more rigorous physiologic test
of platelet function and fibrin generation not captured by static clotting assays and TEG
[137,138].
To the best of our knowledge, our results are the first real-time platelet function
testing of whole blood samples from trauma patients using microfluidic technology. One
previous study by Jacoby et al. has assessed platelet function following trauma using a
platelet function analyzer (PFA-100) with citrated whole blood. The PFA-100 is a cartridgebased flow system that aspirates citrated whole blood in capillaries. It measures aperture
closure time following blood clotting on a membrane coated with collagen/ADP or
collagen/epinephrine. Their study reported decreased closure times at initial trauma patient
presentation indicating increased platelet function and hypercoagulability. Contrary to the
Jacoby et al. report, we observed noticeable decreases in platelet adhesion to collagen and
secondary platelet aggregation when we rapidly assessed platelet function in trauma patients
(n = 20) at 100s -1 over collagen surfaces (Figure 6-5). Furthermore, when comparing our
microfluidic assay results to clinical patient data, we found no correlation between platelet
function and injury severity score (ISS), or platelet function and the diagnosis of traumatic
brain injury (TBI). All 14 patients displaying decreased platelet function had physiological
Hct levels and platelet counts. With respect to the clinical static plasma clotting assays, 13 of
the 14 patients with decreased platelet function were within the normal PTT reference range
(20.8-34.4) [23]. These results indicate that patient hematocrit levels, platelet counts, and
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plasma-based clotting tests are largely inadequate in assessing the contribution of platelet
function to the acute phase of TIC.
Interestingly, of the 7 patients that did require blood products post microfluidic
testing, 4 patients had decreased platelet function as initially assessed by whole blood
microfluidic testing. A single patient (#31) was transfused with 14 units of blood products
within 12 hrs of arrival. Microfluidic testing of this patient detected decreased platelet
function upon initial presentation and continuous attenuated platelet function up to 72 hours
post admission (Figure 8-21).
Important distinctions exist between assays that evaluate platelets under non-flow
conditions and microfluidics that allow platelets to accumulate on a surface to levels >200fold that of whole blood levels. We demonstrated that microfluidic assay of trauma patient
samples is a global test of whole blood clotting function under flow with the capability of
detecting platelet dysfunction. In future work, a comparison of microfluidic assay with
platelet aggregometry or platelet mapping-TEG may provide further insights into platelet
dysfunction during TIC. Microfluidic assay allows determination of: (1) platelet recruitment
to the collagen surface, (2) total platelet accumulation, (3) platelet accumulation rate, and (4)
time to full channel occlusion. These metrics could be compared to platelet mapping-TEG
metrics such as maximum clot strength (MAThrombin), the contribution of ADP receptors
(MAADP), and the contribution of the arachidonic acid pathway (MAAA). For example, we
previously observed a relationship between aPTT and platelet accumulation rates on collagen
surfaces for hemophilic blood from patients with increase bleeding risks (10). Finally, while
all trauma patient samples were collected within one hour of injury. Further validation in the
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whole blood microfluidic assay is required to examine how a variation in time of sample
collection within the one hour time window affects platelet function under flow as
derangements in trauma patient platelet function is thought to occur rapidly prior to hospital
admissions.
The high throughput nature of microfluidic whole blood testing however, will enable
testing of fresh platelets, stored platelets, and other current and novel drugs used to restore
platelet function during the acute phase of trauma-induced coagulopathy. In a previous
study, we have shown a novel method to assess the incorporation of culture-derived platelets
from human peripheral blood cells into developing human thrombi under flow (28). Using
similar techniques, future studies should test whether stored platelets can incorporate into
trauma patient thrombi under flow. Successful adherence and incorporation of stored
platelets into patient thrombi formed ex vivo could indicate the high potential of these
platelets to restore platelet function in acute traumatic coagulopathy.
The mechanisms underlying trauma platelet dysfunction have yet to be elucidated
and require further investigation outside of microfluidic testing. Groups have postulated that
platelet function downregulation can occur during trauma. Previous studies suggest the
presence of dysfunctional circulating platelets following activation in response to tissue
damage [121,123]. Platelet receptor proteolysis may be another putative pathway in which
platelet function is down-regulated in trauma patients. Previous reports describe proteolysis
of platelet GPVI and GPIb-IX-V receptors (29,30). Ectodomain shedding of platelet
adhesion receptors is a plausible physiologic mechanism in which platelets can respond to
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cases of severe endothelial injury following trauma yet prevent uncontrolled thrombus
growth that leads to systemic clotting.
In this study, we have used microfluidic technology to effectively evaluate current
resuscitation strategies and hyperfibrinolysis showing more rapid detection of impaired
hemostasis and coagulation than what is capable with current technologies. Furthermore,
we also tested trauma patient platelet function using this high throughput method. The fast
identification of platelet function defects in trauma patients using whole blood microfluidic
assays indicate a potential novel 15 min test to help guide coagulopathy treatments in the
future.
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7

FUTURE WORK

7.1 A role for FXIIIa-mediated clot stability independent of fibrin
polymerization
7.1.1

Introduction
Factor XIII (FXIII) is a coagulation protein that plays an essential role in physiologic

hemostasis where it can regulate fibrinolysis[141], wound healing[142], and
angiogenesis[143]. Clinically, FXIII deficiency results in hemorrhage and impaired wound
healing[144]. FXIII is a plasma protransglutaminase composed of 2 A (FXIII-A) and 2 B
(FXIII-B) subunits that circulate as a heterotetrameric zymogen (FXIII-A2B2)[145]. FXIII
activation occurs when thrombin cleaves an N-terminal activation peptide from FXIII-A,
and calcium mediates the dissociation of the inhibitory FXIII-B subunits, producing
FXIIIa[145]. FXIIIa confers clot stability by cross-linking fibrin fibers in the fibrin matrix,
thus altering its rheologic properties. FXIII originates from a family of transglutaminases
(TG), TG are known to catalyze the formation of covalent ε-(γ-glutamyl) lysyl bond where a
lysine ε-amino group is cross-linked to the glutamine of a γ-carboxymide group[141].
FXIIIa can also cross-link inhibitors of fibrinolysis to fibrin, further enhancing
fibrin’s insolubility and plasmin resistance. Inhibitors cross-linked to fibrin include α2antiplasmin (α2AP), thrombin activatable fibrinolysis inhibitor (TAFI), and plasminogen
activator inhibitor-2. In all, there are twenty-five FXIIIa substrates that can be divided into
five categories: coagulation factors, components of the fibrinolytic system, adhesive and
extracellular matrix proteins, intracellular cytoskeletal proteins, and others[145]. Previous
work has shown a critical role of cross-linked α2AP in stabilizing fibrin. This was
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demonstrated by either the rapid lysis of clots formed in the absence of α2AP or when α2AP
activity is neutralized[146]. Moreover, in addition to being present in plasma, FXIII-A is also
present in platelets in large quantities[147–149]. The concentration of FXIII-A is 100X
greater in the platelet cytoplasm than in plasma[150]. Recently, Mitchell et al. have shown
that activated platelets externalize this pool of FXIII-A onto their membranes and that this
pool is functional in cross-linking α2AP and confers lytic resistance in platelet rich thrombi
under flow[151].
The (patho)physiologic roles for FXIIIa activity derived from either platelet FXIII-A
(cFXIII) or plasma FXIIIa (FXIIIa) are still not well-understood. Previous research has
shown that human and murine whole blood clots formed in the absence of plasma FXIII or
in the presence of a small molecular inhibitor for FXIIIa have reduced red blood cell
retention and are significantly smaller than control clots[9]. Further work proved that FXIIIa
mediates red blood cell retention in clots by cross-linking fibrin alpha chains[152]. Using
microfluidic hemostasis models and whole blood perfusion under flow we aimed to delineate
the ability of cFXIII and FXIIIa to confer platelet-rich thrombus stability independent of
polymerized fibrin.

7.1.2
7.1.2.1

Materials and Methods
Materials
The following reagents were stored according to manufacturer’s instructions: Corn

Trypsin Inhibitor (CTI, Haematologic Technologies, Essex Junction, VT), phycoerythrin
(PE) mouse anti-human monoclonal CD61 (αIIbβ3) antibody (clone VI-PL2, Becton Dickson,
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Franklin Lakes, NJ). Fibrinogen from human plasma, Alexa Fluor 647 conjugate (Invitrogen
Life Technologies, Carlsbad, CA). Equine fibrillar collagen type I (Chronopar, Chronolog,
Havertown, PA), Dade Innovin (Siemens Healthcare USA, Malvern, PA), 1,3,4,5Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride (T101) (Zedira, Darmstadt,
Germany), Gly-Pro-Arg Pro (Billerica, Massachusetts, EMD Millipore), Sylgard 184 Silicone
Elastomer Kit (Sylgard, Ellsworth Adhesives, Germantown, WI), Iodacetamide (Sigma
Aldrich, St. Louis, MO).
7.1.2.2

Blood Collection and preparation
Phlebotomy was approved by the University of Pennsylvania Institutional Review

Board and performed on consenting donors in accordance with the Declaration of Helsinki.
Donors abstained from alcohol 48 h prior to blood donation and were free of oral
medication for a minimum of 7 days prior to donation.
7.1.2.3

Microfluidic Assay
Whole blood was taken from healthy donors using standard phlebotomy techniques.

Blood was drawn into 40 µg/ml CTI or FPR-chloromethylketone (PPACK, Haematologic
Technologies, Essex Junction, VT, 100 µM final concentration). CTI inhibits the contact
pathway for studies of surface-triggered coagulation while PPACK inhibits thrombin
generation in order to examine platelet function in the absence of thrombin in vitro. Blood
samples were treated with 0.125 µg/ml fluorescently conjugated anti-CD61a antibody to
label platelets and fluorescently conjugated fibrinogen to label fibrin(ogen) 5 min prior to
initiation of flow assays. All healthy donor microfluidic experiments were completed within
45 min of phlebotomy.
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Microfluidic fabrication methods and device specifications were previously described
[24,33,34]. Microfluidic channels ran perpendicularly over a 250 µm wide strip of patterned
equine fibrillar collagen type I (Chronopar, Chronolog) or Tissue Factor (TF) bearing
collagen type I surfaces (Dade Innovin, Siemens Healthcare USA, Malvern, PA).
Epifluorescent microscopy and image acquisition were performed in real-time as previously
described [23,24].
Blood samples were perfused at an initial venous wall shear rate of 200 s-1 or an
initial arterial wall shear rate of 800 s-1 in a previously designed pressure relief mode for 20
min [37]. Platelet and fibrin accumulation were analyzed as previously described [24].

7.1.3
7.1.3.1

Results
Nonspecific FXIIIa inhibitor confers gross platelet instability in the presence of GPRP at constant
flow conditions
To investigate the fibrin-independent role of FXIIIa activity and function, non-

selective FXIIIa inhibitor iodoacetamide was used ex vivo in the presence or absence of
GPRP, a short four peptide sequence that inhibits fibrin polymerization. Following
incubation with iodoacetamide and GPRP, whole blood was perfused over a TF/collagen
surface under venous shear rates. Decreases in platelet fluorescence intensity were observed
over time in the absence of GPRP indicating a thrombin dependent role of FXIIIa (Figure
7-1A). The addition of exogenous iodoacetamide had not effect of fibrin initiation and
accumulation over time (Figure 7-1B). A combination of GPRP and iodoacetamide resulted
in gross platelet thrombus instability as detected by the sharp changes in platelet
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fluorescence over time (Figure 7-1B; red line). Exogenous GPRP completely inhibited
fibrin generation under flow independent of iodoacetamide consistent with previous studies
under flow (Figure 7-1B) [37].

Figure 7-1 Inhibition of FXIIIa in the presence or absence of fibrin polymerization
(±GPRP) on TF/collagen surfaces at 200 s-1.
(A & B), Platelet deposition dynamics measured by platelet fluorescence in the presence or absence of GPRP (5 mM). (C
& D), Fibrin deposition dynamics measured by fibrin fluorescence in the presence or absence of GPRP (5 mM). Lines with
shaded traces and points are mean and standard deviation of 4 clotting events measured in 45 sec intervals over 10 min for
one healthy donor.
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7.1.4

Discussion
Here we demonstrate for the first time a potential role for FXIIIa stability of platelet

rich thrombi under flow in the absence of fibrin. Further work must be done to elucidate the
mechanisms by which FXIIIa can stabilize platelet rich clots. It is unclear whether the
weakened clot architecture and thrombus disintegration is due to the cellular form of FXIIIa
(cFXIIIa) or the plasma-derived form (FXIIIa). More specific FXIIIa inhibitors with micromolar affinity such as 1,3,4,5-Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride (T101)
should be tested ex vivo. T101 can be used exogenously in the presence or absence of
thrombin inhibitors over collagen or collagen/TF surfaces. Pressure relief conditions can be
used to build occlusive clots under flow for a more rigorous test of platelet/fibrin clot
strength and stability. To further elucidate the role of cFXIIIa, GR145503 can be used to
abate platelet aggregation under flow in order to study platelet GPVI and collagen
interactions. Finally, fluorescent amine donor substrates can be used to detect
transglutaminase activity under flow to delineate the contributions of FXIIIa activity
emanating from platelets or platelet-bound fibrin(ogen).
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APPENDIX

8.1 Microfluidic ASA Phenotyping Supplemental Material
8.1.1
8.1.1.1

Supplemental Discussion
Discussion: Statistical significant inhibition
For those subjects with < 25 % inhibition, the % inhibition was too small to be

statistically significant due to the error in the measurement, but not due to the initial platelet
deposition size. Statistical significance of inhibition was not correlated with initial platelet
deposit size (FI300s) (Fig. S1). The other 12 subjects with ≤ 25 % inhibition displayed
statistically significant inhibition as a group (27 % ± 15 %; p < 0.001, n = 12). Eleven of 28
subjects with less than 25 % inhibition following ASA ingestion did not reach statistical
significance because of the percent error in the smaller signal, not because their original platelet
deposition at t = 0 was low. With more sampling at the 0 µM ex vivo ASA condition (eg. 4
lanes per device), we anticipate that donors with < 25 % inhibition of FI300s following ASA
ingestion would be detected with statistical significance. In fact, the microfluidic approach
detected only 1 out of 28 donors (donor # 253) that failed to display any decrease at all in
platelet deposition after ASA ingestion (Fig. 3A).
8.1.1.2

Discussion: Timing of primary versus secondary phase of platelet accumulation
The starting time for the secondary aggregation phase (150 sec) is a phase in which a

significant platelet monolayer has already deposited on the collagen surface, thus the majority
of the collagen surface has been covered with adherent platelets (Fig. S2). The effect of COX1 inhibitors added ex vivo to whole blood after 150 sec of platelet deposition on collagen in
this microfluidic device is a time-scale consistent with previous findings in Ref. 19 (Flamm et
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al., Blood. 2012). Thus, growth in platelet coverage in two dimensions is significant between
60 -150 sec while after 150 sec, thrombus growth in the third dimension becomes significant
under flow mediated by soluble agonists such as thromboxane A2 and ADP in this device.
8.1.1.3

Discussion: R value and future studies
The R-value in Fig. 4 helps to internally normalize each donor (since we cannot

normalize to a pooled plasma result, for example). The R-value also has the property of scoring
the effect of ASA on platelet deposition with R = 1 representing the cut-off between native
blood (R > 1 for almost all donors) and ASA ingestion (R < 1 for most but not all donors).
The results in Fig. 4F set the stage to identify individuals (blue points) worthy of future study
who derive no functional response to aspirin (possibly due to higher ADP release or ADP
sensitivity), despite the expectation of their COX-1 being fully acetylated and thromboxane
synthesis being strongly inhibited. Ideally, such a future study would involve both healthy
donors and patients with cardiovascular risk.
8.1.1.4

Discussion: Receiver-Operator Curve Analysis
A rigorous approach to assay validation was completed using an objective receiver-

operator curve (ROC) approach. Two cases were tested in this approach and are presented as
follows.
CASE I:

0 µM ASA (Period 1 and 2) vs. 26-hr ASA ingestion

The R-value is a metric of secondary aggregation that normalizes the late stage platelet
deposition rate to early stage deposition rate for each blood sample. Receiver Operator Curve
(ROC) analysis was conducted with JLABROC4v1.0.1 (Dr. J. Eng, Johns Hopkins Univ.,
available

through

public

domain

software

at
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www.rad.jhmi.edu/jeng/javarad/roc/JROCFITi.html based on LABROC4, Dr. C. Metz,
Univ. Chicago). In comparing 56 measurement of the R-value for subjects not taking ASA (at
t = 0 during Period 1 and 2) [true full COX-1 activity] to 28 individual measurements of Rvalue for subjects taking 325 mg ASA [true full COX-1 inhibition], the receiver-operator curve
had an area under curve (ROC AUC) = 0.741, indicative of an adequate, but not outstanding
diagnostic discrimination between the two populations (Fig. S3). Interestingly, the assay had
high discrimination (high true positive rate with low false positive rate) at an R-value ~ 1 where
the true positive fraction TPF was 71 % (sensitivity) and the false positive fraction FPF was
36 % (specificity = 1 – FPF = 64 %).
INPUT DATA
Scores from the 28 actually negative cases:
(True INHIBITION of ASA: t = 26 hr following ASA ingestion)
1.1233

0.6034

0.7836

0.9767

0.7722

0.8585

0.8080

0.7077

1.6151

0.8603

0.9088

0.8099

1.2039

1.3272

0.8068

1.5131

0.7501

0.9849

0.8680

0.7233

0.9317

0.4908

0.8485

0.4195

0.6296

0.8973

0.9438

1.7459

Scores from the 56 actually positive cases:
(True Full COX1 activity: Period 1 and 2 at t=0; 0 ASA )
0.7416

0.8656

1.1536

1.2645

1.2050

1.1738

0.8545

0.9592

1.3055

1.1071

1.1600

1.2014

1.4020

1.3010

1.5024

0.8560

1.6547

1.0767

1.3708

1.4339

1.4688

0.8096

1.2178

1.0163

1.0863
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1.0642

1.1327

1.1241

0.9999

1.0100

1.9264

1.2613

0.3817

1.1537

0.6803

1.0146

1.4208

1.3810

0.9649

1.4063

1.8150

1.2511

1.4529

0.4988

1.1964

1.1595

1.5706

1.2382

1.3985

1.1455

1.4131

1.2984

1.0613

1.3313

0.9103

1.5890
OPERATING POINTS CORRESPONDING TO THE INPUT DATA
FPF:

0.0000

0.0000

0.0357

0.0357

0.0714

TPF:

0.0000

0.0357

0.0357

0.0536

0.0536

FPF:

0.0714

0.1071

0.1071

0.1429

0.1429

TPF:

0.0893

0.0893

0.3036

0.3036

0.4643

FPF:

0.1786

0.1786

0.2143

0.2143

0.2857

TPF:

0.4643

0.6429

0.6429

0.8036

0.8036

FPF:

0.2857

0.3571

0.3571

0.4643

0.4643

TPF:

0.8393

0.8393

0.8571

0.8571

0.8750

FPF:

0.5357

0.5357

0.6071

0.6071

0.7857

TPF:

0.8750

0.9107

0.9107

0.9286

0.9286

FPF:

0.7857

0.8571

0.8571

0.9286

0.9286

TPF:

0.9464

0.9464

0.9643

0.9643

0.9821

PF:

1.0000

1.0000

TPF:

0.9821

1.0000

FINAL ESTIMATES OF BINORMAL ROC PARAMETERS A AND B:
A = 0.9531

Std. Error (A) = 0.2659

B = 1.0831

Std. Error (B) = 0.2050

Correlation (A, B) = 0.2561
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AREA UNDER ROC CURVE:
Area under fitted curve (Az) = 0.7410
Estimated std. error = 0.0568
Trapezoidal (Wilcoxon) area = 0.7659
Estimated std. error = 0.0514
ESTIMATED BINORMAL ROC CURVE, WITH LOWER AND UPPER BOUNDS
OF THE ASYMMETRIC 95% CONFIDENCE INTERVAL FOR TRUE-POSITIVE
FRACTION AT A VARIETY OF FALSE-POSITIVE FRACTIONS:
FPF

TPF 95% Conf. Interv.

0.005 0.0331 (0.0021, 0.2107)
0.010 0.0586 (0.0060, 0.2676)
0.020 0.1017 (0.0167, 0.3388)
0.030 0.1391 (0.0297, 0.3884)
0.040 0.1727 (0.0442, 0.4276)
0.050 0.2036 (0.0596, 0.4605)
0.060 0.2323 (0.0756, 0.4891)
0.070 0.2593 (0.0921, 0.5145)
0.080 0.2847 (0.1089, 0.5375)
0.090 0.3088 (0.1259, 0.5586)
0.100 0.3317 (0.1429, 0.5781)
0.110 0.3537 (0.1600, 0.5962)
0.120 0.3746 (0.1770, 0.6131)
0.130 0.3948 (0.1940, 0.6291)
0.140 0.4141 (0.2108, 0.6442)
0.150 0.4327 (0.2274, 0.6585)
0.200 0.5166 (0.3078, 0.7209)
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0.250 0.5882 (0.3823, 0.7719)
0.300 0.6501 (0.4506, 0.8147)
0.400 0.7515 (0.5692, 0.8818)
0.500 0.8297 (0.6671, 0.9298)
0.600 0.8901 (0.7489, 0.9627)
0.700 0.9358 (0.8187, 0.9834)
0.800 0.9689 (0.8799, 0.9947)
0.900 0.9904 (0.9357, 0.9992)
0.950 0.9969 (0.9636, 0.9999)
ESTIMATED RELATIONSHIP BETWEEN THE CRITICAL TEST RESULT
VALUE (WHICH SEPARATES "POSITIVE" RESULTS FROM "NEGATIVE"
RESULTS) AND ITS CORRESPONDING OPERATING POINT PROJECTED
ONTO THE FITTED BINORMAL ROC CURVE:

CASE (+ = Full COX1, 0 ASA; - = No COX1, 325 ASA)
Critical test
CASE

R-VALUE

(FPF, TPF)

+

1.9264

(0.0008, 0.0069)

+

1.8150

(0.0038, 0.0265)

-

1.7459

(0.0071, 0.0443)

+

1.6547

(0.0105, 0.0608)

-

1.6151

(0.0140, 0.0768)

+

1.5890

(0.0176, 0.0922)

+

1.5706

(0.0214, 0.1073)

-

1.5131

(0.0254, 0.1224)

+

1.5024

(0.0294, 0.1370)

+

1.4688

(0.0335, 0.1515)
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+

1.4529

(0.0379, 0.1660)

+

1.4339

(0.0424, 0.1804)

+

1.4208

(0.0471, 0.1949)

+

1.4131

(0.0519, 0.2094)

+

1.4063

(0.0570, 0.2239)

+

1.4020

(0.0622, 0.2384)

+

1.3985

(0.0675, 0.2529)

+

1.3810

(0.0731, 0.2673)

+

1.3708

(0.0788, 0.2818)

+

1.3313

(0.0847, 0.2962)

-

1.3272

(0.0907, 0.3106)

+

1.3055

(0.0969, 0.3248)

+

1.3010

(0.1032, 0.3389)

+

1.2984

(0.1096, 0.3529)

+

1.2645

(0.1163, 0.3670)

+

1.2613

(0.1231, 0.3810)

+

1.2511

(0.1301, 0.3951)

+

1.2382

(0.1374, 0.4091)

+

1.2178

(0.1448, 0.4231)

+

1.2050

(0.1524, 0.4371)

-

1.2039

(0.1602, 0.4510)

+

1.2014

(0.1681, 0.4647)

+

1.1964

(0.1762, 0.4784)

+

1.1738

(0.1845, 0.4920)

+

1.1600

(0.1930, 0.5057)

+

1.1595

(0.2018, 0.5193)

+

1.1537

(0.2108, 0.5329)
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+

1.1536

(0.2201, 0.5465)

+

1.1455

(0.2296, 0.5602)

+

1.1327

(0.2394, 0.5738)

+

1.1241

(0.2496, 0.5876)

-

1.1233

(0.2601, 0.6012)

+

1.1071

(0.2705, 0.6145)

+

1.0863

(0.2812, 0.6276)

+

1.0767

(0.2923, 0.6409)

+

1.0642

(0.3037, 0.6541)

+

1.0613

(0.3155, 0.6674)

+

1.0163

(0.3277, 0.6807)

+

1.0146

(0.3402, 0.6939)

+

1.0100

(0.3533, 0.7072)  Optimal Discrimination by R value = 1

+

0.9999

(0.3668, 0.7205)  (Sensitivity ~ 71 %, Specificity ~ 64 %)

-

0.9849

(0.3808, 0.7339)

-

0.9767

(0.3948, 0.7466)

+

0.9649

(0.4087, 0.7590)

+

0.9592

(0.4231, 0.7713)

-

0.9438

(0.4382, 0.7836)

-

0.9317

(0.4532, 0.7955)

+

0.9103

(0.4683, 0.8070)

-

0.9088

(0.4838, 0.8183)

-

0.8973

(0.4994, 0.8293)

-

0.8680

(0.5150, 0.8399)

+

0.8656

(0.5308, 0.8501)

-

0.8603

(0.5469, 0.8601)

-

0.8585

(0.5632, 0.8698)
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+

0.8560

(0.5797, 0.8792)

+

0.8545

(0.5967, 0.8884)

-

0.8485

(0.6144, 0.8976)

-

0.8099

(0.6323, 0.9064)

+

0.8096

(0.6504, 0.9149)

-

0.8080

(0.6691, 0.9232)

-

0.8068

(0.6879, 0.9311)

-

0.7836

(0.7068, 0.9385)

-

0.7722

(0.7258, 0.9455)

-

0.7501

(0.7447, 0.9521)

+

0.7416

(0.7639, 0.9583)

-

0.7233

(0.7840, 0.9644)

-

0.7077

(0.8043, 0.9700)

+

0.6803

(0.8251, 0.9753)

-

0.6296

(0.8472, 0.9804)

-

0.6034

(0.8696, 0.9850)

+

0.4988

(0.8927, 0.9892)

-

0.4908

(0.9186, 0.9931)

-

0.4195

(0.9452, 0.9964)

+

0.3817

(0.9773, 0.9991)

Fitted ROC Area: 0.741
Fitted points
FPF

TPF

Lower

Upper

0.0000

0.0000

0.0000

0.0000

0.0050

0.0331

0.0021

0.2107

0.0100

0.0586

0.0060

0.2676
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0.0200

0.1017

0.0167

0.3388

0.0300

0.1391

0.0297

0.3884

0.0400

0.1727

0.0442

0.4276

0.0500

0.2036

0.0596

0.4605

0.0600

0.2323

0.0756

0.4891

0.0700

0.2593

0.0921

0.5145

0.0800

0.2847

0.1089

0.5375

0.0900

0.3088

0.1259

0.5586

0.1000

0.3317

0.1429

0.5781

0.1100

0.3537

0.1600

0.5962

0.1200

0.3746

0.1770

0.6131

0.1300

0.3948

0.1940

0.6291

0.1400

0.4141

0.2108

0.6442

0.1500

0.4327

0.2274

0.6585

0.2000

0.5166

0.3078

0.7209

0.2500

0.5882

0.3823

0.7719

0.3000

0.6501

0.4506

0.8147

0.4000

0.7515

0.5692

0.8818

0.5000

0.8297

0.6671

0.9298

0.6000

0.8901

0.7489

0.9627

0.7000

0.9358

0.8187

0.9834

0.8000

0.9689

0.8799

0.9947

0.9000

0.9904

0.9357

0.9992

0.9500

0.9969

0.9636

0.9999

1.0000

1.0000

1.0000

1.0000
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CASE II:

0 µM ASA (Period 1 and 2) VS. 500 µM ASA Ex Vivo

In comparing 56 measurement of the R-value for subjects not taking ASA (at t = 0 during
Period 1 and 2) [true full COX-1 activity] to 56 individual measurements of R-value for ex
vivo 500 µM ASA addition [true full COX-1 inhibition], the receiver-operator curve had an
area under curve (ROC AUC) = 0.783, indicative of a good, but not outstanding diagnostic
discrimination between the two populations (Fig. S3). Interestingly, the assay had optimal
discrimination (best true positive rate and minimum false positive rate) at an R-value ~ 1 where
the true positive fraction TPF was 75 % (sensitivity) and the false positive fraction FPF was
33 % (specificity = 1 – FPF = 67 %).
INPUT DATA
Scores from the 56 actually negative cases:
True Inhibition of COX1 with 500 uM ASA
0.5468

0.7292

0.6258

0.8920

0.8226

0.9299

0.7806

0.7691

1.1218

0.7727

1.1059

0.8476

1.0033

1.0534

0.8654

0.8333

0.8730

0.9148

0.8196

1.2122

1.3131

0.6908

1.1451

0.2065

0.9521

0.8769

1.0290

0.8648

0.9114

1.4386

1.0893

0.8516

0.1217

0.8566

0.6950

0.6501

0.9521

0.8055

1.2264

0.8961

1.6720

0.5441

0.8210

0.4755

0.8776

1.1593

0.7903

0.5619

1.1969

1.1594

0.8804

0.6476

0.8153

0.8193

0.7628

1.3335
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Scores from the 56 actually positive cases:
True Full COX1 activity: Period 1 and 2 at t = 0; 0 ASA
0.7416

0.8656

1.1536

1.2645

1.2050

1.1738

0.8545

0.9592

1.3055

1.1071

1.1600

1.2014

1.4020

1.3010

1.5024

0.8560

1.6547

1.0767

1.3708

1.4339

1.4688

0.8096

1.2178

1.0163

1.0863

1.0642

1.1327

1.1241

0.9999

1.0100

1.9264

1.2613

0.3817

1.1537

0.6803

1.0146

1.4208

1.3810

0.9649

1.4063

1.8150

1.2511

1.4529

0.4988

1.1964

1.1595

1.5706

1.2382

1.3985

1.1455

1.4131

1.2984

1.0613

1.3313

0.9103

1.5890
OPERATING POINTS CORRESPONDING TO THE INPUT DATA
FPF:

0.0000

0.0000

0.0179

0.0179

0.0357

TPF:

0.0000

0.0357

0.0357

0.1429

0.1429

FPF:

0.0357 0.0536 0.0536 0.0714 0.0714

TPF:

0.2857 0.2857 0.3036 0.3036 0.4286

FPF:

0.0893 0.0893 0.1071 0.1071 0.1250

TPF:

0.4286 0.4464

FPF:

0.1250

0.1607

0.1607

0.1786

0.1786

TPF:

0.5536

0.5536

0.6071

0.6071

0.6429

FPF:

0.1964

0.1964

0.2321

0.2321

0.2679

TPF:

0.6429

0.6607

0.6607

0.7321

0.7321

FPF:

0.2679

0.2857

0.2857

0.3750

0.3750

TPF:

0.7857

0.7857

0.8393

0.8393

0.8571

0.4464

0.4821

0.4821
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FPF:

0.4821

0.4821

0.5357

0.5357

0.6786

TPF:

0.8571

0.8750

0.8750

0.9107

0.9107

FPF:

0.6786

0.7857

0.7857

0.8393

0.8393

TPF:

0.9286

0.9286

0.9464

0.9464

0.9643

FPF:

0.9464

0.9464

0.9643

0.9643

1.0000

TPF:

0.9643

0.9821

0.9821

1.0000

1.0000

FINAL ESTIMATES OF BINORMAL ROC PARAMETERS A AND B:
A = 1.0714

Std. Error (A) = 0.2145

B = 0.9357

Std. Error (B) = 0.1519

Correlation (A, B) = 0.3923

AREA UNDER ROC CURVE:
Area under fitted curve (Az) = 0.7830
Estimated std. error = 0.0423
Trapezoidal (Wilcoxon) area = 0.7943
Estimated std. error = 0.0425

ESTIMATED BINORMAL ROC CURVE, WITH LOWER AND UPPER BOUNDS
OF THE ASYMMETRIC 95% CONFIDENCE INTERVAL FOR TRUE-POSITIVE
FRACTION AT A VARIETY OF FALSE-POSITIVE FRACTIONS:

FPF

TPF 95% Conf. Interv.

0.005 0.0903 (0.0199, 0.2666)
0.010 0.1344 (0.0392, 0.3259)
0.020 0.1975 (0.0747, 0.3976)
0.030 0.2455 (0.1072, 0.4460)
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0.040 0.2854 (0.1372, 0.4837)
0.050 0.3199 (0.1653, 0.5148)
0.060 0.3506 (0.1916, 0.5417)
0.070 0.3784 (0.2165, 0.5654)
0.080 0.4038 (0.2401, 0.5867)
0.090 0.4273 (0.2626, 0.6060)
0.100 0.4491 (0.2840, 0.6238)
0.110 0.4696 (0.3044, 0.6403)
0.120 0.4888 (0.3239, 0.6556)
0.130 0.5070 (0.3427, 0.6701)
0.140 0.5242 (0.3607, 0.6836)
0.150 0.5405 (0.3780, 0.6964)
0.200 0.6118 (0.4555, 0.7518)
0.250 0.6703 (0.5209, 0.7964)
0.300 0.7194 (0.5771, 0.8335)
0.400 0.7981 (0.6693, 0.8910)
0.500 0.8580 (0.7425, 0.9321)
0.600 0.9046 (0.8031, 0.9611)
0.700 0.9408 (0.8553, 0.9805)
0.800 0.9685 (0.9017, 0.9924)
0.900 0.9884 (0.9453, 0.9984)
0.950 0.9955 (0.9679, 0.9996)
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ESTIMATED RELATIONSHIP BETWEEN THE CRITICAL TEST RESULT
VALUE (WHICH SEPARATES "POSITIVE" RESULTS FROM "NEGATIVE"
RESULTS) AND ITS CORRESPONDING OPERATING POINT PROJECTED
ONTO THE FITTED BINORMAL ROC CURVE:
Critical test
Truth result value

(FPF, TPF)

+

1.9264

(0.0001, 0.0077)

+

1.8150

(0.0008, 0.0293)

-

1.6720

(0.0018, 0.0486)

+

1.6547

(0.0028, 0.0647)

+

1.5890

(0.0041, 0.0801)

+

1.5706

(0.0055, 0.0955)

+

1.5024

(0.0071, 0.1110)

+

1.4688

(0.0090, 0.1264)

+

1.4529

(0.0110, 0.1419)

-

1.4386

(0.0132, 0.1571)

+

1.4339

(0.0154, 0.1715)

+

1.4208

(0.0178, 0.1856)

+

1.4131

(0.0204, 0.1998)

+

1.4063

(0.0232, 0.2140)

+

1.4020

(0.0261, 0.2282)

+

1.3985

(0.0293, 0.2424)

+

1.3810

(0.0326, 0.2566)

+

1.3708

(0.0361, 0.2707)

+
-

1.3335
1.3313
1.3131

(0.0398, 0.2847)
(0.0436, 0.2983)
(0.0474, 0.3116)
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+

1.3055

(0.0514, 0.3246)

+

1.3010

(0.0556, 0.3375)

+

1.2984

(0.0599, 0.3503)

+

1.2645

(0.0643, 0.3631)

+

1.2613

(0.0690, 0.3759)

+

1.2511

(0.0739, 0.3888)

+

1.2382

(0.0790, 0.4015)

+
-

1.2264
1.2178
1.2122

(0.0843, 0.4141)
(0.0896, 0.4265)
(0.0951, 0.4387)

+

1.2050

(0.1007, 0.4507)

+

1.2014

(0.1065, 0.4626)

-

1.1969

(0.1124, 0.4743)

+

1.1964

(0.1184, 0.4858)

+

1.1738

(0.1245, 0.4972)

+

1.1600

(0.1309, 0.5086)

+

1.1595

(0.1375, 0.5200)

-

1.1594

(0.1444, 0.5314)

-

1.1593

(0.1512, 0.5424)

+

1.1537

(0.1581, 0.5531)

+

1.1536

(0.1651, 0.5637)

+

1.1455

(0.1725, 0.5745)

-

1.1451

(0.1800, 0.5852)

+

1.1327

(0.1876, 0.5955)

+

1.1241

(0.1954, 0.6058)

+

1.1218
1.1071

(0.2035, 0.6162)
(0.2116, 0.6263)
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-

1.1059

(0.2199, 0.6363)

-

1.0893

(0.2282, 0.6460)

+

1.0863

(0.2364, 0.6554)

+

1.0767

(0.2449, 0.6647)

+

1.0642

(0.2538, 0.6741)

+

1.0613

(0.2629, 0.6837)

-

1.0534

(0.2724, 0.6932)

-

1.0290

(0.2818, 0.7023)

+

1.0163

(0.2911, 0.7111)

+

1.0146

(0.3007, 0.7199)

+

1.0100

(0.3107, 0.7289)

-

1.0033

(0.3210, 0.7378)

+

0.9999

(0.3313, 0.7464)

Optimal Discrimination by R value = 1

+

0.9649

(0.3418, 0.7549)

(Sensitivity ~ 75 %, Specificity ~ 67 %)

+

0.9592

(0.3528, 0.7636)

+

0.9521

(0.3697, 0.7765)

-

0.9299

(0.3867, 0.7888)

-

0.9148

(0.3980, 0.7966)

-

0.9114

(0.4092, 0.8042)

+

0.9103

(0.4204, 0.8115)

-

0.8961

(0.4320, 0.8189)

-

0.8920

(0.4437, 0.8261)

-

0.8804

(0.4553, 0.8331)

-

0.8776

(0.4669, 0.8398)

-

0.8769

(0.4785, 0.8464)

-

0.8730

(0.4900, 0.8527)

+

0.8656

(0.5017, 0.8589)

144

-

0.8654

(0.5136, 0.8650)

-

0.8648

(0.5255, 0.8710)

-

0.8566

(0.5375, 0.8769)

+

0.8560

(0.5495, 0.8826)

+

0.8545

(0.5619, 0.8882)

-

0.8516

(0.5744, 0.8938)

-

0.8476

(0.5871, 0.8993)

-

0.8333

(0.5998, 0.9046)

-

0.8226

(0.6125, 0.9097)

-

0.8210

(0.6252, 0.9147)

-

0.8196

(0.6379, 0.9195)

-

0.8193

(0.6506, 0.9242)

-

0.8153

(0.6634, 0.9287)

+

0.8096

(0.6763, 0.9331)

-

0.8055

(0.6893, 0.9374)

-

0.7903

(0.7024, 0.9416)

-

0.7806

(0.7156, 0.9457)

-

0.7727

(0.7288, 0.9496)

-

0.7691

(0.7419, 0.9534)

-

0.7628

(0.7551, 0.9571)

+

0.7416

(0.7684, 0.9606)

-

0.7292

(0.7820, 0.9641)

-

0.6950

(0.7957, 0.9675)

-

0.6908

(0.8094, 0.9707)

+

0.6803

(0.8232, 0.9738)

-

0.6501

(0.8375, 0.9768)

-

0.6476

(0.8519, 0.9798)

145

-

0.6258

(0.8663, 0.9825)

-

0.5619

(0.8806, 0.9851)

-

0.5468

(0.8950, 0.9876)

-

0.5441

(0.9094, 0.9899)

+
+

0.4988

(0.9240, 0.9921)

0.4755

(0.9394, 0.9942)

0.3817

(0.9555, 0.9961)

-

0.2065

(0.9734, 0.9980)

-

0.1217

(0.9930, 0.9996)

FPF

TPF

Lower

Upper

0.0000

0.0000

0.0000

0.0000

0.0050

0.0903

0.0199

0.2666

0.0100

0.1344

0.0392

0.3259

0.0200

0.1975

0.0747

0.3976

0.0300

0.2455

0.1072

0.4460

0.0400

0.2854

0.1372

0.4837

0.0500

0.3199

0.1653

0.5148

0.0600

0.3506

0.1916

0.5417

0.0700

0.3784

0.2165

0.5654

0.0800

0.4038

0.2401

0.5867

0.0900

0.4273

0.2626

0.6060

0.1000

0.4491

0.2840

0.6238

0.1100

0.4696

0.3044

0.6403

0.1200

0.4888

0.3239

0.6556

0.1300

0.5070

0.3427

0.6701

0.1400

0.5242

0.3607

0.6836

146

0.1500

0.5405

0.3780

0.6964

0.2000

0.6118

0.4555

0.7518

0.2500

0.6703

0.5209

0.7964

0.3000

0.7194

0.5771

0.8335

0.4000

0.7981

0.6693

0.8910

0.5000

0.8580

0.7425

0.9321

0.6000

0.9046

0.8031

0.9611

0.7000

0.9408

0.8553

0.9805

0.8000

0.9685

0.9017

0.9924

0.9000

0.9884

0.9453

0.9984

0.9500

0.9955

0.9679

0.9996

1.0000

1.0000

1.0000

1.0000

8.1.2

Final Platelet Fluorescence (FI300s), Platelet Deposition Rates, R-values

Subject
ID

R
(0 µM
ASA)
Period
2
0 hr

R
(500
µM
ASA)
Period
1
0 hr

R
(500
µM
ASA)
Period
2
0 hr

R
(0 µM ASA)
Period 1
26 hr

FI300s
(0 µM
ASA)
Period 1
0 hr

FI300s
(0 µM
ASA)
Period 2
0 hr

F'(300-150s)
(0 µM
ASA)
Period 1
0 hr

F'(300-150s)
(0 µM
ASA)
Period 2
0 hr

R
(0 µM
ASA)
Period
1
0 hr

217

3078

5937

10.00

21.60

0.7416

0.9999

0.5468

0.9114

1.1233

246

4495

4363

13.72

17.79

0.8656

1.0100

0.7292

1.4386

0.6034

272

11079

9864

44.07

47.81

1.1536

1.9264

0.6258

1.0893

0.7836

259

6336

9246

26.72

37.94

1.2645

1.2613

0.8920

0.8516

0.9767

262

8436

12890

35.38

55.55

1.2050

0.3817

0.8226

0.1217

0.7722

225

7541

2648

30.12

24.02

1.1738

1.1537

0.9299

0.8566

0.8585

250

5413

5949

18.30

7.94

0.8545

0.6803

0.7806

0.6950

0.8080

241

10253

2471

36.37

9.58

0.9592

1.0146

0.7691

0.6501

0.7077

283

10178

6100

44.50

27.75

1.3055

1.4208

1.1218

0.9521

1.6151

268

4225

7404

16.40

32.43

1.1071

1.3810

0.7727

0.8055

0.8603

203

2058

1312

8.46

5.06

1.1600

0.9649

1.1059

1.2264

0.9088

248

4111

5946

16.76

26.76

1.2014

1.4063

0.8476

0.8961

0.8099

239

8521

6571

36.17

36.43

1.4020

1.8150

1.0033

1.6720

1.2039

147

216

3862

4308

16.76

17.80

1.3010

1.2511

1.0534

0.5441

1.3272

226

4686

1977

20.91

8.92

1.5024

1.4529

0.8654

0.8210

0.8068

235

4627

3430

17.27

7.49

0.8560

0.4988

0.8333

0.4755

1.5131

238

3438

3268

17.31

40.92

1.6547

1.1964

0.8730

0.8776

0.7501

240

5172

3616

20.74

14.85

1.0767

1.1595

0.9148

1.1593

0.9849

255

6294

2484

27.70

20.29

1.3708

1.5706

0.8196

0.7903

0.8680

212

3177

6139

14.75

23.87

1.4339

1.2382

1.2122

0.5619

0.7233

231

6148

3207

17.55

14.60

1.4688

1.3985

1.3131

1.1969

0.9317

243

4194

5141

14.43

19.58

0.8096

1.1455

0.6908

1.1594

0.4908

278

2028

5208

8.85

24.08

1.2178

1.4131

1.1451

0.8804

0.8485

293

5477

4994

19.70

20.97

1.0163

1.2984

0.2065

0.6476

0.4195

253

3243

1441

12.87

12.02

1.0863

1.0613

0.9521

0.8153

0.6296

256

12716

16498

47.96

67.36

1.0642

1.3313

0.8769

0.8193

0.8973

277

7539

7548

26.62

25.54

1.1327

0.9103

1.0290

0.7628

0.9438

282

10221

6506

42.15

29.99

1.1241

1.5890

0.8648

1.3335

1.7459

Average

6020

5588

24

25

1.16

1.21

0.88

0.89

0.93

Stdev

2888

5576

24

25

0.22

0.34

0.22

0.32

0.31

Table 6. Microfluidic ASA Phenotyping Quantification Metrics
8.1.3

Total platelet accumulation with no in vitro ASA addition at 0 hr vs. %
inhibition

148

Figure 8-1 Total platelet accumulation with no ex vivo ASA addition at 0 hr vs. %
inhibition.

8.1.4

Collagen % surface coverage by platelet with no in vitro addition of agonists
in PPACK inhibited whole blood

Figure 8-2 % surface coverage by platelets on collagen with no in vitro addition of
agonists in PPACK treated whole blood in the 8-channel microfluidic device.

149

8.1.5

ROC Curve Case I: 0 µM ASA (Period 1 & 2) vs. 26 h ASA ingestion

Figure 8-3 ROC Curve Case I: 0 µM in vitro ASA (Period 1 and 2) vs. 26 h ASA
ingestion

150

8.1.6

ROC Curve Case II: 0 µM ASA (Period 1 & 2) vs. 500 µM ASA in vitro

Figure 8-4 ROC Curve Case II: 0 µM in vitro ASA (Period 1 and 2) vs. 500 µM in vitro
ASA
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8.2 Detection of platelet sensitivity to inhibitors of COX-1, P2Y1, and
P2Y12 using a whole blood microfluidic assay: Supplemental
Material
8.2.1
8.2.1.1

Supplemental Materials and Methods
Response to ex vivo 2MeSAMP and MRS2179 dosing at venous and arterial shear rates
For combined venous (200s-1) and arterial wall shear rate (1000s-1) studies, blood was

collected from 5 healthy donors; one donor of the 5 tested was not examined in the primary
study of this work. Blood collection, labeling, addition of antagonists, and exclusion criteria
for donors for these assays were identical as the main protocol. PPACK treated whole blood
was perfused through the device within 40 min of phlebotomy. For dose-response testing of
P2Y12 and P2Y1 antagonists, 8 distinct concentrations of either antagonist previously
incubated with whole blood is perfused through a single 8 channel device with 3 devices
tested simultaneously at the same wall shear rate. A custom stage insert holds 3 microfluidic
devices, allowing 24 simultaneous platelet aggregation events under flow to be imaged in 15 s
intervals. The protocol is repeated with the second wall shear rate. The order of which wall
shear rate was tested first was randomized. Final ex vivo concentrations of 2 MeSAMP and
MRS 2179 used are as indicated [2 MeSAMP: 0, 0.1, 0.5, 1, 5, 10, 50, 100 µM; MRS 2179: 0,
0.01, 0.05, 0.1, 0.5, 1, 5, 10 µM]. The respective arterial wall shear rate of 1000s-1 was
established in other assays with the same microfluidic device[34,37,64].
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8.2.2

Healthy donor phenotyping of platelet function response to P2Y1 or P2Y12
antagonists under flow, baseline final platelet fluorescence values
Intradonor variability of FI300s(0): Different Devices

Donor

Device 1

Device 1

Device 2

Device 2

Device 3

Device 3

Average

1

1545.77

1311.61

1454.20

1465.33

1462.44

1427.59

1444.49

76.23

5.3%

2

1640.33

2082.70

1452.06

1724.67

1705.70

2142.69

1791.36

267.59

14.9%

3

2014.25

2308.29

2428.46

2477.85

2942.26

2311.79

2413.82

304.88

12.6%

4

5037.89

4563.72

3806.69

4905.00

5745.34

5360.22

4902.77

671.39

13.7%

5

4386.49

4335.76

3090.64

4468.44

5418.45

5067.75

4461.28

798.04

17.9%

6

3711.38

4644.85

2933.58

3587.71

2991.93

3083.38

3261.60

650.42

19.9%

7

5733.93

6521.59

4891.77

3956.05

4928.05

3210.83

4862.83

1188.78

24.4%

8

5733.93

6521.59

4891.77

3956.05

4928.05

3210.83

4873.70

1188.78

24.4%

9

3441.47

2539.59

2246.24

2417.76

2426.44

2420.57

2614.30

431.38

16.5%

10

2357.16

2053.67

2276.70

2366.31

1664.21

2792.64

2251.78

374.66

16.6%

12883.99

11644.54

10971.13

15391.014

14979.67

13283.74

1778.34

13.4%

4524.30

3737.88

3845.12

4509.46

4182.54

4196.52

702.77

16.3%

11
Avg

13832.1
4494.06

SD

CV%

Intradonor variability of FI300s(0): Same Device

Donor

Avg D1

SD D1

CV% D1

Avg D2

SD D2

CV% D2

Avg D3

SD D3

CV%
D3

1

1428.69

165.58

11.6%

1459.76

7.87

0.5%

1445.01

24.64

1.7%

2

1861.51

312.81

16.8%

1588.37

192.77

12.1%

1924.20

309.00

16.1%

3

2161.27

207.92

9.6%

2453.15

34.92

1.4%

2627.03

445.81

17.0%

4

4800.80

335.29

7.0%

3806.69

776.62

20.4%

5552.78

272.32

4.9%

5

4361.12

35.88

0.8%

3779.54

974.25

25.8%

5243.18

248.10

4.7%

6

4178.12

660.07

15.8%

3260.65

462.54

14.2%

3037.66

64.66

2.1%

7

6127.76

556.96

9.1%

4423.91

661.65

15.0%

4069.44

1214.26

29.8%

8

6127.76

556.96

9.1%

4423.91

661.65

15.0%

4069.44

1214.26

29.8%

9

2990.53

637.72

21.3%

2332.00

121.28

5.2%

2426.44

4.15

0.2%

10

2205.41

214.60

9.7%

2321.50

63.36

2.7%

2228.43

797.92

35.8%

11

13358.04

670.42

5.0%

11307.84

476.17

4.2%

15185.34

290.87

1.9%

Avg

4509.18

395.84

11.0%

3741.57

403.01

11.0%

4346.27

444.18

13.1%

Table 7. Intradonor variability of platelet fluorescence intensity on collagen
[FI300s(0)]: same 8-channel device or cross-device coefficient of variability (CV)
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8.2.3

Healthy donor phenotyping of platelet function response to P2Y1 or P2Y12
antagonists under flow: Intradonor R(0) variability
Intradonor variability of R(0): Different Devices

Donor

Device 1

Device 1

Device 2

Device 2

Device 3

Device 3

Average

SD

CV%

1

0.682

0.814

0.867

0.752

0.725

0.609

0.741

0.092

12.4%

2

1.096

1.269

1.040

1.091

0.983

0.816

1.049

0.149

14.2%

3

1.657

1.522

1.772

1.713

1.800

2.067

1.755

0.182

10.4%

4

2.210

2.540

1.170

1.830

1.805

1.469

1.839

0.493

26.8%

5

1.200

1.141

1.014

1.165

1.396

1.143

1.176

0.125

10.6%

6

1.219

1.335

1.075

0.942

1.086

1.153

1.095

0.135

12.3%

7

1.174

1.153

0.803

0.930

0.802

0.949

1.002

0.163

16.3%

8

1.232

1.127

0.733

0.948

1.193

0.974

1.035

0.187

18.0%

9

0.914

0.911

0.978

1.169

1.167

1.206

1.028

0.138

13.4%

10

0.917

0.882

0.948

0.861

0.745

1.447

0.967

0.245

25.3%

11

1.249

1.074

1.373

1.272

1.083

1.182

1.206

0.116

9.6%

Avg

1.232

1.252

1.070

1.152

1.162

1.183

1.172

0.184

15.4%

Intradonor variability of R(0): Same Device

Donor

Avg D1

SD D1

CV% D1

Avg D2

SD D2

CV% D2

Avg D3

SD
D3

CV%
D3

1

0.748

0.094

12.6%

0.809

0.081

10.1%

0.667

0.082

12.2%

2

1.182

0.122

10.3%

1.066

0.036

3.3%

0.900

0.118

13.2%

3

1.590

0.095

6.0%

1.742

0.042

2.4%

1.934

0.189

9.8%

4

2.375

0.233

9.8%

1.170

0.466

39.8%

1.637

0.238

14.5%

5

1.170

0.042

3.6%

1.089

0.107

9.8%

1.270

0.179

14.1%

6

1.277

0.082

6.4%

1.008

0.094

9.3%

1.119

0.047

4.2%

7

1.163

0.015

1.3%

0.866

0.089

10.3%

0.876

0.104

11.9%

8

1.179

0.074

6.3%

0.841

0.152

18.1%

1.084

0.155

14.3%

9

0.912

0.002

0.2%

1.074

0.135

12.6%

1.167

0.027

2.3%

10

0.900

0.025

2.8%

0.905

0.061

6.8%

1.096

0.496

45.2%

11

1.162

0.124

10.7%

1.323

0.071

5.4%

1.133

0.070

6.2%

Avg

1.242

0.083

0.064

1.081

0.121

0.116

1.171

0.155

13.2%
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Table 8. Intradonor variability of R(0): same 8-channel device or cross-device
coefficient of variability (CV)
8.2.4

Concentration-dependent response of platelet function under flow to ex vivo
2MeSAMP or MRS2179 at initial venous and arterial wall shear rates

Figure 8-5 Response to ex vivo P2Y12 or P2Y1 inhibition by incubation with
2MeSAMP or MRS2179 respectively at 200 s-1 and 1000 s-1 initial wall shear rates.
(A, B), Average IC50 curves for 2MeSAMP and MRS 2179 at venous and arterial shear rates. Nine microfluidic
assays were run at each initial wall shear rate for a total of 3 donors. Each point on the dose response curve is
an average of 9 clotting events under flow. 95% CI for ex vivo 2MeSAMP addition were 6.62-14.11 µM and
1.02-30.20 µM at 200 s-1 and 1000s-1 respectively and 0.029-0.164 µM, 0.03-1.87 µM for MRS 2179 at 200 s-1
and 1000s-1 respectively.
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8.3 Recombinant factor VIIa enhances platelet deposition from flowing
hemophilic blood but requires the contact way to promote fibrin
deposition: Supplemental Material
8.3.1
8.3.1.1

Supplemental Material and Methods
Validation of the dependency of fibrin generation on the contact pathway in the microfluidic
hemostasis model and the role of rFVIIa in a cell free system
To isolate platelet poor plasma (PPP), WB was collected from healthy donors in 1

part sodium citrate from Sigma (St. Louis, MO) to 9 parts blood and 4 µg/ml CTI. Samples
were subsequently centrifuged at 1000 g for 10 min. FXI, FIX, and FVIII-deficient plasma
samples were purchased from Haematologic Technologies (Essex Junction, VT). Factordeficient plasma samples were inhibited with 4 µg/ml CTI. Five minutes prior to
experimentation, normal pooled plasma (n = 3 donors) or factor-deficient plasma were
treated with fluorescently conjugated anti-fibrin antibody, recalcified with 10 mM CaCl2, and
indicated concentrations of rFVIIa were added. Two microfluidic devices were tested
allowing 16 simultaneous collagen strips to be imaged in 30 sec intervals. Healthy pooled
plasma, FXI, FIX, or FVIII-deficient plasma samples were tested in replicate on each 8channel device. Plasma samples were perfused at an initial local wall shear rate of 100s-1 for a
total perfusion time of 20 minutes.
8.3.1.2

FVIIa Fluorogenic Substrate detection
The fluorogenic FVIIa substrate D-Phe-Pro-Arg-6-amino-1-naphthalenesulfonamide

(D-FPR-ANSNH C4H9 · 2 HCl) was obtained from Haematologic Technologies (Essex
Junction, VT). Prior to experimentation, D-FPR-ANSNH C4H9 2*HCl (50 µM) was added
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to each well in a 384 well plate (Nunc, Thermo Scientific, Waltham, MA). A fluoroskan
(Fluoroskan Ascent, Thermo Scientific, Waltham, MA) detected the fluorescence of the
released ANSN reporter group. Addition of low or high CTI occurred at 1 min followed by
addition of rFVIIa at 5 min. Each well was read twice per minute for 90 minutes. Fractional
conversion of the fluorogenic substrate was determined according to:
(Equation 8-1)
𝐶=

𝐹 − 𝐹𝑚𝑖𝑛
𝐹𝑚𝑎𝑥 − 𝐹𝑚𝑖𝑛

where C is the fractional conversion, F is the instantaneous fluorescence at any time, Fmin or
Fmax is the respective minimum or maximum fluorescence for an individual well.

8.3.1.3

Thrombin Fluorogenic Substrate detection
The fluorogenic thrombin substrate t-Butyloxycarbonyl-β-benzyl-L-aspartyl-L-prolyl-

L-arginine-4 methylcoumaryl-7-amide [Boc-Asp(OBzl)-Pro-Arg-AMC] was obtained from
Peptide International (Louisville, KY). Lipids, L-α-phosphatidylcholine (PC), L-αphosphatidyserine (PS) were purchased from Avanti Polar Lipids (Alabaster, AL). WB was
collected in two syringes containing 1 part sodium citrate to 9 parts blood and either 4
µg/ml or 40 µg/ml CTI. To isolate platelet poor plasma (PPP), WB was centrifuged at 1000
g for 10 min. Citrated and high or low CTI-inhibited PPP was diluted 1:10 in HBS and
recalcified to 10 mM final calcium concentration in all wells. Prior to experimentation all
wells were pre-loaded with indicated concentrations of rFVIIa and 5 µM PC:PS vesicles. To
ensure simultaneous detection of thrombin activity, Boc-Asp(OBzl)-Pro-Arg-AMC (10 µM)
was added simultaneously to all wells with distinct conditions in a 384 well plate and the
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fluorescence of the released aminomethylcoumarin (AMC) was measured. Each well was
read twice per minute for 90 minutes and fractional conversion of the substrate was
determined as previously described.
8.3.1.4

Assessment of platelet-rFVIIa function in the microfluidic hemostasis model in the complete absence
of thrombin
WB was drawn into 4 µg/ml CTI and either 1 µM FXa inhibitor apixaban

(Selleckchem. Houston, TX) or 100 µM H-D-Phe-Pro-Arg-chloromethylketone
(Haematologic Technologies. Essex Junction, VT), or a combination of both with low CTI.
Blood samples were treated with fluorescently conjugated anti-CD41a antibody and
fluorescently conjugated anti-fibrin antibody to label platelets and fibrin respectively as
previously mentioned. Blood samples were also treated with vehicle HBS buffer or 4 nM
rFVIIa. Two microfluidic devices were tested allowing 16 simultaneous thrombi to be
imaged in 60 sec intervals. Conditions were tested at minimum in replicate with 2 different
forms of anti-coagulation (ie. Low CTI vs. Low CTI + Apixaban + PPACK) tested on each
device. Blood samples were perfused at a local wall shear rate of 100s-1. The total perfusion
time was 15 min for all flow assays. Platelet and fibrin accumulation were analyzed in the
same manner as previously mentioned.
8.3.2

Supplemental Discussion
Though potent thrombin inhibitors have been used in study of rFVIIa, the effect of

the contact pathway with in vitro flow assays is not often considered[153,154]. Enhancement
of fibrin formation under flow conditions by rFVIIa have been shown previously[76,154,155].
However, these studies used heparin or citrate as anticoagulants, not considering contact
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pathway-associated thrombin generation as FXII activation is known to occur independently
of heparin or plasma calcium. In these prior studies, thrombin was most likely already present
prior to perfusion through activation of the contact pathway. Thus rFVIIa mediated fibrin
generation could be due to FXIIa in these cases. Interestingly, only a triple cocktail of
anticoagulants blocking thrombin with a potent thrombin inhibitor (PPACK), FXa inhibitor
(Apixaban), and FXIIa inhibitor (CTI) completely abolished the platelet effects from rFVIIa
(Supplemental Figure S4). This establishes a requirement for thrombin in order to observe
substantial effects from rFVIIa.
In platelet poor plasma (PPP) under static conditions, contact pathway engagement
and rFVIIa initiated thrombin faster when compared to strong contact pathway inhibition
with high CTI (Supplemental Figure S5). Under flow conditions, ex vivo rFVIIa had no
effect on fibrin generation from healthy PPP or factor-deficient plasma (Supplemental
Figure S1). We anticipate that potentiation of rFVIIa function by the contact pathway requires
the platelet surface or platelet-derived products. Future studies would involve carefully
titrating varying levels of FVIII, FIX, or FXI into hemophillic WB to examine the role of the
contact pathway in rFVIIa function.
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8.3.3

Fibrin fluorescence at t = 10 min for low CTI-inhibited recalcified healthy
pooled plasma, FXI, FIX, or FVIII-deficient plasma ± rFVIIa

Figure 8-6. Representative images at 10 min of fibrin fluorescence intensity for low
CTI-inhibited recalcified healthy pooled plasma, FXI, FIX, or FVIII-deficient
plasma ± rFVIIa.
Fibrin initiation and accumulation was observed in the corners of the microfluidic channels in areas of low flow
where coagulation factors accumulate for healthy pooled plasma (A&E). In healthy pooled plasma,
accumulation of fibrin fibers was independent of rFVIIa. No fibrin fluorescence signal was detected in all
factor-deficient plasma samples (B-D, F-H) with or without rFVIIa. The scale bar indicates 50 µm.

160

8.3.4

Detection of CTI interaction with rFVIIa with fluorogenic FVIIa substrate

Figure 8-7 Conversion of fluorogenic FVIIa substrate in the absence or presence of
low or high CTI with 400 nM rFVIIa
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8.3.5

Effect of exogenous rFVIIa in two additional severely FVIII-deficient patients
#57 and #56

Figure 8-8 Effect of exogenous rFVIIa in severely FVIII-deficient patient #57 and 56
after recovery of critical factor levels to 9 and 10% respectively due to therapy.
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(A), Platelet and fibrin fluorescence over time in high or low CTI-inhibited WB for patient #57. (B), Platelet
and fibrin fluorescence in high or low CTI-inhibited WB for patient #56. Timing of recent hemostatic therapy
is as indicated. Shaded traces are the standard deviation of two clotting events measured in 60 sec intervals over
15 min. Dashed lines indicate full channel occlusion.

8.3.6

Effect of ex vivo rFVIIa to WB under flow with inhibition of the contact
pathway, thrombin, and FXa

Figure 8-9 Exogenous rFVIIa addition to WB anti-coagulated with low CTI, PPACK
and direct FXa inhibitor Apixaban
(A), Platelet fluorescence dynamics with exogenous rFVIIa addition in thrombin-inhibited flow environment.
(B), Fibrin fluorescence dynamics with exogenous rFVIIa addition in thrombin-inhibited flow environment.
Shaded traces are standard deviation of 4 clotting events measured in 30 sec intervals
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8.3.7

Detection of contact pathway mediated rFVIIa efficacy using fluorogenic
thrombin substrate

Figure 8-10 Conversion of fluorogenic thrombin substrate in low or high CTI
inhibited PPP upon addition of indicated concentrations of rFVIIa
(A), Detection of thrombin activity in recalcified high CTI-inhibited PPP supplemented with rFVIIa and
PS:PC vesicles. (B), Detection of thrombin activity in recalcified low CTI-inhibited PPP supplemented with
rFVIIa and PS:PC vesicles. Traces are average of 4 repeats per condition.

8.4 Ex vivo recapitulation of trauma-induced coagulopathy and
preliminary assessment of trauma patient platelet function under
flow using microfluidic technology
8.4.1
8.4.1.1

Supplementary Materials and Methods
Blood collection
Whole blood was collected from healthy donors either into 100 μM PPACK or into

an empty BD syringe. 1 mL of whole blood from the empty syringe was then aliquoted into
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four separate tubes containing 10 μL PPACK at 1, 2, 3, and 4 min after the initial blood
draw to mimic phlebotomy blood collection methods in the HUP trauma and resuscitation
bay.

8.4.1.2

Validation by flow cytometry that minor delays in anticoagulation do not affect platelet activation
All fluorescent antibodies were purchased from BD Biosciences. Each well of a flat-

bottom 96 well plate (Corning, Corning, NY, USA) was loaded with 72 μL HBS, 2 μL of
Cy5 annexin V, 2 μL PE anti-CD62P, and 4 μL FITC PAC-1. Each row received 10 μL of
1:10 diluted whole blood inhibited at 0, 1, 2, 3, 4 min post-phlebotomy. ADP and collagen
(final concentration 50 μM and 100 nM respectively) were selected as agonists to stimulate
platelet activation. Ten minutes prior to flow cytometry analysis, 10 μL of a 10X stock of the
appropriate agonist or HBS was added, giving a final volume of 100 μL. Accuri C6 flow
cytometer with CSampler was used for plate handling. The sample flow rate was set to slow,
and samples were analyzed for 1 min following the 10 minute incubation with agonist(s).
8.4.1.3

Validation of thrombin inhibition by 100 uM PPACK in whole blood anticoagulated up to 4
min after initial phlebotomy
Fluorogenic thrombin substrate Boc-Val-Pro-Arg-methylcoumarinamide (Boc-VPR-

MCA) was obtained from Bachem (King of Prussia, PA). Boc-VPR-MCA diluted in HBS
was added to each well in a 384 well plate (Corning). Whole blood anticoagulated with 100
µM PPACK at 0, 1, 2, 3, 4 min post-phlebotomy was diluted in HBS. Diluted whole blood
was added simultaneously to each row of substrate to ensure a simultaneous detection of
thrombin activity yielding a final concentration of 9 μM Boc-VPR-MCA and 20% whole
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blood. A fluoroskan (Fluoroskan Ascent, Thermo Scientific, Waltham, MA) detected the
fluorescence of the released aminomethylcoumarin (AMC) reporter group. Each well was
read twice per minute for 45 min. Fractional conversion of the fluorogenic substrate was
determined according to (Equation 8-1).

8.4.2

Ex vivo protocol to mimic modules of trauma-induced coagulopathy in the 8channel device under pressure relief flow regimes

Figure 8-11 Ex vivo protocol to mimic resuscitation-induced hemodilution and
hyperfibrinolysis in the 8-channel microfluidic device under pressure relief mode
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(A), WB is inhibited with 40 µg/ml CTI or 100 µM PPACK and diluted with saline, PPP or PRP to mimic Hct
lowering. To promote a 'lytic state' exogenous tPA (0-50 nM) was added to whole blood. (B), Flow through a
cross section of a pair of microfluidic channels was previously modeled using COMSOL. The growing clot
with variable height was represented by a trapezoidal shape in a single channel[37]. Pressure relief mode was
recreated by setting the flow rate at the outlet to 4 µl/min. (C), Shear rate calculated at the wall in the center of
the model clot[37]. (D), Flow rate calculated at the wall in center of the model clot[37].

8.4.3

Platelet accumulation fluorescence dynamics and total platelet accumulation
at 900 sec (Healthy subject vs Trauma patient #24: Response to ex vivo
MRS2179, GSNO, iloprost)
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Figure 8-12 Platelet accumulation dynamics measured by platelet fluorescence and
total platelet accumulation morphology at 900 sec in representative healthy donor
and trauma patient (#24) in response to ex vivo MRS2179, GSNO, or iloprost.
(A), Total platelet accumulation at 900 sec following ex vivo treatment with antagonists MRS2179, GSNO, or
iloprost. (B), Platelet fluorescence dynamics in representative healthy donor in the presence of indicated
concentrations of ex vivo MRS 2179, GSNO, or iloprost. (C), Platelet fluorescence dynamics in trauma patient
(#24) in the presence of indicated concentrations of ex vivo MRS 2179, GSNO, or iloprost. Shaded traces are
the mean and standard deviation of 4 clotting events from each healthy donor or patient.
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8.4.4

P-selectin expression measured by p-selectin antibody staining and platelet
accumulation in representative healthy donor and trauma patient #9.

Figure 8-13 Dynamic p-selectin expression and platelet accumulation in
representative healthy donor and trauma patient (9).
(A), Overlay of platelet deposition (red) and p-selectin expression (aqua) over the time course of the flow
assay. (B), Platelet fluorescence and p-selectin expression dynamics over time in three healthy donors in
comparison to a trauma patient (#9). Shaded traces are the mean and standard deviation of a minimum of 4
clotting evens from each donor or patient.
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8.4.5

Gross thrombus instability due to the lytic state at venous shear rates

Figure 8-14 Disintegration of platelet aggregates and fibrin accumulation in response
to exogenous tPA ± εACA at venous shear rates.
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 200s -1. (B), Platelet
fluorescence intensities vs. time with exogenous tPA ± εACA added. (C), Fibrin fluorescence intensities vs.
time with exogenous tPA ± εACA added. Shaded traces are the average and standard deviation of two clotting
events.
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8.4.6

Gross thrombus instability due to the lytic state at arterial shear rates

Figure 8-15 Disintegration of platelet aggregates and fibrin accumulation in response
to exogenous tPA ± εACA at arterial shear rates
(A), Overlay of platelets (red) and fluorescent fibrinogen (yellow) deposition at 1222 s-1 over the time course of
the 20 min assay. (B), Platelet fluorescence intensities vs. time with exogenous tPA ± εACA added. (C), Fibrin
fluorescence intensities vs. time with exogenous tPA ± εACA added. Shaded traces are the average and
standard deviation of two clotting events.
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8.4.7

Detection of platelet desensitization from stimulation of WB anticoagulated
with PPACK up to 4 min post phlebotomy with ADP or collagen in flow
cytometry

Figure 8-16 Stimulation of whole blood anticoagulated with 100 µM PPACK up to 4
min post-phlebotomy with ADP or collagen in flow cytometry
The percentage of platelets staining positive for PAC-1 expression (A), P-Selectin expression (B), and PS
exposure (C) upon stimulation with indicated agonists in 1% whole blood samples anticoagulated with 100 µM
PPACK at 0, 1, 2, 3, 4 min following initial blood draw. These results indicate that platelets were not
significantly activated for up to 3 minutes in the syringe prior to anticoagulation. Markers are the average and
standard deviation of 3 measurements from 3 donors.
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8.4.8

Detection of thrombin using a fluorogenic thrombin-sensitive substrate in WB
anticoagulated with PPACK up to 4 min post phlebotomy

Figure 8-17 Conversion of fluorogenic thrombin-sensitive substrate in whole blood
anticoagulated with 100 µM PPACK up to 4 min post-phlembotomy
To evaluate whether 100 µM PPACK fully inhibits thrombin generation post-phlebotomy, the conversion of
the thrombin sensitive flurogenic substrate was measured for 45 min. A delay of up to 4 min prior to
anticoagulation with PPACK does not illicit thrombin generation. Shaded traces are the average and standard
deviation of 12 measurements from 3 donors.
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8.4.9

Trauma Patient #36 platelet function under flow at venous shear rates

Figure 8-18 Trauma patient #36
(A) Total platelet accumulation at 900 sec. (B) Platelet deposition dynamics at venous shear rates (100s-1).
Shaded trace is the mean and standard deviation of 4 clotting events from patient #36.
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8.4.10 Comparison of baseline platelet accumulation on collagen (healthy subjects vs.
trauma patients)

Figure 8-19 Comparison of healthy and trauma patient total platelet accumulation at
900 sec
Bars are average and standard deviation from the indictated number of donors or patients tested (n) at 4
clotting events per donor or patient. **p<0.001
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8.4.11 Comparison of response to ex vivo addition of MRS2179, GSNO, or iloprost
(healthy subjects vs trauma patients)

Figure 8-20 Ex vivo addition of GSNO reduced total platelet accumulation more
significantly in trauma patients then healthy donors
Trauma patients responded less to ex vivo antagonism with MRS 2179 or iloprost. Bars are average and
standard deviation from the indictated number of donors or patients tested (n) at 4 clotting events per donor or
patient. **MRS 2179: p = 0.003, GSNO: p < 0.001, Iloprost: p < 0.001
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8.4.12 Platelet function measured by platelet fluorescence over time post-admissions
for massively transfused patient #31

Figure 8-21 Platelet fluorescence vs. time for massively transfused patient #31
Shaded traces are the average and standard deviation of 4 clotting events.
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